

An inflammatory cytokine signature predicts COVID-19

Nature Medicine

26, 1636-1643

DOI: [10.1038/s41591-020-1051-9](https://doi.org/10.1038/s41591-020-1051-9)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Pneumonia in the face of COVID-19. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L863-L866.	1.3	5
2	Inflammatory phenotyping predicts clinical outcome in COVID-19. Respiratory Research, 2020, 21, 245.	1.4	72
3	COVID-19: Staging of a New Disease. Cancer Cell, 2020, 38, 594-597.	7.7	48
4	Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. New England Journal of Medicine, 2020, 383, 2333-2344.	13.9	1,102
5	â€œAmerica Firstâ€œ Will Destroy U.S. Science. Cell, 2020, 183, 841-844.	13.5	1
6	Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 3594-3596.e3.	2.0	72
7	The bumpy road to achieve herd immunity in COVID-19. Journal of Immunoassay and Immunochemistry, 2020, 41, 928-945.	0.5	30
8	Cytokine Storms in Cancer and COVID-19. Cancer Cell, 2020, 38, 598-601.	7.7	66
9	Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell, 2020, 183, 996-1012.e19.	13.5	1,494
10	Commentary: A Human Pluripotent Stem Cell-Based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids. Frontiers in Endocrinology, 2020, 11, 585922.	1.5	4
11	The immunology of SARS-CoV-2 infections and vaccines. Seminars in Immunology, 2020, 50, 101422.	2.7	85
12	Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. Critical Care, 2020, 24, 666.	2.5	120
13	Letter to the Editor in response to Chen et al. 2020. Respiratory Research, 2020, 21, 315.	1.4	0
14	Cytokine Storm. New England Journal of Medicine, 2020, 383, 2255-2273.	13.9	1,911
15	The dysregulated innate immune response in severe COVID-19 pneumonia that could drive poorer outcome. Journal of Translational Medicine, 2020, 18, 457.	1.8	61
16	Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine, 2020, 29-30, 100630.	3.2	454
17	Cancer therapy and treatments during COVID-19 era. Advances in Biological Regulation, 2020, 77, 100739.	1.4	30
18	Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19. Cell, 2020, 183, 1479-1495.e20.	13.5	449

#	ARTICLE	IF	CITATIONS
19	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. <i>Frontiers in Immunology</i> , 2020, 11, 562264.	2.2	8
20	Intensive Care Unit-Acquired Weakness: Not Just Another Muscle Atrophying Condition. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7840.	1.8	51
21	COVID-19-Associated Neurological Disorders: The Potential Route of CNS Invasion and Blood-Brain Barrier Relevance. <i>Cells</i> , 2020, 9, 2360.	1.8	125
22	Monocyte <sc>HLA-DR</sc> Measurement by Flow Cytometry in <sc>COVID</sc>-19 Patients: An Interim Review. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2020, 97, 1217-1221.	1.1	60
23	A "Window of Therapeutic Opportunity" for Anti-Cytokine Therapy in Patients With Coronavirus Disease 2019. <i>Frontiers in Immunology</i> , 2020, 11, 572635.	2.2	11
24	Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. <i>Lancet Rheumatology</i> , The, 2020, 2, e653-e655.	2.2	119
25	The dynamic changes in cytokine responses in COVID-19: a snapshot of the current state of knowledge. <i>Nature Immunology</i> , 2020, 21, 1146-1151.	7.0	82
26	Prognostic factors in patients admitted to an urban teaching hospital with COVID-19 infection. <i>Journal of Translational Medicine</i> , 2020, 18, 354.	1.8	41
27	The Virological, Immunological, and Imaging Approaches for COVID-19 Diagnosis and Research. <i>SLAS Technology</i> , 2020, 25, 522-544.	1.0	18
28	Increased interleukin-6 and macrophage chemoattractant protein-1 are associated with respiratory failure in COVID-19. <i>Scientific Reports</i> , 2020, 10, 21697.	1.6	65
29	Can Natural Killer Cells Be a Principal Player in Anti-SARS-CoV-2 Immunity?. <i>Frontiers in Immunology</i> , 2020, 11, 586765.	2.2	28
30	Investigating the Potential for Ultraviolet Light to Modulate Morbidity and Mortality From COVID-19: A Narrative Review and Update. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 616527.	1.1	17
31	The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. <i>Med</i> , 2020, 1, 90-102.	2.2	87
32	Emerging Telemedicine Tools for Remote COVID-19 Diagnosis, Monitoring, and Management. <i>ACS Nano</i> , 2020, 14, 16180-16193.	7.3	178
33	<p>>GM-CSF: A Promising Target in Inflammation and Autoimmunity</p>. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 225-240.	2.7	59
34	ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis. <i>Cytokine</i> , 2020, 136, 155256.	1.4	26
35	The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7). <i>Addiction</i> , 2021, 116, 1319-1368.	1.7	266
36	Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia. <i>JAMA Internal Medicine</i> , 2021, 181, 32.	2.6	654

#	ARTICLE	IF	CITATIONS
37	Effect of IBD medications on COVID-19 outcomes: results from an international registry. <i>Gut</i> , 2021, 70, 725-732.	6.1	240
38	Risk factors for severe and critically ill COVID-19 patients: A review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 428-455.	2.7	904
39	T cell immunity to SARS-CoV-2 following natural infection and vaccination. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 211-217.	1.0	88
40	The unfinished story of hydroxychloroquine in COVID-19: The right anti-inflammatory dose at the right moment?. <i>International Journal of Infectious Diseases</i> , 2021, 103, 1-2.	1.5	9
41	Sex differences in COVID-19: candidate pathways, genetics of ACE2, and sex hormones. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2021, 320, H296-H304.	1.5	123
42	Rapid single-molecule digital detection of protein biomarkers for continuous monitoring of systemic immune disorders. <i>Blood</i> , 2021, 137, 1591-1602.	0.6	21
43	A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111037.	2.5	58
44	Synergism of TNF- α and IFN- β Triggers Inflammatory Cell Death, Tissue Damage, and Mortality in SARS-CoV-2 Infection and Cytokine Shock Syndromes. <i>Cell</i> , 2021, 184, 149-168.e17.	13.5	923
45	A digital protein microarray for COVID-19 cytokine storm monitoring. <i>Lab on A Chip</i> , 2021, 21, 331-343.	3.1	30
46	Genetic influences on viral-induced cytokine responses in the lung. <i>Mucosal Immunology</i> , 2021, 14, 14-25.	2.7	34
47	Immunity and coagulation and fibrinolytic processes may reduce the risk of severe illness in pregnant women with coronavirus disease 2019. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 224, 393.e1-393.e25.	0.7	9
48	Liver Fibrosis Index FIB-4 Is Associated With Mortality in COVID-19. <i>Hepatology Communications</i> , 2021, 5, 434-445.	2.0	38
49	Tackling the COVID-19 "cytokine storm" with microRNA mimics directly targeting the 3'UTR of pro-inflammatory mRNAs. <i>Medical Hypotheses</i> , 2021, 146, 110415.	0.8	32
50	A comprehensive review on sarilumab in COVID-19. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 615-626.	1.4	31
51	Severe Acute Respiratory Syndrome Coronavirus 2-Induced Immune Activation and Death of Monocyte-Derived Human Macrophages and Dendritic Cells. <i>Journal of Infectious Diseases</i> , 2021, 223, 785-795.	1.9	127
52	Severe hyperalgesia and pain during botulinum toxin injection avoiding application in a patient 1 week after COVID-19 infection. <i>Journal of Cosmetic Dermatology</i> , 2021, 20, 755-756.	0.8	5
53	IL-6 in inflammation, autoimmunity and cancer. <i>International Immunology</i> , 2021, 33, 127-148.	1.8	500
54	Paper biosensors for detecting elevated IL-6 levels in blood and respiratory samples from COVID-19 patients. <i>Sensors and Actuators B: Chemical</i> , 2021, 330, 129333.	4.0	49

#	ARTICLE	IF	CITATIONS
55	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	15.2	473
56	Pathogenesis guided therapeutic management of COVID-19: an immunological perspective. <i>International Reviews of Immunology</i> , 2021, 40, 54-71.	1.5	10
57	Immunopathology of Hyperinflammation in COVID-19. <i>American Journal of Pathology</i> , 2021, 191, 4-17.	1.9	372
60	Hidden in plain sight: sex and gender in global pandemics. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 48-53.	1.5	8
61	Procalcitonin accurately predicts mortality but not bacterial infection in COVID-19 patients admitted to intensive care unit. <i>Irish Journal of Medical Science</i> , 2021, 190, 1649-1652.	0.8	35
62	Severe COVID-19 and Sepsis: Immune Pathogenesis and Laboratory Markers. <i>Microorganisms</i> , 2021, 9, 159.	1.6	41
64	COVID-19 in Association With Development, Course, and Treatment of Systemic Autoimmune Rheumatic Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 611318.	2.2	17
65	Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 249-260.	1.3	7
66	Various Cellular and Molecular Axis Involved in the Pathogenesis of Asthma. , 2021, , 53-95.		0
67	Cytokines in Innate Immunity. , 2021, , .		0
68	Repression of transcription by the glucocorticoid receptor: A parsimonious model for the genomics era. <i>Journal of Biological Chemistry</i> , 2021, 296, 100687.	1.6	27
69	Control and prevention of infectious diseases from a One Health perspective. <i>Genetics and Molecular Biology</i> , 2021, 44, e20200256.	0.6	38
70	Systemic Inflammatory Index Is a Novel Predictor of Intubation Requirement and Mortality after SARS-CoV-2 Infection. <i>Pathogens</i> , 2021, 10, 58.	1.2	29
71	Illuminating the immunopathology of SARS-CoV-2. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 33-41.	0.7	11
72	Cytokines and Chemokines in SARS-CoV-2 Infections: Therapeutic Strategies Targeting Cytokine Storm. <i>Biomolecules</i> , 2021, 11, 91.	1.8	67
73	Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients. <i>Annals of Intensive Care</i> , 2021, 11, 9.	2.2	70
74	Exploring the rationale for thermotherapy in COVID-19. <i>International Journal of Hyperthermia</i> , 2021, 38, 202-212.	1.1	6
75	Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial. <i>Clinical and Translational Medicine</i> , 2021, 11, e297.	1.7	90

#	ARTICLE	IF	CITATIONS
77	Severe COVID-19 Lung Infection in Older People and Periodontitis. <i>Journal of Clinical Medicine</i> , 2021, 10, 279.	1.0	35
78	Genetic risk for severe COVID-19 correlates with lower inflammatory marker levels in a SARS-CoV-2-negative cohort. <i>Clinical and Translational Immunology</i> , 2021, 10, e1292.	1.7	4
79	Immunity, virus evolution, and effectiveness of SARS-CoV-2 vaccines. <i>Brazilian Journal of Medical and Biological Research</i> , 2021, 54, e10725.	0.7	9
80	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110422.	1.4	4
81	NF- κ B signalling as a pharmacological target in COVID-19: potential roles for IKK β inhibitors. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2021, 394, 561-567.	1.4	49
82	An immune-based biomarker signature is associated with mortality in COVID-19 patients. <i>JCI Insight</i> , 2021, 6, .	2.3	269
84	Immune Profiling to Determine Early Disease Trajectories Associated With Coronavirus Disease 2019 Mortality Rate: A Substudy from the ACTT-1 Trial. <i>Journal of Infectious Diseases</i> , 2021, 223, 1339-1344.	1.9	2
85	Vaccine responses in ageing and chronic viral infection. <i>Oxford Open Immunology</i> , 2021, 2, .	1.2	3
87	Simple prognostic factors and change of inflammatory markers in patients with severe coronavirus disease 2019: a single-center observational study. <i>Acute Medicine & Surgery</i> , 2021, 8, e683.	0.5	8
88	Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. <i>Genome Medicine</i> , 2021, 13, 7.	3.6	193
89	C-reactive protein and clinical outcomes in patients with COVID-19. <i>European Heart Journal</i> , 2021, 42, 2270-2279.	1.0	255
90	Protective Immune Trajectories in Early Viral Containment of Non-Pneumonic SARS-CoV-2 Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
91	Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. <i>Journal of Infectious Diseases</i> , 2021, 224, 1839-1848.	1.9	176
92	Expression of the SARS-CoV-2 Receptor ACE2 and Proinflammatory Cytokines Induced by the Periodontopathic Bacterium <i>Fusobacterium nucleatum</i> in Human Respiratory Epithelial Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1352.	1.8	41
93	An overview of proteomic methods for the study of "cytokine storms". <i>Expert Review of Proteomics</i> , 2021, 18, 83-91.	1.3	3
94	The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System. <i>Frontiers in Immunology</i> , 2021, 12, 627579.	2.2	49
96	Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequelae. <i>PLoS ONE</i> , 2021, 16, e0246803.	1.1	43
97	Can Echinacea be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019. <i>Heliyon</i> , 2021, 7, e05990.	1.4	25

#	ARTICLE	IF	CITATIONS
98	Macrophage Migration Inhibitory Factor (MIF) Plasma Concentration in Critically Ill COVID-19 Patients: A Prospective Observational Study. <i>Diagnostics</i> , 2021, 11, 332.	1.3	19
99	Development and validation of a prognostic COVID-19 severity assessment (COSA) score and machine learning models for patient triage at a tertiary hospital. <i>Journal of Translational Medicine</i> , 2021, 19, 56.	1.8	41
100	A neutrophil activation signature predicts critical illness and mortality in COVID-19. <i>Blood Advances</i> , 2021, 5, 1164-1177.	2.5	241
101	Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. <i>Science</i> , 2021, 371, .	6.0	2,268
102	In Silico Screening of Natural Products Isolated from Mexican Herbal Medicines against COVID-19. <i>Biomolecules</i> , 2021, 11, 216.	1.8	24
103	Macrophage Responses to Environmental Stimuli During Homeostasis and Disease. <i>Endocrine Reviews</i> , 2021, 42, 407-435.	8.9	21
105	Characterization and Biomarker Analyses of Post-COVID-19 Complications and Neurological Manifestations. <i>Cells</i> , 2021, 10, 386.	1.8	125
107	COVID-19 and cardiovascular problems in elderly patients: Food for thought. <i>Aging Medicine (Milton Tj ETQq1 10,784314,rgBT /Over</i>	0.9	4
109	Persistent COVID-19-associated neurocognitive symptoms in non-hospitalized patients. <i>Journal of NeuroVirology</i> , 2021, 27, 191-195.	1.0	95
110	Pathophysiology of acute respiratory syndrome coronavirus 2 infection: a systematic literature review to inform EULAR points to consider. <i>RMD Open</i> , 2021, 7, e001549.	1.8	14
111	Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 609204.	1.8	22
114	Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1127-1141.	0.9	9
115	SARS-CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges. <i>Infectious Disease Reports</i> , 2021, 13, 102-125.	1.5	24
117	How Do Inflammatory Mediators, Immune Response and Air Pollution Contribute to COVID-19 Disease Severity? A Lesson to Learn. <i>Life</i> , 2021, 11, 182.	1.1	11
118	Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1255-1268.	1.8	23
119	Multistate Modeling of COVID-19 Patients Using a Large Multicentric Prospective Cohort of Critically Ill Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 544.	1.0	10
120	Neurosteroid allopregnanolone (3 α ,5 α -THP) inhibits inflammatory signals induced by activated MyD88-dependent toll-like receptors. <i>Translational Psychiatry</i> , 2021, 11, 145.	2.4	44
122	Elastase and exacerbation of neutrophil innate immunity are involved in multi-organ visceral manifestations of COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1846-1858.	2.7	59

#	ARTICLE	IF	CITATIONS
123	Interleukin-6 Is a Biomarker for the Development of Fatal Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia. <i>Frontiers in Immunology</i> , 2021, 12, 613422.	2.2	228
125	Low Vitamin D Status at Admission as a Risk Factor for Poor Survival in Hospitalized Patients With COVID-19: An Italian Retrospective Study. <i>Journal of the American College of Nutrition</i> , 2022, 41, 250-265.	1.1	41
128	Could Dietary Factors Reduce COVID-19 Mortality Rates? Moderating the Inflammatory State. <i>Journal of Alternative and Complementary Medicine</i> , 2021, 27, 176-178.	2.1	10
131	Daylight is critical to preserve 5-methoxytryptophol levels in suspected and confirmed COVID-19 patients. <i>Medical Hypotheses</i> , 2021, 147, 110504.	0.8	1
132	P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thromboinflammation. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 241-252.	1.7	17
133	Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications. <i>Life Sciences</i> , 2021, 267, 118923.	2.0	28
135	The Activin/Follistatin Axis Is Severely Deregulated in COVID-19 and Independently Associated With In-Hospital Mortality. <i>Journal of Infectious Diseases</i> , 2021, 223, 1544-1554.	1.9	16
137	Adaptive immunity to SARS-CoV-2 and COVID-19. <i>Cell</i> , 2021, 184, 861-880.	13.5	1,364
139	SARS-CoV-2 Triggers an MDA-5-Dependent Interferon Response Which Is Unable To Control Replication in Lung Epithelial Cells. <i>Journal of Virology</i> , 2021, 95, .	1.5	168
141	Adaptive Metabolic and Inflammatory Responses Identified Using Accelerated Aging Metrics Are Linked to Adverse Outcomes in Severe SARS-CoV-2 Infection. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, e117-e126.	1.7	11
142	VCAM-1: closing the gap between lipotoxicity and endothelial dysfunction in nonalcoholic steatohepatitis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	13
143	Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 295-304.	5.2	232
144	High dimensional profiling identifies specific immune types along the recovery trajectories of critically ill COVID19 patients. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 3987-4002.	2.4	13
145	Targeting Cytokine Storm in COVID-19: A Role of Online Hemodiafiltration with Asymmetric Cellulose Triacetate in Maintenance Hemodialysis Patients—A Report of 10 Cases. <i>Case Reports in Nephrology</i> , 2021, 2021, 1-7.	0.2	5
146	Interrogation of the cellular immunome of cancer patients with regard to the COVID-19 pandemic. , 2021, 9, e002087.		7
148	Coronavirus disease 2019 (COVID-19) and autoimmunity. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 5-30.	0.2	28
149	COVID-19 and liver disease: mechanistic and clinical perspectives. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 348-364.	8.2	272
151	Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	88

#	ARTICLE	IF	CITATIONS
152	Exosomes from COVID-19 Patients Carry Tenascin-C and Fibrinogen-Î² in Triggering Inflammatory Signals in Cells of Distant Organ. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3184.	1.8	44
153	The Role of Immunological and Clinical Biomarkers to Predict Clinical COVID-19 Severity and Response to Therapyâ€”A Prospective Longitudinal Study. <i>Frontiers in Immunology</i> , 2021, 12, 646095.	2.2	13
154	Electrochemical sensing: A prognostic tool in the fight against COVID-19. <i>TrAC - Trends in Analytical Chemistry</i> , 2021, 136, 116198.	5.8	40
156	Targeting MMP-Regulation of Inflammation to Increase Metabolic Tolerance to COVID-19 Pathologies: A Hypothesis. <i>Biomolecules</i> , 2021, 11, 390.	1.8	28
158	Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. <i>Cell Death and Disease</i> , 2021, 12, 258.	2.7	113
159	The Characterization of Disease Severity Associated IgG Subclasses Response in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 632814.	2.2	62
160	Effects of Different Dialysis Strategies on Inflammatory Cytokine Profile in Maintenance Hemodialysis Patients with COVID-19: A Randomized Trial. <i>Journal of Clinical Medicine</i> , 2021, 10, 1383.	1.0	6
161	Managing thrombosis and cardiovascular complications of COVID-19: answering the questions in COVID-19-associated coagulopathy. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1003-1011.	1.0	12
162	SARS2 simplified scores to estimate risk of hospitalization and death among patients with COVID-19. <i>Scientific Reports</i> , 2021, 11, 4945.	1.6	19
165	Î±1-Antitrypsin: Key Player or Bystander in Acute Respiratory Distress Syndrome?. <i>Anesthesiology</i> , 2021, 134, 792-808.	1.3	6
166	COVID-19 and HIV-Associated Immune Reconstitution Inflammatory Syndrome: Emergence of Pathogen-Specific Immune Responses Adding Fuel to the Fire. <i>Frontiers in Immunology</i> , 2021, 12, 649567.	2.2	14
167	mRNA-lncRNA Co-Expression Network Analysis Reveals the Role of lncRNAs in Immune Dysfunction during Severe SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 402.	1.5	30
169	T Cell Activation, Highly Armed Cytotoxic Cells and a Shift in Monocytes CD300 Receptors Expression Is Characteristic of Patients With Severe COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 655934.	2.2	50
171	COVID-19 convalescent plasma composition and immunological effects in severe patients. <i>Journal of Autoimmunity</i> , 2021, 118, 102598.	3.0	92
172	Single-cell meta-analysis of SARS-CoV-2 entry genes across tissues and demographics. <i>Nature Medicine</i> , 2021, 27, 546-559.	15.2	261
173	Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications. <i>Nature Communications</i> , 2021, 12, 1618.	5.8	168
174	The neuropsychiatric manifestations of COVID-19: Interactions with psychiatric illness and pharmacological treatment. <i>Biomedicine and Pharmacotherapy</i> , 2021, 135, 111200.	2.5	69
175	Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. <i>European Respiratory Journal</i> , 2021, 57, 2100048.	3.1	152

#	ARTICLE	IF	CITATIONS
176	The Effect of Chronic and Inhospital Exposure to Renin-Angiotensin System Inhibitors on the Outcome and Inflammatory State of Coronavirus Disease 2019 Adult Inpatients. <i>International Journal of Hypertension</i> , 2021, 2021, 1-9.	0.5	2
178	Low type I interferon response in COVID-19 patients: Interferon response may be a potential treatment for COVID-19. <i>Biomedical Reports</i> , 2021, 14, 43.	0.9	18
179	Severe covid-19 pneumonia: pathogenesis and clinical management. <i>BMJ, The</i> , 2021, 372, n436.	3.0	240
180	A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2721.	1.8	73
182	In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2. <i>Viruses</i> , 2021, 13, 558.	1.5	27
183	Brain dysfunction in COVID-19 and CAR-T therapy: cytokine storm-associated encephalopathy. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 968-979.	1.7	52
184	The first 12 months of COVID-19: a timeline of immunological insights. <i>Nature Reviews Immunology</i> , 2021, 21, 245-256.	10.6	325
185	Cigarette Smoke Exposure, Pediatric Lung Disease, and COVID-19. <i>Frontiers in Physiology</i> , 2021, 12, 652198.	1.3	6
186	IL-33 expression in response to SARS-CoV-2 correlates with seropositivity in COVID-19 convalescent individuals. <i>Nature Communications</i> , 2021, 12, 2133.	5.8	44
188	Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome. <i>Frontiers in Pharmacology</i> , 2021, 12, 650295.	1.6	23
189	Highlights from a year in a pandemic. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	4
191	The unbalanced p53/SIRT1 axis may impact lymphocyte homeostasis in COVID-19 patients. <i>International Journal of Infectious Diseases</i> , 2021, 105, 49-53.	1.5	38
192	Toward the Rapid Diagnosis of Sepsis: Detecting Interleukin-6 in Blood Plasma Using Functionalized Screen-Printed Electrodes with a Thermal Detection Methodology. <i>Analytical Chemistry</i> , 2021, 93, 5931-5938.	3.2	31
193	Temporal profiling of cytokines in passively expressed sweat for detection of infection using wearable device. <i>Bioengineering and Translational Medicine</i> , 2021, 6, e10220.	3.9	44
194	Tocilizumab in Treatment for Patients With COVID-19. <i>JAMA Internal Medicine</i> , 2021, 181, 1017-1018.	2.6	3
198	Analysis of cytokines in SARS-CoV-2 or COVID-19 patients in Erbil city, Kurdistan Region of Iraq. <i>PLoS ONE</i> , 2021, 16, e0250330.	1.1	40
199	Longitudinal assessment of IFN-I activity and immune profile in critically ill COVID-19 patients with acute respiratory distress syndrome. <i>Critical Care</i> , 2021, 25, 140.	2.5	27
200	BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. <i>Cell</i> , 2021, 184, 2167-2182.e22.	13.5	131

#	ARTICLE	IF	CITATIONS
201	Randomized placebo-controlled pilot clinical trial on the efficacy of ayurvedic treatment regime on COVID-19 positive patients. <i>Phytomedicine</i> , 2021, 84, 153494.	2.3	63
202	Interleukin 6, soluble interleukin 2 receptor alpha (CD25), monocyte colony-stimulating factor, and hepatocyte growth factor linked with systemic hyperinflammation, innate immunity hyperactivation, and organ damage in COVID-19 pneumonia. <i>Cytokine</i> , 2021, 140, 155438.	1.4	44
203	Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. <i>Trends in Immunology</i> , 2021, 42, 293-311.	2.9	62
204	SARS-CoV-2 Switches on MAPK and NF κ B Signaling via the Reduction of Nuclear DUSP1 and DUSP5 Expression. <i>Frontiers in Pharmacology</i> , 2021, 12, 631879.	1.6	50
205	Aging versus youth: Endocrine aspects of vulnerability for COVID-19. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, , 1.	2.6	6
206	Commentary: Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment. <i>Frontiers in Immunology</i> , 2021, 12, 682195.	2.2	1
207	Letter to the editor: Vitamin D levels in acute illness and clinical severity in COVID-19 patients. <i>Respiratory Research</i> , 2021, 22, 102.	1.4	3
208	Predictors of Mortality in Critically Ill COVID-19 Patients Demanding High Oxygen Flow: A Thin Line between Inflammation, Cytokine Storm, and Coagulopathy. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-9.	1.9	26
209	Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6. <i>Journal of Clinical Medicine</i> , 2021, 10, 1583.	1.0	21
210	Systemic and organ-specific immune-related manifestations of COVID-19. <i>Nature Reviews Rheumatology</i> , 2021, 17, 315-332.	3.5	194
211	Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm. <i>Frontiers in Immunology</i> , 2021, 12, 642860.	2.2	15
212	Plasma biomarker profiling of PIMS-TS, COVID-19 and SARS-CoV2 seropositive children – a cross-sectional observational study from southern India.. <i>EBioMedicine</i> , 2021, 66, 103317.	2.7	26
213	DP1 prostanoid receptor activation increases the severity of an acute lower respiratory viral infection in mice via TNF- α -induced immunopathology. <i>Mucosal Immunology</i> , 2021, 14, 963-972.	2.7	9
214	Evolution of the Human Cytokine Response from Acute Illness to Disease Resolution in SARS-Cov-2 Infection – Implications for Therapeutic Monitoring and Therapeutic Targets. <i>Journal of Clinical Immunology</i> , 2021, 41, 1162-1164.	2.0	2
215	Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19. <i>Cancer Discovery</i> , 2021, 11, 1336-1344.	7.7	20
216	Acute SARS-CoV-2 pneumonitis with cytotoxic CD8 positive T-lymphocytes: Case report and review of the literature. <i>Pathology Research and Practice</i> , 2021, 220, 153380.	1.0	6
217	Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury. <i>JCI Insight</i> , 2021, 6, .	2.3	86
218	The impact of COVID-19 infection on the cytokine profile of pregnant women: A prospective case-control study. <i>Cytokine</i> , 2021, 140, 155431.	1.4	58

#	ARTICLE	IF	CITATIONS
219	Cancer as a prospective sequela of long COVID-19. <i>BioEssays</i> , 2021, 43, e2000331.	1.2	50
220	COVID-19 and the human innate immune system. <i>Cell</i> , 2021, 184, 1671-1692.	13.5	524
221	Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. <i>New England Journal of Medicine</i> , 2021, 384, 1503-1516.	13.9	762
223	Endothelial cell, myeloid, and adaptive immune responses in SARS-CoV-2 infection. <i>FASEB Journal</i> , 2021, 35, e21577.	0.2	13
224	Immunoglobulin G Immune Complexes May Contribute to Neutrophil Activation in the Course of Severe Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021, 224, 575-585.	1.9	23
225	An Immuno-Cardiac Model for Macrophage-Mediated Inflammation in COVID-19 Hearts. <i>Circulation Research</i> , 2021, 129, 33-46.	2.0	40
226	Dynamic changes in serum IL-6, IL-8, and IL-10 predict the outcome of ICU patients with severe COVID-19. <i>Annals of Palliative Medicine</i> , 2021, 10, 3706-3714.	0.5	44
227	Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19. <i>Cell</i> , 2021, 184, 1836-1857.e22.	13.5	167
228	Gout, Rheumatoid Arthritis, and the Risk of Death Related to Coronavirus Disease 2019: An Analysis of the UK Biobank. <i>ACR Open Rheumatology</i> , 2021, 3, 333-340.	0.9	37
229	Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 349-359.	5.2	161
230	Association of Psychiatric Disorders With Mortality Among Patients With COVID-19. <i>JAMA Psychiatry</i> , 2021, 78, 380.	6.0	263
231	The Prospects of tumor necrosis factor \pm inhibitors use in patients with COVID-19. <i>Sovremennaya Revmatologiya</i> , 2021, 15, 89-93.	0.1	0
234	Attenuating the Effects of Novel COVID-19 (SARS-CoV-2) Infection-Induced Cytokine Storm and the Implications. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 1487-1510.	1.6	50
235	The cytokine storm in COVID-19: Further advances in our understanding the role of specific chemokines involved. <i>Cytokine and Growth Factor Reviews</i> , 2021, 58, 82-91.	3.2	81
236	Critical Illness and Systemic Inflammation Are Key Risk Factors of Severe Acute Kidney Injury in Patients With COVID-19. <i>Kidney International Reports</i> , 2021, 6, 905-915.	0.4	22
237	COVID-19 is not over and age is not enough: Using frailty for prognostication in hospitalized patients. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 1116-1127.	1.3	60
238	Dual Nature of Type I Interferons in SARS-CoV-2-Induced Inflammation. <i>Trends in Immunology</i> , 2021, 42, 312-322.	2.9	86
240	The initial infectious dose of SARS-CoV-2 and the severity of the disease: possible impact on the incubation period. <i>Future Virology</i> , 2021, 16, 369-373.	0.9	3

#	ARTICLE	IF	CITATIONS
241	Neuron-specific enolase serum levels in COVID-19 are related to the severity of lung injury. PLoS ONE, 2021, 16, e0251819.	1.1	15
242	Cellular and plasma proteomic determinants of COVID-19 and non-COVID-19 pulmonary diseases relative to healthy aging. Nature Aging, 2021, 1, 535-549.	5.3	22
243	Increased Peripheral Blood Neutrophil Activation Phenotypes and Neutrophil Extracellular Trap Formation in Critically Ill Coronavirus Disease 2019 (COVID-19) Patients: A Case Series and Review of the Literature. Clinical Infectious Diseases, 2022, 74, 479-489.	2.9	87
244	Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials. Lung, 2021, 199, 239-248.	1.4	24
245	Single-cell RNA sequencing of blood antigen-presenting cells in severe COVID-19 reveals multi-process defects in antiviral immunity. Nature Cell Biology, 2021, 23, 538-551.	4.6	114
246	Impact of age to ferritin and neutrophilâ€”lymphocyte ratio as biomarkers for intensive care requirement and mortality risk in COVIDâ€”19 patients in Makassar, Indonesia. Physiological Reports, 2021, 9, e14876.	0.7	14
247	Infectionâ€”induced inflammation from specific inborn errors of immunity to COVIDâ€”19. FEBS Journal, 2021, 288, 5021-5041.	2.2	12
248	Galectin-9, a Player in Cytokine Release Syndrome and a Surrogate Diagnostic Biomarker in SARS-CoV-2 Infection. MBio, 2021, 12, .	1.8	53
250	TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation. Cell, 2021, 184, 2618-2632.e17.	13.5	80
251	Circulating extracellular vesicles are endowed with enhanced procoagulant activity in SARS-CoV-2 infection. EBioMedicine, 2021, 67, 103369.	2.7	61
252	Pointâ€”ofâ€”care detection of cytokines in cytokine storm management and beyond: Significance and challenges. View, 2021, 2, 20210003.	2.7	37
254	Bidirectional associations and common inflammatory biomarkers in COVID-19 and mental health disorders: A window of opportunity for future research?. Brain, Behavior, & Immunity - Health, 2021, 13, 100237.	1.3	10
255	In Vivo Models to Study the Pathogenesis of Extra-Respiratory Complications of Influenza A Virus Infection. Viruses, 2021, 13, 848.	1.5	7
256	Association of endothelial activation assessed through endothelin-I precursor peptide measurement with mortality in COVID-19 patients: an observational analysis. Respiratory Research, 2021, 22, 148.	1.4	7
257	Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses. Pathogens, 2021, 10, 565.	1.2	57
258	Time for tocilizumab in COVID-19?. Intensive Care Medicine, 2021, 47, 692-694.	3.9	8
260	The intersection of COVID-19 and cancer: signaling pathways and treatment implications. Molecular Cancer, 2021, 20, 76.	7.9	42
261	IL-6â€”based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts. Journal of Allergy and Clinical Immunology, 2021, 147, 1652-1661.e1.	1.5	14

#	ARTICLE	IF	CITATIONS
262	Therapeutic strategies to fight COVID-19: Which is the <i>status artis</i> ? British Journal of Pharmacology, 2022, 179, 2128-2148.	2.7	33
263	Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet, The, 2021, 397, 1637-1645.	6.3	1,374
265	High levels of TNF α in patients with COVID-19 refractory to tocilizumab. European Journal of Cancer, 2021, 149, 102-104.	1.3	5
267	COVID-19 in trauma: a propensity-matched analysis of COVID and non-COVID trauma patients. European Journal of Trauma and Emergency Surgery, 2021, 47, 1335-1342.	0.8	12
268	Tocilizumab in COVID-19: some clarity amid controversy. Lancet, The, 2021, 397, 1599-1601.	6.3	29
269	Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Reports Medicine, 2021, 2, 100287.	3.3	183
270	Peripheral and lung resident memory T cell responses against SARS-CoV-2. Nature Communications, 2021, 12, 3010.	5.8	111
271	Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. Infectious Diseases of Poverty, 2021, 10, 71.	1.5	42
273	Immune profiling of COVID-19: preliminary findings and implications for the pandemic. , 2021, 9, e002550.		15
274	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. Advanced Drug Delivery Reviews, 2021, 172, 314-338.	6.6	75
275	Soft Wearable Healthcare Materials and Devices. Advanced Healthcare Materials, 2021, 10, e2100577.	3.9	71
276	Functional and Radiological Improvement in a COVID-19 Pneumonia Patient Treated With Steroids. Cureus, 2021, 13, e15257.	0.2	0
277	Current Strategies of Antiviral Drug Discovery for COVID-19. Frontiers in Molecular Biosciences, 2021, 8, 671263.	1.6	75
278	Delayed production of neutralizing antibodies correlates with fatal COVID-19. Nature Medicine, 2021, 27, 1178-1186.	15.2	183
279	Shared inflammatory pathways and therapeutic strategies in COVID-19 and cancer immunotherapy. , 2021, 9, e002392.		9
280	Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic. Phytomedicine Plus, 2021, 1, 100027.	0.9	23
283	Organoids to Dissect Gastrointestinal Virus-Host Interactions: What Have We Learned?. Viruses, 2021, 13, 999.	1.5	11
284	Efficacy of a Polyphenolic, Standardized Green Tea Extract for the Treatment of COVID-19 Syndrome: A Proof-of-Principle Study. Covid, 2021, 1, 2-12.	0.7	21

#	ARTICLE	IF	CITATIONS
287	Differential Cytokine Signatures of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Influenza Infection Highlight Key Differences in Pathobiology. <i>Clinical Infectious Diseases</i> , 2022, 74, 254-262.	2.9	28
292	Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19. <i>Leukemia</i> , 2021, 35, 2710-2714.	3.3	42
295	African Americans and European Americans exhibit distinct gene expression patterns across tissues and tumors associated with immunologic functions and environmental exposures. <i>Scientific Reports</i> , 2021, 11, 9905.	1.6	15
296	SARS-CoV-2 uses a multipronged strategy to impede host protein synthesis. <i>Nature</i> , 2021, 594, 240-245.	13.7	182
297	TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. <i>Nature Immunology</i> , 2021, 22, 829-838.	7.0	364
298	High levels of eicosanoids and docosanoids in the lungs of intubated COVID-19 patients. <i>FASEB Journal</i> , 2021, 35, e21666.	0.2	95
299	Impact of COVID-19 in Liver Disease Progression. <i>Hepatology Communications</i> , 2021, 5, 1138-1150.	2.0	39
300	Temporal Kinetics of RNAemia and Associated Systemic Cytokines in Hospitalized COVID-19 Patients. <i>MSphere</i> , 2021, 6, e0031121.	1.3	15
301	COVID-19 Severity in Obesity: Leptin and Inflammatory Cytokine Interplay in the Link Between High Morbidity and Mortality. <i>Frontiers in Immunology</i> , 2021, 12, 649359.	2.2	47
302	Immune-Based Prediction of COVID-19 Severity and Chronicity Decoded Using Machine Learning. <i>Frontiers in Immunology</i> , 2021, 12, 700782.	2.2	108
303	Interleukin-6: obstacles to targeting a complex cytokine in critical illness. <i>Lancet Respiratory Medicine</i> , 2021, 9, 643-654.	5.2	120
304	Immunological imprinting of the antibody response in COVID-19 patients. <i>Nature Communications</i> , 2021, 12, 3781.	5.8	149
305	Progress in cardiac research: from rebooting cardiac regeneration to a complete cell atlas of the heart. <i>Cardiovascular Research</i> , 2021, 117, 2161-2174.	1.8	23
306	Cytokine Release Syndrome By T-cell "Redirecting Therapies: Can We Predict and Modulate Patient Risk?. <i>Clinical Cancer Research</i> , 2021, 27, 6083-6094.	3.2	9
307	IL-13 is a driver of COVID-19 severity. <i>JCI Insight</i> , 2021, 6, .	2.3	80
308	Analysis of sex-specific risk factors and clinical outcomes in COVID-19. <i>Communications Medicine</i> , 2021, 1, .	1.9	23
309	On the role of artificial intelligence in medical imaging of COVID-19. <i>Patterns</i> , 2021, 2, 100269.	3.1	41
311	Cytokine signatures of end organ injury in COVID-19. <i>Scientific Reports</i> , 2021, 11, 12606.	1.6	24

#	ARTICLE	IF	CITATIONS
312	Replication Kinetics, Cell Tropism, and Associated Immune Responses in SARS-CoV-2- and H5N1 Virus-Infected Human Induced Pluripotent Stem Cell-Derived Neural Models. <i>MSphere</i> , 2021, 6, e0027021.	1.3	26
313	Intestinal Host Response to SARS-CoV-2 Infection and COVID-19 Outcomes in Patients With Gastrointestinal Symptoms. <i>Gastroenterology</i> , 2021, 160, 2435-2450.e34.	0.6	118
315	Prognostic parameters of in-hospital mortality in COVID-19 patients: An Italian experience. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13629.	1.7	31
316	COVID-19 Gastrointestinal Symptoms and Attenuation of the Immune Response to SARS-CoV-2. <i>Gastroenterology</i> , 2021, 160, 2251-2254.	0.6	4
317	Unbiased identification of clinical characteristics predictive of COVID-19 severity. <i>Clinical and Experimental Medicine</i> , 2022, 22, 137-149.	1.9	2
318	Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk. <i>Annals of Pharmacotherapy</i> , 2021, , 106002802110288.	0.9	7
320	Dissecting the common and compartment-specific features of COVID-19 severity in the lung and periphery with single-cell resolution. <i>IScience</i> , 2021, 24, 102738.	1.9	6
321	Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19. <i>Scientific Reports</i> , 2021, 11, 13308.	1.6	50
322	Mucosal-associated invariant T cell responses differ by sex in COVID-19. <i>Med</i> , 2021, 2, 755-772.e5.	2.2	24
323	Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease. <i>Immunity</i> , 2021, 54, 1257-1275.e8.	6.6	230
324	The Conundrum of "Long-COVID-19": A Narrative Review. <i>International Journal of General Medicine</i> , 2021, Volume 14, 2491-2506.	0.8	111
325	Senolytics reduce coronavirus-related mortality in old mice. <i>Science</i> , 2021, 373, .	6.0	184
326	Multi-dimensional and longitudinal systems profiling reveals predictive pattern of severe COVID-19. <i>IScience</i> , 2021, 24, 102752.	1.9	9
327	COVID-19: Sleep, Circadian Rhythms and Immunity " Repurposing Drugs and Chronotherapeutics for SARS-CoV-2. <i>Frontiers in Neuroscience</i> , 2021, 15, 674204.	1.4	8
328	COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. , 2021, 9, e002630.		76
329	Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection. <i>Journal of Translational Medicine</i> , 2021, 19, 272.	1.8	19
330	Cytokine Overproduction and Immune System Dysregulation in alloHSCT and COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 658896.	2.2	14
332	Acute Respiratory Distress Syndrome and Time to Weaning Off the Invasive Mechanical Ventilator among Patients with COVID-19 Pneumonia. <i>Journal of Clinical Medicine</i> , 2021, 10, 2935.	1.0	11

#	ARTICLE	IF	CITATIONS
333	A single transcript for the prognosis of disease severity in COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 12174.	1.6	9
334	Relative COVID-19 Viral Persistence and Antibody Kinetics. <i>Pathogens</i> , 2021, 10, 752.	1.2	9
335	The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer. <i>ESMO Open</i> , 2021, 6, 100123.	2.0	10
336	COVID-19 and RA share an SPP1 myeloid pathway that drives PD-L1+ neutrophils and CD14+ monocytes. <i>JCI Insight</i> , 2021, 6, .	2.3	35
337	Single-cell epigenomic landscape of peripheral immune cells reveals establishment of trained immunity in individuals convalescing from COVID-19. <i>Nature Cell Biology</i> , 2021, 23, 620-630.	4.6	67
338	Neutrophils and COVID-19: Active Participants and Rational Therapeutic Targets. <i>Frontiers in Immunology</i> , 2021, 12, 680134.	2.2	54
339	Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19. <i>European Journal of Internal Medicine</i> , 2021, 88, 52-62.	1.0	14
340	Distinct cytokine profiles associated with COVID-19 severity and mortality. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 2098-2107.	1.5	47
341	Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context. <i>Lancet Respiratory Medicine</i> , 2021, 9, 655-664.	5.2	88
342	Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19. <i>Npj Regenerative Medicine</i> , 2021, 6, 37.	2.5	31
343	TNF α -Induced LDL Cholesterol Accumulation Involve Elevated LDLR Cell Surface Levels and SR-B1 Downregulation in Human Arterial Endothelial Cells. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6236.	1.8	7
344	Glycyrrhizic Acid for COVID-19: Findings of Targeting Pivotal Inflammatory Pathways Triggered by SARS-CoV-2. <i>Frontiers in Pharmacology</i> , 2021, 12, 631206.	1.6	18
345	Soluble Suppression of Tumorigenicity-2 Associates With Ventilator Dependence in Coronavirus Disease 2019 Respiratory Failure. , 2021, 3, e0480.		5
346	Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?. <i>Journal of Clinical Neuroscience</i> , 2021, 88, 163-172.	0.8	35
347	Strategies to DAMPen COVID-19-mediated lung and systemic inflammation and vascular injury. <i>Translational Research</i> , 2021, 232, 37-48.	2.2	30
348	SARS-CoV-2 Infection and Significance of Oral Health Management in the Era of "the New Normal with COVID-19". <i>International Journal of Molecular Sciences</i> , 2021, 22, 6527.	1.8	15
349	Caracterizaço Demogrfica, Curso Clnico e Fatores de Risco para Mortalidade em Doentes Hospitalizados com COVID-19: Experincia de um Hospital Tercirio Portugus na Primeira Vaga da Pandemia. <i>Revista De Medicina Intern, Neurologie, Psihiatrie, Neurochirurgie, Dermato-venerologie Medicina Intern</i> , 2021, 28, 145-154.	0.0	1
351	Predication of oxygen requirement in COVID-19 patients using dynamic change of inflammatory markers: CRP, hypertension, age, neutrophil and lymphocyte (CHANeL). <i>Scientific Reports</i> , 2021, 11, 13026.	1.6	10

#	ARTICLE	IF	CITATIONS
353	Encephalopathies Associated With Severe COVID-19 Present Neurovascular Unit Alterations Without Evidence for Strong Neuroinflammation. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	34
354	Extracorporeal Blood Purification in Moderate and Severe COVID-19 Patients: A Prospective Cohort Study. <i>Blood Purification</i> , 2022, 51, 233-242.	0.9	18
355	A comprehensive insight into the role of zinc deficiency in the renin-angiotensin and kinin-kallikrein system dysfunctions in COVID-19 patients. <i>Saudi Journal of Biological Sciences</i> , 2021, 28, 3540-3547.	1.8	4
357	End-stage kidney disease and COVID-19 in an urban safety-net hospital in Boston, Massachusetts. <i>PLoS ONE</i> , 2021, 16, e0252679.	1.1	4
360	Distinct clinical and immunological profiles of patients with evidence of SARS-CoV-2 infection in sub-Saharan Africa. <i>Nature Communications</i> , 2021, 12, 3554.	5.8	21
361	Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19. <i>Advanced Drug Delivery Reviews</i> , 2021, 178, 113848.	6.6	6
362	An Impaired Inflammatory and Innate Immune Response in COVID-19. <i>Molecules and Cells</i> , 2021, 44, 384-391.	1.0	13
363	COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma. <i>HemaSphere</i> , 2021, 5, e603.	1.2	35
364	Clinical significance of measuring serum cytokine levels as inflammatory biomarkers in adult and pediatric COVID-19 cases: A review. <i>Cytokine</i> , 2021, 142, 155478.	1.4	57
365	Notch4 signaling limits regulatory T-cell-mediated tissue repair and promotes severe lung inflammation in viral infections. <i>Immunity</i> , 2021, 54, 1186-1199.e7.	6.6	71
366	COVID-19 ARDS is characterized by higher extravascular lung water than non-COVID-19 ARDS: the PiCCOVID study. <i>Critical Care</i> , 2021, 25, 186.	2.5	32
368	Lessons from a local effort to screen for SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, e2108044118.	3.3	1
369	SARS-CoV-2 infection paralyzes cytotoxic and metabolic functions of the immune cells. <i>Heliyon</i> , 2021, 7, e07147.	1.4	15
370	Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19. <i>Cell Discovery</i> , 2021, 7, 42.	3.1	23
371	SARS-CoV-2 signaling pathway map: A functional landscape of molecular mechanisms in COVID-19. <i>Journal of Cell Communication and Signaling</i> , 2021, 15, 601-608.	1.8	15
372	SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target. <i>Cell Research</i> , 2021, 31, 847-860.	5.7	102
373	Intermediate versus standard dose heparin prophylaxis in COVID-19 ICU patients: A propensity score-matched analysis. <i>Thrombosis Research</i> , 2021, 203, 57-60.	0.8	8
374	The Quality of SARS-CoV-2â€“Specific T Cell Functions Differs in Patients with Mild/Moderate versus Severe Disease, and T Cells Expressing Coinhibitory Receptors Are Highly Activated. <i>Journal of Immunology</i> , 2021, 207, 1099-1111.	0.4	34

#	ARTICLE	IF	CITATIONS
376	Discovery of potential imaging and therapeutic targets for severe inflammation in COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 14151.	1.6	8
377	Relevance of BET Family Proteins in SARS-CoV-2 Infection. <i>Biomolecules</i> , 2021, 11, 1126.	1.8	11
378	Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 230.	3.8	139
379	Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. <i>Cell Reports</i> , 2021, 36, 109414.	2.9	75
380	Serum IL-6: A potential biomarker of mortality among SARS-CoV-2 infected patients in Mexico. <i>Cytokine</i> , 2021, 143, 155543.	1.4	14
381	Boosted Pro-Inflammatory Activity in Human PBMCs by Lipopolysaccharide and SARS-CoV-2 Spike Protein Is Regulated by α -1 Antitrypsin. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7941.	1.8	10
382	The RECOVERY trial: cardiovascular implications of a large, simple randomized trial in COVID-19. <i>Cardiovascular Research</i> , 2021, 117, e110-e113.	1.8	3
383	Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein. <i>Phytomedicine</i> , 2021, 87, 153583.	2.3	30
384	Acute Lung Injury Biomarkers in the Prediction of COVID-19 Severity: Total Thiol, Ferritin and Lactate Dehydrogenase. <i>Antioxidants</i> , 2021, 10, 1221.	2.2	23
386	Potential of Point-of-Care and At-Home Assessment of Immune Status via Rapid Cytokine Detection and Questionnaire-Based Anamnesis. <i>Sensors</i> , 2021, 21, 4960.	2.1	5
388	An aberrant inflammatory response in severe COVID-19. <i>Cell Host and Microbe</i> , 2021, 29, 1043-1047.	5.1	24
389	Lower peripheral blood Toll-like receptor 3 expression is associated with an unfavorable outcome in severe COVID-19 patients. <i>Scientific Reports</i> , 2021, 11, 15223.	1.6	20
390	Delirium and Associated Factors in a Cohort of Hospitalized Patients With Coronavirus Disease 2019. <i>Journal of the Academy of Consultation-Liaison Psychiatry</i> , 2022, 63, 3-13.	0.2	9
391	Insights into Innate Immune Response Against SARS-CoV-2 Infection. <i>Romanian Journal of Laboratory Medicine</i> , 2021, 29, 255-269.	0.1	3
392	Corticosteroids for COVID-19. <i>Journal of Intensive Medicine</i> , 2021, 1, 14-25.	0.8	40
393	Tocilizumab in COVID-19 therapy: who benefits, and how?. <i>Lancet, The</i> , 2021, 398, 299-300.	6.3	6
394	Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. <i>Nature Communications</i> , 2021, 12, 4117.	5.8	170
395	Distinctive features of severe SARS-CoV-2 pneumonia. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	49

#	ARTICLE	IF	CITATIONS
396	Chronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity. <i>Nature Communications</i> , 2021, 12, 4314.	5.8	29
397	COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 29-35.	0.7	37
398	Molecular Mechanisms of Palmitic Acid Augmentation in COVID-19 Pathologies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7127.	1.8	9
399	Complement Anaphylatoxins and Inflammatory Cytokines as Prognostic Markers for COVID-19 Severity and In-Hospital Mortality. <i>Frontiers in Immunology</i> , 2021, 12, 668725.	2.2	49
400	Comprehensive Profiling of Inflammatory Factors Revealed That Growth Differentiation Factor-15 Is an Indicator of Disease Severity in COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 662465.	2.2	20
401	Impact of statins in patients with COVID-19. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 637-640.	0.4	9
404	Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators. <i>American Journal of Pathology</i> , 2021, 191, 1193-1208.	1.9	14
406	Sex-based clinical and immunological differences in COVID-19. <i>BMC Infectious Diseases</i> , 2021, 21, 647.	1.3	33
408	Altered microRNA expression in COVID-19 patients enables identification of SARS-CoV-2 infection. <i>PLoS Pathogens</i> , 2021, 17, e1009759.	2.1	107
409	COVID-19 Recombinant mRNA Vaccines and Serious Ocular Inflammatory Side Effects: Real or Coincidence?. <i>Journal of Ophthalmic and Vision Research</i> , 2021, 16, 490-501.	0.7	62
410	The RNA sensor MDA5 detects SARS-CoV-2 infection. <i>Scientific Reports</i> , 2021, 11, 13638.	1.6	93
411	Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.. <i>EClinicalMedicine</i> , 2021, 37, 100981.	3.2	55
414	Immune Signature Linked to COVID-19 Severity: A SARS-Score for Personalized Medicine. <i>Frontiers in Immunology</i> , 2021, 12, 701273.	2.2	5
415	Chronic Obstructive Pulmonary Disease Patients Have Increased Levels of Plasma Inflammatory Mediators Reported Upregulated in Severe COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 678661.	2.2	7
416	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. <i>Nature Reviews Immunology</i> , 2021, 21, 475-484.	10.6	434
417	Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome. <i>Medicine (United States)</i> , 2021, 100, e26705.	0.4	9
418	Distinct immunological signatures discriminate severe COVID-19 from non-SARS-CoV-2-driven critical pneumonia. <i>Immunity</i> , 2021, 54, 1578-1593.e5.	6.6	75
419	Sensing Inflammation Biomarkers with Electrolyte-Gated Organic Electronic Transistors. <i>Advanced Healthcare Materials</i> , 2021, 10, e2100955.	3.9	16

#	ARTICLE	IF	CITATIONS
420	Structural Insight into the Binding of Cyanovirin-N with the Spike Glycoprotein, Mpro and PLpro of SARS-CoV-2: Protein-Protein Interactions, Dynamics Simulations and Free Energy Calculations. <i>Molecules</i> , 2021, 26, 5114.	1.7	11
421	Comprehensive Analysis of the Systemic Transcriptomic Alternations and Inflammatory Response during the Occurrence and Progress of COVID-19. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 1-17.	1.9	13
423	Wharton's Jelly Mesenchymal Stem Cell-Derived Extracellular Vesicles Reduce SARS-CoV2-Induced Inflammatory Cytokines Under High Glucose and Uremic Toxin Conditions. <i>Stem Cells and Development</i> , 2021, 30, 758-772.	1.1	15
424	Cytokine levels in sputum, not serum, may be more helpful for indicating the damage in the lung and the prognosis of severe COVID-19 – A case series. <i>Journal of Infection</i> , 2021, 83, e6-e9.	1.7	6
426	Different Profiles of Antibodies and Cytokines Were Found Between Severe and Moderate COVID-19 Patients. <i>Frontiers in Immunology</i> , 2021, 12, 723585.	2.2	11
427	Cytokine, cytokine storm and their role in fatalities of COVID-19. <i>Journal of Infectious Diseases and Immunity</i> , 2021, 13, 20-29.	0.3	0
428	COVID-19: Inflammatory Profile. <i>Annual Review of Medicine</i> , 2022, 73, 65-80.	5.0	43
429	Canonical NF- κ B Promotes Lung Epithelial Cell Tumour Growth by Downregulating the Metastasis Suppressor CD82 and Enhancing Epithelial-to-Mesenchymal Cell Transition. <i>Cancers</i> , 2021, 13, 4302.	1.7	2
430	Sex Differences in Immunity to Viral Infections. <i>Frontiers in Immunology</i> , 2021, 12, 720952.	2.2	123
431	CIDO ontology updates and secondary analysis of host responses to COVID-19 infection based on ImmPort reports and literature. <i>Journal of Biomedical Semantics</i> , 2021, 12, 18.	0.9	9
432	A case-control study on the association between periodontitis and coronavirus disease (COVID-19). <i>Journal of Periodontology</i> , 2022, 93, 584-590.	1.7	62
433	Challenges in interpreting cytokine data in COVID-19 affect patient care and management. <i>PLoS Biology</i> , 2021, 19, e3001373.	2.6	7
434	The Association Between Mycobacteria-Specific Antigen-Induced Cytokines and Host Response to Latent Tuberculosis Infection Treatment in a Chinese Population. <i>Frontiers in Microbiology</i> , 2021, 12, 716900.	1.5	6
436	Sex-biased clinical presentation and outcomes from COVID-19. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1072-1073.	2.8	7
437	Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID-19 – Mechanisms and Therapeutic Targets. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-15.	1.9	66
439	Qing-Fei-Pai decoction and wogonoside exert anti-inflammatory action through downregulating USP14 to promote the degradation of activating transcription factor 2. <i>FASEB Journal</i> , 2021, 35, e21870.	0.2	11
440	High-dose intravenous immunoglobulins as a therapeutic option in critical illness polyneuropathy accompanying SARS-CoV-2 infection: A case-based review of the literature (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1182.	0.8	10
441	Severe COVID-19 is associated with endothelial activation and abnormal glycosylation of von Willebrand factor in patients undergoing hemodialysis. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12582.	1.0	10

#	ARTICLE	IF	CITATIONS
442	The incidence of myopericarditis in patients with COVID-19. <i>Journal of Cardiovascular and Thoracic Research</i> , 2021, 13, 203-207.	0.3	6
444	Cerebrospinal fluid in COVID-19 neurological complications: Neuroaxonal damage, anti-SARS-Cov2 antibodies but no evidence of cytokine storm. <i>Journal of the Neurological Sciences</i> , 2021, 427, 117517.	0.3	50
445	The clinical spectrum of SARS-CoV-2 infection in Gaucher disease: Effect of both a pandemic and a rare disease that disrupts the immune system. <i>Molecular Genetics and Metabolism</i> , 2022, 135, 115-121.	0.5	3
446	Severe COVID-19 Patients Show an Increase in Soluble TNFR1 and ADAM17, with a Relationship to Mortality. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8423.	1.8	32
447	Thromboembolism and Bleeding in COVID-19. <i>J</i> , 2021, 4, 476-485.	0.6	1
448	The cytokines HGF and CXCL13 predict the severity and the mortality in COVID-19 patients. <i>Nature Communications</i> , 2021, 12, 4888.	5.8	67
449	Inflammasome activation at the crux of severe COVID-19. <i>Nature Reviews Immunology</i> , 2021, 21, 694-703.	10.6	210
450	Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 368-380.e3.	1.5	59
451	Systemic IL-15, IFN- β , and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients. <i>Cell Reports</i> , 2021, 36, 109504.	2.9	137
452	The NIH Lipo-COVID Study: A Pilot NMR Investigation of Lipoprotein Subfractions and Other Metabolites in Patients with Severe COVID-19. <i>Biomedicines</i> , 2021, 9, 1090.	1.4	22
453	Profound Treg perturbations correlate with COVID-19 severity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	104
454	An Adverse Outcomes Approach to Study the Effects of SARS-CoV-2 in 3D Organoid Models. <i>Journal of Molecular Biology</i> , 2022, 434, 167213.	2.0	6
455	The Immunological Factors Predisposing to Severe Covid-19 Are Already Present in Healthy Elderly and Men. <i>Frontiers in Immunology</i> , 2021, 12, 720090.	2.2	9
456	Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study. <i>Science Immunology</i> , 2021, 6, .	5.6	20
457	COVID19-associated cardiomyocyte dysfunction, arrhythmias and the effect of Canakinumab. <i>PLoS ONE</i> , 2021, 16, e0255976.	1.1	11
459	Low-density lipoprotein cholesterol levels are associated with poor clinical outcomes in COVID-19. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2619-2627.	1.1	26
460	Ablation of PDE4B protects from <i>Pseudomonas aeruginosa</i> -induced acute lung injury in mice by ameliorating the cytostorm and associated hypothermia. <i>FASEB Journal</i> , 2021, 35, e21797.	0.2	5
461	Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection. <i>Journal of Biological Chemistry</i> , 2021, 297, 100925.	1.6	43

#	ARTICLE	IF	CITATIONS
462	Sex and Gender Differences in Testing, Hospital Admission, Clinical Presentation, and Drivers of Severe Outcomes From COVID-19. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab448.	0.4	41
463	Longitudinal metabolomics of human plasma reveals prognostic markers of COVID-19 disease severity. <i>Cell Reports Medicine</i> , 2021, 2, 100369.	3.3	61
464	Electroanatomic substrate of atrial fibrillation in patients after COVID-19. <i>Russian Journal of Cardiology</i> , 2021, 26, 4526.	0.4	5
465	COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 713560.	1.1	76
466	Anti-inflammatory effects of GLP-1 in patients with COVID-19. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 373-381.	2.0	12
467	Effect of BCG vaccination on proinflammatory responses in elderly individuals. <i>Science Advances</i> , 2021, 7, .	4.7	23
468	To zinc or not to zinc for COVID-19 prophylaxis or treatment?. <i>Journal of Medical Microbiology</i> , 2021, 70, .	0.7	4
469	Single-cell transcriptome identifies FCGR3B upregulated subtype of alveolar macrophages in patients with critical COVID-19. <i>iScience</i> , 2021, 24, 103030.	1.9	13
470	Elements of Th1/Th2 response and disease severity in COVID-19 patients: A short report. <i>Journal of Medical Virology</i> , 2022, 94, 404-406.	2.5	4
472	A Biosafety Level 2 Mouse Model for Studying Betacoronavirus-Induced Acute Lung Damage and Systemic Manifestations. <i>Journal of Virology</i> , 2021, 95, e0127621.	1.5	23
473	Risk Factors of Mortality for Patients Receiving Venovenous Extracorporeal Membrane Oxygenation for COVID-19 Acute Respiratory Distress Syndrome. <i>Surgical Infections</i> , 2021, 22, 1086-1092.	0.7	16
474	Ultraviolet-A light reduces cellular cytokine release from human endotracheal cells infected with Coronavirus. <i>Photodiagnosis and Photodynamic Therapy</i> , 2021, 35, 102457.	1.3	2
475	A systematic review on the effects of Echinacea supplementation on cytokine levels: Is there a role in COVID-19?. <i>Metabolism Open</i> , 2021, 11, 100115.	1.4	15
476	Hypotheses on the neuroimmune cross-talk between COVID-19 and neuropsychiatric disorders. <i>Psychoneuroendocrinology</i> , 2021, 131, 105359.	1.3	0
478	Complex biological patterns of soluble cytokines and CD163 in childhood necessitating age-specific reference intervals for evidence-based clinical interpretation. <i>Clinical Biochemistry</i> , 2021, 98, 35-41.	0.8	1
479	Respiratory Nasal Mucosa in Chronic Rhinosinusitis with Nasal Polyps versus COVID-19: Histopathology, Electron Microscopy Analysis and Assessing of Tissue Interleukin-33. <i>Journal of Clinical Medicine</i> , 2021, 10, 4110.	1.0	10
480	Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. <i>Science Immunology</i> , 2021, 6, eabd0205.	5.6	26
481	Antibiotic Prescriptions Targeting Bacterial Respiratory Infections in Admitted Patients with COVID-19: A Prospective Observational Study. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2575-2591.	1.8	7

#	ARTICLE	IF	CITATIONS
482	COVID-19 vaccine-induced myocarditis: Case report with literature review. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2021, 15, 102205.	1.8	65
483	Focus on the decisions to forego life-sustaining therapies during ICU stay of patients with cirrhosis and COVID-19: a case control study from the prospective COVID-ICU database. <i>Journal of Hepatology</i> , 2021, , .	1.8	2
484	Single-cell analysis of COVID-19, sepsis, and HIV infection reveals hyperinflammatory and immunosuppressive signatures in monocytes. <i>Cell Reports</i> , 2021, 37, 109793.	2.9	29
485	Tie2 activation protects against prothrombotic endothelial dysfunction in COVID-19. <i>JCI Insight</i> , 2021, 6, .	2.3	35
486	COVID-19 and obesity: fighting two pandemics with intermittent fasting. <i>Trends in Endocrinology and Metabolism</i> , 2021, 32, 706-720.	3.1	23
487	Commentary: Special care considerations in older adults hospitalized with COVID-19. <i>Aging and Health Research</i> , 2021, 1, 100023.	0.5	1
488	Interleukin-6 as potential mediator of long-term neuropsychiatric symptoms of COVID-19. <i>Psychoneuroendocrinology</i> , 2021, 131, 105295.	1.3	83
489	Biomarkers of Post-COVID Depression. <i>Journal of Clinical Medicine</i> , 2021, 10, 4142.	1.0	52
490	Circulating acetylated polyamines correlate with Covid-19 severity in cancer patients. <i>Aging</i> , 2021, 13, 20860-20885.	1.4	9
491	Identification of potential therapeutic targets and mechanisms of COVID-19 through network analysis and screening of chemicals and herbal ingredients. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	14
492	Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions. <i>Translational Psychiatry</i> , 2021, 11, 499.	2.4	35
493	Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. <i>Immunity</i> , 2021, 54, 2143-2158.e15.	6.6	155
495	Estradiol Inhibits Human Brain Vascular Pericyte Migration Activity: A Functional and Transcriptomic Analysis. <i>Cells</i> , 2021, 10, 2314.	1.8	6
497	Factors associated with inflamm-aging in institutionalized older people. <i>Scientific Reports</i> , 2021, 11, 18333.	1.6	4
498	Pregnancy alters interleukin-1 beta expression and antiviral antibody responses during severe acute respiratory syndrome coronavirus 2 infection. <i>American Journal of Obstetrics and Gynecology</i> , 2021, 225, 301.e1-301.e14.	0.7	27
499	Uncovering the Depths of the Human Proteome: Antibody-based Technologies for Ultrasensitive Multiplexed Protein Detection and Quantification. <i>Molecular and Cellular Proteomics</i> , 2021, 20, 100155.	2.5	36
500	The Serum Metabolome of Moderate and Severe COVID-19 Patients Reflects Possible Liver Alterations Involving Carbon and Nitrogen Metabolism. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9548.	1.8	56
501	On Deep Landscape Exploration of COVID-19 Patients Cells and Severity Markers. <i>Frontiers in Immunology</i> , 2021, 12, 705646.	2.2	9

#	ARTICLE	IF	CITATIONS
502	Increased Hepatic Expression of SARS-CoV-2 Entry Points and Proinflammatory Cytokines in Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 239-241.e3.	2.4	3
503	Sex Differences in Respiratory Viral Pathogenesis and Treatments. <i>Annual Review of Virology</i> , 2021, 8, 393-414.	3.0	39
505	Sex Differences in Adverse Reactions to an Inactivated SARS-CoV-2 Vaccine Among Medical Staff in China. <i>Frontiers in Medicine</i> , 2021, 8, 731593.	1.2	10
506	Impact of SARS-CoV-2 Infection (COVID-19) on Cytochromes P450 Activity Assessed by the Geneva Cocktail. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 110, 1358-1367.	2.3	36
507	LOX-1-Expressing Immature Neutrophils Identify Critically-Ill COVID-19 Patients at Risk of Thrombotic Complications. <i>Frontiers in Immunology</i> , 2021, 12, 752612.	2.2	14
508	Alterations in Circulating Monocytes Predict COVID-19 Severity and Include Chromatin Modifications Still Detectable Six Months after Recovery. <i>Biomedicines</i> , 2021, 9, 1253.	1.4	28
509	Fatal cytokine release syndrome by an aberrant FLIP/STAT3 axis. <i>Cell Death and Differentiation</i> , 2022, 29, 420-438.	5.0	14
510	Coronavirus induces diabetic macrophage-mediated inflammation via SETDB2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	26
511	Accumulation of CD28null Senescent T-Cells Is Associated with Poorer Outcomes in COVID19 Patients. <i>Biomolecules</i> , 2021, 11, 1425.	1.8	12
512	Discrimination of COVID-19 From Inflammation-Induced Cytokine Storm Syndromes Using Disease-Related Blood Biomarkers. <i>Arthritis and Rheumatology</i> , 2021, 73, 1791-1799.	2.9	36
513	COVID-19 prevalence and outcomes in patients receiving biologic therapies at an infusion center in New York City. <i>Clinical Immunology</i> , 2021, 230, 108803.	1.4	3
514	Use of Tocilizumab May Avoid the Need of Invasive Ventilation. <i>Cureus</i> , 2021, 13, e17822.	0.2	0
515	Clinical value of blood markers to assess the severity of coronavirus disease 2019. <i>BMC Infectious Diseases</i> , 2021, 21, 921.	1.3	13
517	Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e638-e647.	2.2	30
518	Tumor Necrosis Factor-Alpha Exacerbates Viral Entry in SARS-CoV2-Infected iPSC-Derived Cardiomyocytes. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9869.	1.8	11
519	COVID-19 and chronic kidney disease: a comprehensive review. <i>Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia</i> , 2021, 43, 383-399.	0.4	32
521	Perforin, COVID-19 and a possible pathogenic auto-inflammatory feedback loop. <i>Scandinavian Journal of Immunology</i> , 2021, 94, e13102.	1.3	11
522	A hitchhiker's guide through the COVID-19 galaxy. <i>Clinical Immunology</i> , 2021, 232, 108849.	1.4	3

#	ARTICLE	IF	CITATIONS
523	Mechanisms underlying host defense and disease pathology in response to severe acute respiratory syndrome (SARS)-CoV2 infection: insights from inborn errors of immunity. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2021, 21, 515-524.	1.1	19
524	Biochemistry tests in hospitalized COVID-19 patients: Experience from a Canadian tertiary care centre. <i>Clinical Biochemistry</i> , 2021, 95, 41-48.	0.8	4
525	Self-sustaining IL-8 loops drive a prothrombotic neutrophil phenotype in severe COVID-19. <i>JCI Insight</i> , 2021, 6, .	2.3	71
526	High-value laboratory testing for hospitalized COVID-19 patients: a review. <i>Future Virology</i> , 2021, 16, 691-705.	0.9	11
527	The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection. <i>European Respiratory Journal</i> , 2022, 59, 2100769.	3.1	17
528	Scientific evidence in the COVID-19 treatment: A comprehensive review. <i>World Journal of Virology</i> , 2021, 10, 217-228.	1.3	6
529	Distinct Patterns of Blood Cytokines Beyond a Cytokine Storm Predict Mortality in COVID-19. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 4651-4667.	1.6	24
530	Retrospective analysis of anti-inflammatory therapies during the first wave of COVID-19 at a community hospital. <i>World Journal of Critical Care Medicine</i> , 2021, 10, 244-259.	0.8	2
531	Performance of the Roche IL-6 chemiluminescent immunoassay in patients with COVID-like respiratory symptoms. <i>Journal of Virological Methods</i> , 2021, 296, 114224.	1.0	13
532	Polyphenylene carboxymethylene (PPCM) microbicide repurposed as antiviral against SARS-CoV-2. Proof of concept in primary human undifferentiated epithelial cells. <i>Antiviral Research</i> , 2021, 194, 105162.	1.9	6
533	Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients. <i>Clinical Immunology</i> , 2021, 231, 108828.	1.4	6
534	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	72
535	Evaluation of adalimumab effects in managing severe cases of COVID-19: A randomized controlled trial. <i>International Immunopharmacology</i> , 2021, 99, 107961.	1.7	21
536	Structure-based study of immune receptors as eligible binding targets of coronavirus SARS-CoV-2 spike protein. <i>Journal of Molecular Graphics and Modelling</i> , 2021, 108, 107997.	1.3	3
537	Post-acute sequelae of COVID-19: Evidence of mood & cognitive impairment. <i>Brain, Behavior, & Immunity - Health</i> , 2021, 17, 100347.	1.3	59
538	Synthesis of novel calcium channel blockers with ACE2 inhibition and dual antihypertensive/anti-inflammatory effects: A possible therapeutic tool for COVID-19. <i>Bioorganic Chemistry</i> , 2021, 116, 105272.	2.0	13
539	A distinct association of inflammatory molecules with outcomes of COVID-19 in younger versus older adults. <i>Clinical Immunology</i> , 2021, 232, 108857.	1.4	4
540	Increased LPS levels coexist with systemic inflammation and result in monocyte activation in severe COVID-19 patients. <i>International Immunopharmacology</i> , 2021, 100, 108125.	1.7	40

#	ARTICLE	IF	CITATIONS
541	Cytokine storm in the pathophysiology of COVID-19: Possible functional disturbances of miRNAs. <i>International Immunopharmacology</i> , 2021, 101, 108172.	1.7	19
542	COVID-19, what could sepsis, severe acute pancreatitis, gender differences, and aging teach us?. <i>Cytokine</i> , 2021, 148, 155628.	1.4	12
543	The pulmonary pathology of COVID-19. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 137-150.	1.4	123
544	Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. <i>Stem Cells Translational Medicine</i> , 2021, 10, 660-673.	1.6	281
545	A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2021, 23, e13556.	0.7	17
546	COVID-19 Antiviral and Treatment Candidates: Current Status. <i>Immune Network</i> , 2021, 21, e7.	1.6	8
548	Response to a massive SARS-CoV-2 infection in a nursing home transformed into a caring center. <i>Ageing Clinical and Experimental Research</i> , 2021, 33, 443-450.	1.4	3
549	Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e146.	0.3	25
550	Antiviral activity of Brazilian Green Propolis extract against SARS-CoV-2 (Severe Acute Respiratory) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	0.6	26
551	Development and Evaluation of a Machine Learning-Based In-Hospital COVID-19 Disease Outcome Predictor (CODOP): A Multicontinental Retrospective Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
552	On the role of bacterial metalloproteases in COVID-19 associated cytokine storm. <i>Cell Communication and Signaling</i> , 2021, 19, 7.	2.7	5
554	Serotonin is elevated in COVID-19-associated diarrhoea. <i>Gut</i> , 2021, 70, 2015-2017.	6.1	42
555	Current advances in the detection of COVID-19 and evaluation of the humoral response. <i>Analyst, The</i> , 2021, 146, 382-402.	1.7	25
556	Pancytopenia and Profound Neutropenia as a Sequela of Severe SARS-CoV-2 Infection (COVID-19) With Concern for Bone Marrow Involvement. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab017.	0.4	7
558	Current state of vaccine development and targeted therapies for COVID-19: impact of basic science discoveries. <i>Cardiovascular Pathology</i> , 2021, 50, 107278.	0.7	55
560	Background to new treatments for COVID-19, including its chronicity, through altering elements of the cytokine storm. <i>Reviews in Medical Virology</i> , 2021, 31, 1-13.	3.9	82
561	COVID-19 and Cancer: Current Challenges and Perspectives. <i>Cancer Cell</i> , 2020, 38, 629-646.	7.7	196
562	Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19. <i>ACS Biomaterials Science and Engineering</i> , 2021, 7, 1742-1764.	2.6	16

#	ARTICLE	IF	CITATIONS
563	Old friends meet a new foe. <i>Evolution, Medicine and Public Health</i> , 2020, 2020, 234-248.	1.1	31
564	COVID 19: in the eye of the cytokine storm. <i>European Heart Journal</i> , 2021, 42, 150-151.	1.0	15
565	Coronavirus disease 2019 and neurodegenerative disease: what will the future bring?. <i>Current Opinion in Psychiatry</i> , 2021, 34, 177-185.	3.1	26
601	Intravenous Immunoglobulin for the Treatment of COVID-19: A Promising Tool. <i>Respiration</i> , 2020, 99, 1087-1089.	1.2	21
602	Immunopathology of galectin-3: an increasingly promising target in COVID-19. <i>F1000Research</i> , 2020, 9, 1078.	0.8	23
603	Immunopathology of galectin-3: an increasingly promising target in COVID-19. <i>F1000Research</i> , 2020, 9, 1078.	0.8	59
604	Infection of human Nasal Epithelial Cells with SARS-CoV-2 and a 382-nt deletion isolate lacking ORF8 reveals similar viral kinetics and host transcriptional profiles. <i>PLoS Pathogens</i> , 2020, 16, e1009130.	2.1	98
605	A Disintegrin and Metalloproteinaseâ€”Control Elements in Infectious Diseases. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 608281.	1.1	11
606	Skin and gastrointestinal symptoms in COVID-19. <i>Przegląd Gastroenterologiczny</i> , 2020, 15, 301-308.	0.3	4
607	Integrated miRNA/Cytokine/Chemokine Profiling Reveals Severity-Associated Step Changes and Principal Correlates of Fatality in COVID-19. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
608	Disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic in Marchâ€”October 2020: An exploratory analysis. <i>PLoS ONE</i> , 2021, 16, e0245103.	1.1	1
610	Long Term Immune Response Produced by the SputnikV Vaccine. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11211.	1.8	9
611	A historical cohort study to investigation of statins safety in COVID-19 hospitalized patients. <i>Therapie</i> , 2022, 77, 453-460.	0.6	3
612	Comorbidity-associated glutamine deficiency is a predisposition to severe COVID-19. <i>Cell Death and Differentiation</i> , 2021, 28, 3199-3213.	5.0	37
614	Cytokine signature and COVID-19 prediction models in the two waves of pandemics. <i>Scientific Reports</i> , 2021, 11, 20793.	1.6	41
616	Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion. <i>Seminars in Immunology</i> , 2021, 55, 101508.	2.7	37
618	Could IL-6 predict the clinical severity of COVID-19?. <i>Biyokimya Dergisi</i> , 2021, 46, 499-507.	0.1	8
619	The mediterranean diet: Healthy and sustainable dietary pattern in the time of Sars-Cov-2. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2021, 14, 365-381.	0.2	3

#	ARTICLE	IF	CITATIONS
620	Current Understanding of the Innate Control of Toll-like Receptors in Response to SARS-CoV-2 Infection. <i>Viruses</i> , 2021, 13, 2132.	1.5	29
621	Metabolic Messengers: tumour necrosis factor. <i>Nature Metabolism</i> , 2021, 3, 1302-1312.	5.1	155
622	Effect of Age on Innate and Adaptive Immunity in Hospitalized COVID-19 Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 4798.	1.0	5
623	Signaling pathways in the regulation of cytokine release syndrome in human diseases and intervention therapy. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 367.	7.1	31
624	Design of SARS-CoV-2 PLpro Inhibitors for COVID-19 Antiviral Therapy Leveraging Binding Cooperativity. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 2940-2955.	2.9	102
625	Novel Systemic Inflammation Markers to Predict COVID-19 Prognosis. <i>Frontiers in Immunology</i> , 2021, 12, 741061.	2.2	62
626	Fatty liver on computed tomography scan on admission is a risk factor for severe coronavirus disease. <i>Journal of Infection and Chemotherapy</i> , 2021, , .	0.8	3
627	A poor and delayed anti-SARS-CoV2 IgG response is associated to severe COVID-19 in children. <i>EBioMedicine</i> , 2021, 72, 103615.	2.7	14
628	Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern. <i>ACS Infectious Diseases</i> , 2021, 7, 3034-3051.	1.8	17
630	Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection in Children: One Year after the Onset of the Pandemic in a High-Incidence Area. <i>Viruses</i> , 2021, 13, 2022.	1.5	20
631	Effect of IL-6, IL-8/CXCL8, IP-10/CXCL 10 levels on the severity in COVID 19 infection. <i>International Journal of Clinical Practice</i> , 2021, 75, e14970.	0.8	30
634	Elevated Levels of Neutrophil Activated Proteins, Alpha-Defensins (DEFA1), Calprotectin (S100A8/A9) and Myeloperoxidase (MPO) Are Associated With Disease Severity in COVID-19 Patients. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 751232.	1.8	28
635	Associations between Genetic Variants in the Vitamin D Metabolism Pathway and Severity of COVID-19 among UAE Residents. <i>Nutrients</i> , 2021, 13, 3680.	1.7	20
636	In Silico Prediction, Computational Physico Chemical Analysis in Gymnemic Acids. <i>International Journal of Pharma and Bio Sciences</i> , 2021, 11, .	0.1	0
637	CXCL10 levels at hospital admission predict COVID-19 outcome: hierarchical assessment of 53 putative inflammatory biomarkers in an observational study. <i>Molecular Medicine</i> , 2021, 27, 129.	1.9	41
638	Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease. <i>PLoS ONE</i> , 2021, 16, e0258684.	1.1	5
639	The triumvirate of NF- κ B, inflammation and cytokine storm in COVID-19. <i>International Immunopharmacology</i> , 2021, 101, 108255.	1.7	55
640	Co-infection of SARS-CoV-2 and influenza virus causes more severe and prolonged pneumonia in hamsters. <i>Scientific Reports</i> , 2021, 11, 21259.	1.6	39

#	ARTICLE	IF	CITATIONS
641	Neutrophil Extracellular Trap Formation Potential Correlates with Lung Disease Severity in COVID-19 Patients. <i>Inflammation</i> , 2022, 45, 800-811.	1.7	16
642	What Happens to the Immune System after Vaccination or Recovery from COVID-19?. <i>Life</i> , 2021, 11, 1152.	1.1	5
643	Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1 β , Early Predictors of Severe COVID-19. <i>Microorganisms</i> , 2021, 9, 2259.	1.6	14
645	The Dynamic Immunological Parameter Landscape in Coronavirus Disease 2019 Patients With Different Outcomes. <i>Frontiers in Immunology</i> , 2021, 12, 697622.	2.2	10
646	Prolonged corticosteroid therapy and cytomegalovirus infection in patients with severe COVID-19. <i>Journal of Medical Virology</i> , 2022, 94, 1067-1073.	2.5	12
647	Differential dynamics of peripheral immune responses to acute SARS-CoV-2 infection in older adults. <i>Nature Aging</i> , 2021, 1, 1038-1052.	5.3	10
648	Interferon-alpha or -beta facilitates SARS-CoV-2 pulmonary vascular infection by inducing ACE2. <i>Angiogenesis</i> , 2022, 25, 225-240.	3.7	27
649	Machine-Learning-Assisted Microfluidic Nanoplasmonic Digital Immunoassay for Cytokine Storm Profiling in COVID-19 Patients. <i>ACS Nano</i> , 2021, 15, 18023-18036.	7.3	33
651	Therapeutic mTOR blockade in systemic autoimmunity: Implications for antiviral immunity and extension of lifespan. <i>Autoimmunity Reviews</i> , 2021, 20, 102984.	2.5	16
652	Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1427-1438.	5.2	86
656	Tryptophan, after inflammatory cytokine stimulation, determines plaque vulnerability and risk of myocardial infarction. , 2022, , 81-91.		0
657	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	2.8	86
658	Management of Children with Psoriasis During the COVID-19 Pandemic. <i>Voprosy Sovremennoi Pediatrii - Current Pediatrics</i> , 2021, 20, 441-445.	0.1	0
659	Sympathetic nerve-adipocyte interactions in response to acute stress. <i>Journal of Molecular Medicine</i> , 2021, 100, 151.	1.7	5
660	Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 749657.	1.2	13
661	The predictive value of serum level of cystatin C for COVID-19 severity. <i>Scientific Reports</i> , 2021, 11, 21964.	1.6	9
662	Pathogenic Basis of Thromboinflammation and Endothelial Injury in COVID-19: Current Findings and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12081.	1.8	21
663	Myeloid dysregulation and therapeutic intervention in COVID-19. <i>Seminars in Immunology</i> , 2021, 55, 101524.	2.7	9

#	ARTICLE	IF	CITATIONS
664	A Deep Look Into COVID-19 Severity Through Dynamic Changes in Blood Cytokine Levels. <i>Frontiers in Immunology</i> , 2021, 12, 771609.	2.2	20
665	Syrian hamsters as a model of lung injury with SARS-CoV-2 infection: Pathologic, physiologic, and detailed molecular profiling. <i>Translational Research</i> , 2022, 240, 1-16.	2.2	33
666	Unusual Presentation of a Rare Pneumothorax in a Patient With COVID-19 Pneumonia: A Case Report. <i>Cureus</i> , 2021, 13, e19273.	0.2	0
668	Cytotoxic CD8-positive T-lymphocyte infiltration in the lungs as a histological pattern of SARS-CoV-2 pneumonitis. <i>Pathology</i> , 2022, 54, 404-408.	0.3	4
669	SARS-CoV-2 can infect and propagate in human placenta explants. <i>Cell Reports Medicine</i> , 2021, 2, 100456.	3.3	29
670	Clinical outcomes of intravenous immunoglobulin therapy in COVID-19 related acute respiratory distress syndrome: a retrospective cohort study. <i>BMC Pulmonary Medicine</i> , 2021, 21, 354.	0.8	5
672	SARS-CoV-2 infection mediates differential expression of human endogenous retroviruses and long interspersed nuclear elements. <i>JCI Insight</i> , 2021, 6, .	2.3	26
675	Revisiting matrix metalloproteinase 12: its role in pathophysiology of asthma and related pulmonary diseases. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 54-60.	1.2	11
677	Case Report: Unusual presentation of concomitant gastric outlet obstruction and jaundice complicating giant hepatic angioma. <i>F1000Research</i> , 0, 9, 1355.	0.8	0
678	Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications. <i>Biomedicine and Pharmacotherapy</i> , 2022, 145, 112419.	2.5	34
679	Treatment and therapeutic agents. , 2022, , 121-176.		0
680	The potential of drug delivery nanosystems to treat COVID-19. , 2022, , 307-337.		0
681	Endothelial contribution to COVID-19: an update on mechanisms and therapeutic implications. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 164, 69-82.	0.9	34
682	Functional Effects of Cardiomyocyte Injury in COVID-19. <i>Journal of Virology</i> , 2022, 96, JVI0106321.	1.5	17
683	Emerging Knowledge of the Neurobiology of COVID-19. <i>Psychiatric Clinics of North America</i> , 2022, 45, 29-43.	0.7	11
684	Analysis of transcriptomic data sets supports the role of IL-6 in NETosis and immunothrombosis in severe COVID-19. <i>BMC Genomic Data</i> , 2021, 22, 49.	0.7	13
685	Pleural Mesothelial Cells Modulate the Inflammatory/Profibrotic Response During SARS-CoV-2 Infection. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 752616.	1.6	6
686	Case Report: Tocilizumab for Acute Kidney Graft Dysfunction in Patient Affected by COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 732792.	1.2	3

#	ARTICLE	IF	CITATIONS
687	A Randomized Controlled Trial to Evaluate the Safety and Efficacy of a Novel Inhaled Biologic Therapeutic in Adults with Respiratory Distress Secondary to COVID-19 Infection. <i>Infectious Diseases and Therapy</i> , 2021, , 1.	1.8	1
689	IMPACT of PCSK9 inhibition on clinical outcome in patients during the inflammatory stage of the SARS-COV-2 infection: Rationale and protocol of the IMPACT-SIRIO 5 study. <i>Cardiology Journal</i> , 2022, 29, 140-147.	0.5	9
690	The Renin-Angiotensin System: A Key Role in SARS-CoV-2-Induced COVID-19. <i>Molecules</i> , 2021, 26, 6945.	1.7	41
691	IL 33 Correlates With COVID-19 Severity, Radiographic and Clinical Finding. <i>Frontiers in Medicine</i> , 2021, 8, 749569.	1.2	29
692	Immune-Mediated Glycocalyx Remodeling in Hospitalized COVID-19 Patients. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 307-313.	1.3	12
693	Metformin Suppresses Monocyte Immunometabolic Activation by SARS-CoV-2 Spike Protein Subunit 1. <i>Frontiers in Immunology</i> , 2021, 12, 733921.	2.2	17
694	Impact of the Innate Inflammatory Response on ICU Admission and Death in Hospitalized Patients with COVID-19. <i>Biomedicines</i> , 2021, 9, 1675.	1.4	8
695	Antimicrobial and Antiviral (SARS-CoV-2) Potential of Cannabinoids and Cannabis sativa: A Comprehensive Review. <i>Molecules</i> , 2021, 26, 7216.	1.7	13
696	Complexity of immune responses in COVID-19. <i>Seminars in Immunology</i> , 2021, 55, 101545.	2.7	10
697	Age Related Differences in Monocyte Subsets and Cytokine Pattern during Acute COVID-19â€”A Prospective Observational Longitudinal Study. <i>Cells</i> , 2021, 10, 3373.	1.8	10
698	Pathogenesis and Treatment of Cytokine Storm Induced by Infectious Diseases. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13009.	1.8	34
699	The paradox of immunosuppressants and COVID-19. <i>European Respiratory Journal</i> , 2022, 59, 2102828.	3.1	8
700	COVID-19 Syndrome: Nexus with Herbivory and Exposure Dynamics for Monitoring Livestock Welfare and Agro-Environment. <i>Sustainability</i> , 2021, 13, 12381.	1.6	1
704	Contributing factors common to COVIDâ€™19 and gastrointestinal cancer. <i>Oncology Reports</i> , 2021, 47, .	1.2	6
705	A case report describing the immune response of an infant with congenital heart disease and severe COVID-19. <i>Communications Medicine</i> , 2021, 1, .	1.9	3
706	Outcomes of patients with severe and critical COVID-19 treated with dexamethasone: a prospective cohort study. <i>Emerging Microbes and Infections</i> , 2022, 11, 50-59.	3.0	12
707	Central Nervous System Effects of COVID-19 in People with HIV Infection. <i>Current HIV/AIDS Reports</i> , 2021, 18, 538-548.	1.1	7
708	Covidâ€™19 and Liver Injury: Role of Inflammatory Endotheliopathy, Platelet Dysfunction, and Thrombosis. <i>Hepatology Communications</i> , 2022, 6, 255-269.	2.0	41

#	ARTICLE	IF	CITATIONS
709	WAO-ARIA consensus on chronic cough - Part II: Phenotypes and mechanisms of abnormal cough presentation " Updates in COVID-19. World Allergy Organization Journal, 2021, 14, 100618.	1.6	10
710	A deep learning approach for predicting severity of COVID-19 patients using a parsimonious set of laboratory markers. Science, 2021, 24, 103523.	1.9	15
712	Immunomodulation and Reduction of Thromboembolic Risk in Hospitalized COVID-19 Patients: Systematic Review and Meta-Analysis of Randomized Trials. Journal of Clinical Medicine, 2021, 10, 5366.	1.0	4
713	High Levels of Circulating IL-6 and IL-8 Signature can Predict COVID-19 Severity. Jundishapur Journal of Microbiology, 2021, 14, .	0.2	1
714	Blood Cytokine Analysis Suggests That SARS-CoV-2 Infection Results in a Sustained Tumour Promoting Environment in Cancer Patients. Cancers, 2021, 13, 5718.	1.7	10
715	Influence of SARS-CoV-2 on airway mucus production: A review and proposed model. Veterinary Pathology, 2022, 59, 578-585.	0.8	14
716	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. Science Advances, 2021, 7, eabj5629.	4.7	32
717	Optimized QRT-PCR Approach for the Measurable Impact of Adjuvant Cholecalciferol Therapy in Ameliorating Cytokine Gene Expression. European Journal of Medical and Health Sciences, 2021, 3, 44-50.	0.1	0
718	COVID-lateral damage: cardiovascular manifestations of SARS-CoV-2 infection. Translational Research, 2022, 241, 25-40.	2.2	5
719	Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. Translational Research, 2022, 241, 1-12.	2.2	15
720	Modifying effects of <i>TNF-α</i> , <i>IL-6</i> and <i>VDR</i> genes on the development risk and the course of COVID-19. Pilot study. Drug Metabolism and Personalized Therapy, 2022, 37, 133-139.	0.3	12
721	IFP35 as a promising biomarker and therapeutic target for the syndromes induced by SARS-CoV-2 or influenza virus. Cell Reports, 2021, 37, 110126.	2.9	14
722	People critically ill with COVID-19 exhibit peripheral immune profiles predictive of mortality and reflective of SARS-CoV-2 lung viral burden. Cell Reports Medicine, 2021, 2, 100476.	3.3	11
724	Longitudinal Metabolomics Reveals Ornithine Cycle Dysregulation Correlates With Inflammation and Coagulation in COVID-19 Severe Patients. Frontiers in Microbiology, 2021, 12, 723818.	1.5	17
725	Regulatory T Cells as Predictors of Clinical Course in Hospitalised COVID-19 Patients. Frontiers in Immunology, 2021, 12, 789735.	2.2	23
726	Next generation plasma proteome profiling of COVID-19 patients with mild to moderate symptoms. EBioMedicine, 2021, 74, 103723.	2.7	26
727	Multiscale interactome analysis coupled with off-target drug predictions reveals drug repurposing candidates for human coronavirus disease. Scientific Reports, 2021, 11, 23315.	1.6	10
728	Immunomodulation of COVID-19 severity by helminth co-infection: Implications for COVID-19 vaccine efficacy. Immunity, Inflammation and Disease, 2021, , .	1.3	10

#	ARTICLE	IF	CITATIONS
729	Early Prediction of Disease Progression in Patients with Severe COVID-19 Using C-Reactive Protein to Albumin Ratio. <i>Disease Markers</i> , 2021, 2021, 1-11.	0.6	25
730	Severe COVID-19 and long COVID in a 31-year-old woman with incontinentia pigmenti: A case report. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X21110592.	0.2	0
731	A case report of COVID-19-associated erythema nodosum: a classic presentation with a new trigger. <i>Family Practice</i> , 2022, 39, 936-938.	0.8	5
732	Association of genetic variations in ACE2, TIRAP and factor X with outcomes in COVID-19. <i>PLoS ONE</i> , 2022, 17, e0260897.	1.1	7
735	Integrated miRNA/cytokine/chemokine profiling reveals severity-associated step changes and principal correlates of fatality in COVID-19. <i>IScience</i> , 2022, 25, 103672.	1.9	25
736	Cathepsin B is a potential therapeutic target for coronavirus disease 2019 patients with lung adenocarcinoma. <i>Chemico-Biological Interactions</i> , 2022, 353, 109796.	1.7	11
737	Role of immune mediators in predicting hospitalization of SARS-CoV-2 positive patients. <i>Cytokine</i> , 2022, 150, 155790.	1.4	12
738	Intricate relationship between SARS-CoV-2-induced shedding and cytokine storm generation: A signaling inflammatory pathway augmenting COVID-19. <i>Health Sciences Review</i> , 2022, 2, 100011.	0.6	12
739	SARS- CoV-2 infection and oxidative stress in early-onset preeclampsia. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2022, 1868, 166321.	1.8	7
740	Endothelial injury in COVID-19 and septic patients. <i>Microvascular Research</i> , 2022, 140, 104303.	1.1	7
741	Cangma Huadu granules, a new drug with great potential to treat coronavirus and influenza infections, exert its efficacy through anti-inflammatory and immune regulation. <i>Journal of Ethnopharmacology</i> , 2022, 287, 114965.	2.0	12
742	Gastrointestinal symptoms in patients with coronavirus disease 2019 (COVID-19) – friend or foe?. <i>Przegląd Gastroenterologiczny</i> , 0, , .	0.3	0
743	The Biochemistry and Physiology of A Disintegrin and Metalloproteinases (ADAMs and ADAM-TSs) in Human Pathologies. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2021, , .	0.9	3
744	Management of Hospitalized Adult Patients with Coronavirus 2019 (COVID-19): A Therapeutic Guideline. <i>The Neuroscience Journal of Shefaye Khatam</i> , 2021, 9, 111-118.	0.4	0
745	Ferritin in COVID-19 infection and its diagnostic significance. <i>International Journal of Research in Medical Sciences</i> , 2021, 9, 2858.	0.0	0
747	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. <i>Nature Reviews Cardiology</i> , 2022, 19, 475-495.	6.1	180
748	Vitamin D Inhibits IL-6 Pro-Atherothrombotic Effects in Human Endothelial Cells: A Potential Mechanism for Protection against COVID-19 Infection?. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 27.	0.8	14
749	Maternal-fetal immune responses in pregnant women infected with SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, 320.	5.8	117

#	ARTICLE	IF	CITATIONS
750	Single-cell multi-omics reveals dyssynchrony of the innate and adaptive immune system in progressive COVID-19. <i>Nature Communications</i> , 2022, 13, 440.	5.8	100
751	Identification of Robust Protein Associations With COVID-19 Disease Based on Five Clinical Studies. <i>Frontiers in Immunology</i> , 2021, 12, 781100.	2.2	19
753	Whole-blood cytokine secretion assay as a high-throughput alternative for assessing the cell-mediated immunity profile after two doses of an adjuvanted SARS-CoV-2 recombinant protein vaccine candidate. <i>Clinical and Translational Immunology</i> , 2022, 11, e1360.	1.7	14
754	Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity. <i>Science Translational Medicine</i> , 2022, 14, eabm7853.	5.8	71
755	SARS-CoV-2 infection in dialysis and kidney transplant patients: immunological and serological response. <i>Journal of Nephrology</i> , 2022, , 1.	0.9	7
756	Identification of Parameters Representative of Immune Dysfunction in Patients with Severe and Fatal COVID-19 Infection: a Systematic Review and Meta-analysis. <i>Clinical Reviews in Allergy and Immunology</i> , 2023, 64, 33-65.	2.9	36
758	Before the "cytokine storm": Boosting efferocytosis as an effective strategy against SARS-CoV-2 infection and associated complications. <i>Cytokine and Growth Factor Reviews</i> , 2022, 63, 108-118.	3.2	8
759	The Role of Interleukin-8 in Lung Inflammation and Injury: Implications for the Management of COVID-19 and Hyperinflammatory Acute Respiratory Distress Syndrome. <i>Frontiers in Pharmacology</i> , 2021, 12, 808797.	1.6	57
760	Identification of RAGE and OSM as New Prognosis Biomarkers of Severe Pneumonia. <i>Canadian Respiratory Journal</i> , 2022, 2022, 1-9.	0.8	1
761	Tocilizumab-Induced Unexpected Increase of Several Inflammatory Cytokines in Critically Ill COVID-19 Patients: The Anti-Inflammatory Side of IL-6. <i>Viral Immunology</i> , 2022, 35, 60-70.	0.6	6
763	Comprehensive Immune Profiling Reveals CD56+ Monocytes and CD31+ Endothelial Cells Are Increased in Severe COVID-19 Disease. <i>Journal of Immunology</i> , 2022, 208, 685-696.	0.4	14
764	Comparison of cytokines levels among COVID-19 patients living at sea level and high altitude. <i>BMC Infectious Diseases</i> , 2022, 22, 96.	1.3	17
765	Analysis of Early Biomarkers Associated with the Development of Critical Respiratory Failure in Coronavirus Disease 2019 (COVID-19). <i>Diagnostics</i> , 2022, 12, 339.	1.3	5
766	A New Approach to the Management of COVID-19. Antagonists of IL-6: Siltuximab. <i>Advances in Therapy</i> , 2022, 39, 1126-1148.	1.3	24
767	Immune-Guided Therapy of COVID-19. <i>Cancer Immunology Research</i> , 2022, 10, 384-402.	1.6	20
768	Blocking TNF signaling may save lives in COVID-19 infection. <i>Molecular Biology Reports</i> , 2022, 49, 2303-2309.	1.0	23
769	Innate immunological pathways in COVID-19 pathogenesis. <i>Science Immunology</i> , 2022, 7, eabm5505.	5.6	101
770	A sample-to-answer electrochemical biosensor system for biomarker detection. <i>Lab on A Chip</i> , 2021, 22, 100-107.	3.1	10

#	ARTICLE	IF	CITATIONS
771	The Inversion of IL-6 Levels in Relation to C-Reactive Protein as the Marker for Cytokine Storm Syndrome in COVID-19. SSRN Electronic Journal, 0, , .	0.4	0
772	Cytokine Storm in COVID-19: Immunopathogenesis and Therapy. Medicina (Lithuania), 2022, 58, 144.	0.8	126
773	Acute myocardial injury in patients with COVID-19: Possible mechanisms and clinical implications. World Journal of Clinical Cases, 2022, 10, 762-776.	0.3	12
774	Aging-related cell type-specific pathophysiologic immune responses that exacerbate disease severity in aged COVID-19 patients. Aging Cell, 2022, 21, e13544.	3.0	11
775	5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Early Warning Biomarkers for COVID-19 Progression and Myocardial Injury. Frontiers in Cell and Developmental Biology, 2021, 9, 781267.	1.8	3
776	COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment – Meeting report from an isirv-WHO virtual conference. Antiviral Research, 2022, 197, 105227.	1.9	19
777	Effectiveness of Curcumin on Outcomes of Hospitalized COVID-19 Patients: A Systematic Review of Clinical Trials. Nutrients, 2022, 14, 256.	1.7	76
779	Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. Lancet Rheumatology, The, 2022, 4, e24-e32.	2.2	34
780	Pulmonary infection by SARS-CoV-2 induces senescence accompanied by an inflammatory phenotype in severe COVID-19: possible implications for viral mutagenesis. European Respiratory Journal, 2022, 60, 2102951.	3.1	56
781	Burden of cytokines storm on prognosis of SARS-CoV-2 infection through immune response: dynamic analysis and optimal control with immunomodulatory therapy. European Physical Journal: Special Topics, 2022, 231, 3297-3315.	1.2	7
782	A New Butyrate Releaser Exerts a Protective Action against SARS-CoV-2 Infection in Human Intestine. Molecules, 2022, 27, 862.	1.7	18
783	Hyperinflammatory environment drives dysfunctional myeloid cell effector response to bacterial challenge in COVID-19. PLoS Pathogens, 2022, 18, e1010176.	2.1	20
784	A Peek into Pandora's Box: COVID-19 and Neurodegeneration. Brain Sciences, 2022, 12, 190.	1.1	9
786	Repurposing of Hydroxyurea Against COVID-19: A Promising Immunomodulatory Role. Assay and Drug Development Technologies, 2022, 20, 55-62.	0.6	5
787	Inflammation and Mortality in COVID-19 Hospitalized Patients With and Without Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2022, , .	1.8	8
789	Body composition, physical capacity, and immuno-metabolic profile in community-acquired pneumonia caused by COVID-19, influenza, and bacteria: a prospective cohort study. International Journal of Obesity, 2022, 46, 817-824.	1.6	9
790	Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection. Journal of Biomedical Science, 2022, 29, 1.	2.6	144
791	Changes in peripheral blood cellular morphology as diagnostic markers for COVID-19 infection. International Journal of Laboratory Hematology, 2022, 44, 454-460.	0.7	11

#	ARTICLE	IF	CITATIONS
792	Delayed inflammation decrease is associated with mortality in Tocilizumab-treated critically ill SARS-CoV-2 patients: A retrospective matched-cohort analysis. <i>Innate Immunity</i> , 2022, 28, 3-10.	1.1	1
793	Reply to "Post-COVID 19 neurological syndrome: A new risk factor that modifies the prognosis of patients with dementia". <i>Alzheimer's and Dementia</i> , 2022, 18, 544-544.	0.4	1
794	Prediction of Respiratory Failure and Mortality in COVID-19 Patients Using Long Pentraxin PTX3. <i>Journal of Innate Immunity</i> , 2022, 14, 493-501.	1.8	14
795	Cancer Occurrence as the Upcoming Complications of COVID-19. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 813175.	1.6	12
796	Integrated histopathological, lipidomic, and metabolomic profiles reveal mink is a useful animal model to mimic the pathogenicity of severe COVID-19 patients. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 29.	7.1	12
797	The PDE4 Inhibitor Tanimilast Blunts Proinflammatory Dendritic Cell Activation by SARS-CoV-2 ssRNAs. <i>Frontiers in Immunology</i> , 2021, 12, 797390.	2.2	10
798	Role of Polypeptide Inflammatory Biomarkers in the Diagnosis and Monitoring of COVID-19. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, 59.	0.9	7
799	The mechanism of multiple organ dysfunction syndrome in patients with COVID-19. <i>Journal of Medical Virology</i> , 2022, 94, 1886-1892.	2.5	34
800	Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches. <i>BMB Reports</i> , 2022, 55, 11-19.	1.1	7
801	Advances in clinical outcomes: What we have learned during the COVID-19 pandemic. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 569-578.	1.5	3
802	Continuous Renal Replacement Therapy With oXiris Filter May Not be an Effective Resolution to Alleviate Cytokine Release Syndrome in Non-AKI Patients With Severe and Critical COVID-19. <i>Frontiers in Pharmacology</i> , 2022, 13, 817793.	1.6	13
803	Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation. <i>Inflammation Research</i> , 2022, 71, 293-307.	1.6	29
805	The Association between TNF- α , IL-6, and Vitamin D Levels and COVID-19 Severity and Mortality: A Systematic Review and Meta-Analysis. <i>Pathogens</i> , 2022, 11, 195.	1.2	31
807	No association of Gaucher disease with COVID-19-related outcomes: a nationwide cohort study. <i>Internal Medicine Journal</i> , 2021, , .	0.5	2
809	COVID-19-induced pulmonary sarcoid: A case report and review of the literature. <i>Clinical Imaging</i> , 2022, 83, 152-158.	0.8	13
810	Can infections trigger sarcoidosis?. <i>Clinical Imaging</i> , 2022, 84, 36-37.	0.8	2
811	Evolving mortality and clinical outcomes of hospitalized subjects during successive COVID-19 waves in Catalonia, Spain. <i>Global Epidemiology</i> , 2022, 4, 100071.	0.6	23
813	Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group. <i>European Respiratory Journal</i> , 2022, 60, 2102523.	3.1	31

#	ARTICLE	IF	CITATIONS
814	Interferon- β acts directly on T cells to prolong allograft survival by enhancing regulatory T cell induction through Foxp3 acetylation. <i>Immunity</i> , 2022, 55, 459-474.e7.	6.6	17
815	Pulmonary vascular inflammation with fatal coronavirus disease 2019 (COVID-19): possible role for the NLRP3 inflammasome. <i>Respiratory Research</i> , 2022, 23, 25.	1.4	9
818	Galectin-3 as a potential prognostic biomarker of severe COVID-19 in SARS-CoV-2 infected patients. <i>Scientific Reports</i> , 2022, 12, 1856.	1.6	39
819	Repurposing Ayush-64 for COVID-19: A Computational Study Based on Network Pharmacology and Molecular Docking. <i>Combinatorial Chemistry and High Throughput Screening</i> , 2022, 25, 2089-2102.	0.6	1
820	TNF- β Levels in Respiratory Samples Are Associated with SARS-CoV-2 Infection. <i>Microbiology Spectrum</i> , 2022, 10, e0141121.	1.2	2
821	Co-Administration of Iron and Bioavailable Curcumin Reduces Levels of Systemic Markers of Inflammation and Oxidative Stress in a Placebo-Controlled Randomised Study. <i>Nutrients</i> , 2022, 14, 712.	1.7	12
822	The relationship between peripheral immune response and disease severity in SARS-CoV-2 infected subjects: A cross-sectional study. <i>Immunology</i> , 2022, 165, 481-496.	2.0	17
823	COVID-19 in Patients with Hematologic Malignancies: Outcomes and Options for Treatments. <i>Acta Haematologica</i> , 2022, 145, 244-256.	0.7	7
824	Exploring the Link Between Vitamin D Deficiency and Cytokine Storms in COVID-19 Patients: An In Silico Analysis. <i>Journal of Medicinal Food</i> , 2022, 25, 130-137.	0.8	5
825	Clinical outcomes after IL-6 blockade in patients with COVID-19 and HIV: a case series. <i>AIDS Research and Therapy</i> , 2022, 19, 6.	0.7	4
826	The FCGR2A rs1801274 polymorphism was associated with the risk of death among COVID-19 patients. <i>Clinical Immunology</i> , 2022, 236, 108954.	1.4	7
827	Intravenous administration of BCG protects mice against lethal SARS-CoV-2 challenge. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	62
830	Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 420.	7.1	46
831	An Integrated Pipeline for Prediction of Clostridioides Difficile Infection. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
833	Genomic, proteomic biomarkers and risk factors associated with COVID-19. , 2022, , 95-111.		2
834	Neuro-axonal injury in COVID-19: the role of systemic inflammation and SARS-CoV-2 specific immune response. <i>Therapeutic Advances in Neurological Disorders</i> , 2022, 15, 175628642210805.	1.5	8
835	Coronavirus and Carbon Nanotubes: Seeking Immunological Relationships to Discover Immunotherapeutic Possibilities. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 751-781.	3.3	5
836	Naïve Human Macrophages Are Refractory to SARS-CoV-2 Infection and Exhibit a Modest Inflammatory Response Early in Infection. <i>Viruses</i> , 2022, 14, 441.	1.5	10

#	ARTICLE	IF	CITATIONS
837	Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis. , 2022, 1, e000036.		13
838	Genome-Wide Characterization of SARS-CoV-2 Cytopathogenic Proteins in the Search of Antiviral Targets. MBio, 2022, 13, e0016922.	1.8	14
839	Analysis of serum microRNAs and rs2910164 GC single-nucleotide polymorphism of miRNA-146a in COVID-19 patients. Journal of Immunoassay and Immunochemistry, 2022, 43, 347-364.	0.5	7
840	Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 402-405.	1.4	11
841	Can Panax ginseng help control cytokine storm in COVID-19?. Journal of Ginseng Research, 2022, 46, 337-347.	3.0	7
842	Early Use of Sarilumab in Patients Hospitalized with COVID-19 Pneumonia and Features of Systemic Inflammation: the SARICOR Randomized Clinical Trial. Antimicrobial Agents and Chemotherapy, 2022, 66, AAC0210721.	1.4	22
843	Dichotomous Role of Tumor Necrosis Factor in Pulmonary Barrier Function and Alveolar Fluid Clearance. Frontiers in Physiology, 2021, 12, 793251.	1.3	16
844	Pro-resolving therapies as potential adjunct treatment for infectious diseases: Evidence from studies with annexin A1 and angiotensin-(1-7). Seminars in Immunology, 2022, 59, 101601.	2.7	7
845	Persistent Endothelial Dysfunction in Coronavirus Disease-2019 Survivors Late After Recovery. Frontiers in Medicine, 2022, 9, 809033.	1.2	14
846	Tocilizumab and COVID-19: Timing of Administration and Efficacy. Frontiers in Pharmacology, 2022, 13, 825749.	1.6	27
847	Development and validation of a population-based risk stratification model for severe COVID-19 in the general population. Scientific Reports, 2022, 12, 3277.	1.6	10
849	Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients. Frontiers in Medicine, 2022, 9, 849222.	1.2	2
850	Executable network of SARS-CoV-2-host interaction predicts drug combination treatments. Npj Digital Medicine, 2022, 5, 18.	5.7	5
851	COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences. Frontiers in Cell and Developmental Biology, 2022, 10, 824851.	1.8	51
852	COVID-19: A systematic review and update on prevention, diagnosis, and treatment. MedComm, 2022, 3, e115.	3.1	30
853	Decreased serum levels of angiotensin converting enzyme (ACE)2 and enhanced cytokine levels with severity of COVID-19: normalisation upon disease recovery. Heliyon, 2022, 8, e08957.	1.4	3
854	Progress and Challenges Toward Generation and Maintenance of Long-Lived Memory T Lymphocyte Responses During COVID-19. Frontiers in Immunology, 2021, 12, 804808.	2.2	7
855	Ofelecin i mi Vlaptinâ€™Volume II: Immunity Following Infection or mRNA Vaccination, Drug Therapies and Non-Pharmacological Management at Post-Two Years SARS-CoV-2 Pandemic. Medicina (Lithuania), 2022, 58, 309.	0.8	4

#	ARTICLE	IF	CITATIONS
856	Protective immune trajectories in early viral containment of non-pneumonic SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 1018.	5.8	16
857	Targeting Mononuclear Phagocytes to Treat COVID-19. , 0, , .		0
858	Integrating single-cell sequencing data with GWAS summary statistics reveals CD16+monocytes and memory CD8+T cells involved in severe COVID-19. <i>Genome Medicine</i> , 2022, 14, 16.	3.6	25
859	Novel prognostic determinants of COVID-19-related mortality: A pilot study on severely-ill patients in Russia. <i>PLoS ONE</i> , 2022, 17, e0264072.	1.1	8
860	Individualized Constellation of Killer Cell Immunoglobulin-Like Receptors and Cognate HLA Class I Ligands that Controls Natural Killer Cell Antiviral Immunity Predisposes COVID-19. <i>Frontiers in Genetics</i> , 2022, 13, 845474.	1.1	15
861	Serologic and Cytokine Signatures in Children With Multisystem Inflammatory Syndrome and Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac070.	0.4	13
862	Simultaneous detection of sepsis host response biomarkers in whole blood using electrochemical biosensor. <i>Bioengineering and Translational Medicine</i> , 2022, 7, .	3.9	5
863	CD4 ⁺ T-Cell Dysfunction in Severe COVID-19 Disease Is Tumor Necrosis Factor- α /Tumor Necrosis Factor Receptor 1-Dependent. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1403-1418.	2.5	21
864	Enzyme-Linked Immunosorbent Assay: An Adaptable Methodology to Study SARS-CoV-2 Humoral and Cellular Immune Responses. <i>Journal of Clinical Medicine</i> , 2022, 11, 1503.	1.0	4
865	The Potential Predictive Role of Tumour Necrosis Factor- α , Interleukin-1 β , and Monocyte Chemoattractant Protein-1 for COVID-19 Patients Survival. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 821-829.	1.1	3
866	Kinetics of Severity Biomarkers and Immunological Features of Methylprednisolone Therapy for Severe COVID-19 Patients. <i>Frontiers in Immunology</i> , 2022, 13, 758946.	2.2	0
867	Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab. <i>Journal of Translational Medicine</i> , 2022, 20, 134.	1.8	7
868	SARS-CoV-2 Nsp14 mediates the effects of viral infection on the host cell transcriptome. <i>ELife</i> , 2022, 11, .	2.8	22
869	Facilitating Safe Discharge Through Predicting Disease Progression in Moderate Coronavirus Disease 2019 (COVID-19): A Prospective Cohort Study to Develop and Validate a Clinical Prediction Model in Resource-Limited Settings. <i>Clinical Infectious Diseases</i> , 2022, 75, e368-e379.	2.9	4
870	Cellular therapies for the treatment and prevention of SARS-CoV-2 infection. <i>Blood</i> , 2022, 140, 208-221.	0.6	13
871	Understanding the pathophysiology of typical acute respiratory distress syndrome and severe COVID-19. <i>Expert Review of Respiratory Medicine</i> , 2022, , 1-10.	1.0	12
872	Riboflavin for COVID-19 Adjuvant Treatment in Patients With Mental Health Disorders: Observational Study. <i>Frontiers in Pharmacology</i> , 2022, 13, 755745.	1.6	8
873	Programmed cell death: the pathways to severe COVID-19?. <i>Biochemical Journal</i> , 2022, 479, 609-628.	1.7	30

#	ARTICLE	IF	CITATIONS
874	Hold Breath: Autonomic Neural Regulation of Innate Immunity to Defend Against SARS-CoV-2 Infection. <i>Frontiers in Microbiology</i> , 2021, 12, 819638.	1.5	1
875	COVID-19 and Long-Term Outcomes: Lessons from Other Critical Care Illnesses and Potential Mechanisms. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 67, 275-283.	1.4	11
876	Factors associated with dexamethasone efficacy in COVID-19. A retrospective investigative cohort study. <i>Journal of Medical Virology</i> , 2022, , .	2.5	2
877	Cutting the Gordian knot of heterogeneity: Can integrated systems biology modelling rescue critical care syndromes?. <i>EBioMedicine</i> , 2022, 77, 103884.	2.7	0
878	Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice. <i>Scientific Reports</i> , 2022, 12, 4150.	1.6	9
879	The role of tumor necrosis factor alpha α polymorphism on the clinical states of SARS-CoV-2 infection. <i>Egyptian Journal of Medical Human Genetics</i> , 2022, 23, .	0.5	1
881	Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2. <i>Frontiers in Immunology</i> , 2022, 13, 845887.	2.2	13
882	Circadian Disruption and Occupational Toxicants Exposure Affecting the Immunity of Shift Workers During SARS CoV-2 Pandemic. <i>Frontiers in Public Health</i> , 2022, 10, 829013.	1.3	1
883	Targeting of neutrophil activation in the early phase of the disease for prevention of Coronavirus disease-19 severity. <i>Microbiology and Immunology</i> , 2022, 66, 264-276.	0.7	5
885	Diagnostic and Therapeutic Potential for HNP-1, HBD-1 and HBD-4 in Pregnant Women with COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3450.	1.8	6
886	Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell entry process, and cytokine storm in COVID-19. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 964-986.	1.2	8
887	Oxidative Stress-Related Mechanisms in SARS-CoV-2 Infections. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-15.	1.9	34
888	Impact of biologics and small molecules for inflammatory bowel disease on COVID-19 related hospitalization and mortality: A systematic review and meta-analysis. <i>JGH Open</i> , 2022, 6, 241-250.	0.7	5
889	Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial. <i>Clinical Infectious Diseases</i> , 2022, 75, e380-e388.	2.9	27
891	Correlation of COVID-19 Severity and Immunoglobulin Presence Against Spike and Nucleocapsid Proteins in SARS-CoV-2. <i>Viral Immunology</i> , 2022, , .	0.6	0
892	Association between inflammatory cytokines and anti-SARS-CoV-2 antibodies in hospitalized patients with COVID-19. <i>Immunity and Ageing</i> , 2022, 19, 12.	1.8	23
893	Evaluation of Poor Prognosis in rRT-PCR Positive Covid-19 Cases with Using Deep Transfer Learning Network. <i>Osmaniye Korkut Ata Üniversitesi Fen Bilimleri Enstitüsü Dergisi</i> , 0, , .	0.2	0
894	The Inflammatory Cytokine Imbalance for Miscarriage, Pregnancy Loss and COVID-19 Pneumonia. <i>Frontiers in Immunology</i> , 2022, 13, 861245.	2.2	11

#	ARTICLE	IF	CITATIONS
895	Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. PeerJ, 2022, 10, e13083.	0.9	14
896	When to operate after SARS-CoV-2 infection? A review on the recent consensus recommendation of the DGC/BDC and the DGAJ/BDA. Langenbeck's Archives of Surgery, 2022, 407, 1315-1332.	0.8	5
897	Enhanced SARS-CoV-2-Specific CD4+ T Cell Activation and Multifunctionality in Late Convalescent COVID-19 Individuals. Viruses, 2022, 14, 511.	1.5	2
898	COVID-19 Outcomes and Liver Disease. , 0, , .		0
900	Association of smoking, lung function and COPD in COVID-19 risk: a two-step Mendelian randomization study. Addiction, 2022, 117, 2027-2036.	1.7	25
901	Metabolic Landscape of Bronchoalveolar Lavage Fluid in Coronavirus Disease 2019 at Single Cell Resolution. Frontiers in Immunology, 2022, 13, 829760.	2.2	1
902	Identification of factors impairing exercise capacity after severe COVID-19 pulmonary infection: a 3-month follow-up of prospective COVulnerability cohort. Respiratory Research, 2022, 23, 68.	1.4	19
903	Semen Proteomics of COVID-19 Convalescent Men Reveals Disruption of Key Biological Pathways Relevant to Male Reproductive Function. ACS Omega, 2022, 7, 8601-8612.	1.6	18
904	Understanding the Role of SARS-CoV-2 ORF3a in Viral Pathogenesis and COVID-19. Frontiers in Microbiology, 2022, 13, 854567.	1.5	58
907	Immune-Mediated Inflammatory Responses of Alveolar Epithelial Cells: Implications for COVID-19 Lung Pathology. Biomedicines, 2022, 10, 618.	1.4	16
910	SARS-CoV-2 pathogenesis. Nature Reviews Microbiology, 2022, 20, 270-284.	13.6	404
911	The number of circulating <sc>CD26</sc> expressing cells is decreased in critical <sc>COVID</sc>-19 illness. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2023, 103, 153-161.	1.1	2
912	Oxidative Stress and Inflammatory Status in COVID-19 Outpatients: A Health Center-Based Analytical Cross-Sectional Study. Antioxidants, 2022, 11, 606.	2.2	10
914	Inflammation parameters predict fatal outcome in male COVID-19 patients in a low case-fatality area " a population-based registry study. Infectious Diseases, 2022, 54, 558-571.	1.4	2
915	<i>FURIN</i> gene variants (rs6224/rs4702) as potential markers of death and cardiovascular traits in severe COVID-19. Journal of Medical Virology, 2022, 94, 3589-3595.	2.5	4
916	New AKT-dependent mechanisms of anti-COVID-19 action of high-CBD Cannabis sativa extracts. Cell Death Discovery, 2022, 8, 110.	2.0	10
917	Hyperinflammatory State and Low T1 Adaptive Immune Response in Severe and Critical Acute COVID-19 Patients. Frontiers in Medicine, 2022, 9, 828678.	1.2	6
918	Characterization of memory T cell subsets and common Î³Î³-chain cytokines in convalescent COVID-19 individuals. Journal of Leukocyte Biology, 2022, 112, 201-212.	1.5	15

#	ARTICLE	IF	CITATIONS
919	Association of severity and mortality of Covid-19 cases among acute kidney injury and sexual dimorphism. <i>Molecular Biology Reports</i> , 2022, 49, 6753-6762.	1.0	1
920	COVID-19 and Lung Cancer: A Comprehensive Overview from Outbreak to Recovery. <i>Biomedicines</i> , 2022, 10, 776.	1.4	8
921	Distinct Cellular Immune Responses to SARS-CoV-2 in Pregnant Women. <i>Journal of Immunology</i> , 2022, 208, 1857-1872.	0.4	16
922	Mapping cerebral atrophic trajectory from amnesic mild cognitive impairment to Alzheimer's disease. <i>Cerebral Cortex</i> , 2023, 33, 1310-1327.	1.6	6
923	Association of tumor necrosis factor alpha 308 single nucleotide polymorphism with SARS CoV-2 infection in an Iraqi Kurdish population. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24400.	0.9	8
924	Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis. <i>Lancet Respiratory Medicine</i> , 2022, 10, 545-556.	5.2	30
926	Impact of SARS-CoV-2 on Host Factors Involved in Mental Disorders. <i>Frontiers in Microbiology</i> , 2022, 13, 845559.	1.5	5
927	Detection of SARS-CoV-2 infection by microRNA profiling of the upper respiratory tract. <i>PLoS ONE</i> , 2022, 17, e0265670.	1.1	15
928	COVID-19 therapeutics: Challenges and directions for the future. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2119893119.	3.3	92
929	Temporal transcriptomic analysis using TrendCatcher identifies early and persistent neutrophil activation in severe COVID-19. <i>JCI Insight</i> , 2022, 7, .	2.3	7
931	Characterization of Altered Gene Expression and Histone Methylation in Peripheral Blood Mononuclear Cells Regulating Inflammation in COVID-19 Patients. <i>Journal of Immunology</i> , 2022, 208, 1968-1977.	0.4	8
932	The Role of Cytokines and Chemokines in Severe Acute Respiratory Syndrome Coronavirus 2 Infections. <i>Frontiers in Immunology</i> , 2022, 13, 832394.	2.2	56
933	The Importance of Nutraceuticals in COVID-19: What's the Role of Resveratrol?. <i>Molecules</i> , 2022, 27, 2376.	1.7	16
934	Persistently Elevated Plasma Concentrations of RIPK3, MLKL, HMGB1, and RIPK1 in Patients with COVID-19 in the Intensive Care Unit. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 67, 405-408.	1.4	8
935	FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation. <i>Nature</i> , 2022, 606, 576-584.	13.7	314
936	Potential plants for inflammatory dysfunction in the SARS-CoV-2 infection. <i>Inflammopharmacology</i> , 2022, 30, 749-773.	1.9	3
937	Inhalation of nebulized omega-3 fatty acids mitigate LPS-induced acute lung inflammation in rats: Implications for treatment of COPD and COVID-19. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2022, 179, 102426.	1.0	6
938	A randomized, double-blind, placebo-controlled trial of intravenous alpha-1 antitrypsin for ARDS secondary to COVID-19. <i>Med</i> , 2022, 3, 233-248.e6.	2.2	17

#	ARTICLE	IF	CITATIONS
939	Stratification of COVID-19 patients based on quantitative immune-related gene expression in whole blood. <i>Molecular Immunology</i> , 2022, 145, 17-26.	1.0	4
940	A concise review of mushrooms antiviral and immunomodulatory properties that may combat against COVID-19. , 2022, 1, 100023.		25
941	Profile of COVID-19 Patients in Dr. Moewardi Hospital Surakarta Indonesia. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 9, 1621-1624.	0.1	0
943	Cytokine profile as biomarker of COVID-19 and its correlation with liver function enzymes and other markers of inflammation. <i>Biomedicine (India)</i> , 2021, 41, 747-751.	0.1	0
944	Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic. <i>Frontiers in Immunology</i> , 2021, 12, 789317.	2.2	34
947	Drug repurposing and other strategies for rapid coronavirus antiviral development: lessons from the early stage of the COVID-19 pandemic. , 2021, , 39-68.		0
948	Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19. <i>Clinical Pharmacokinetics</i> , 2022, 61, 155-165.	1.6	8
949	Severe and long-lasting neuropsychiatric symptoms after mild respiratory symptoms caused by COVID-19: A case report. <i>Neuropsychopharmacology Reports</i> , 2022, 42, 114-119.	1.1	8
950	Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19. <i>Journal of Clinical Medicine</i> , 2021, 10, 5815.	1.0	6
951	Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges. <i>PLoS Pathogens</i> , 2021, 17, e1010106.	2.1	12
952	Adult Still's disease: New horizons. <i>Nauchno-Prakticheskaya Revmatologiya</i> , 2021, 59, 645-665.	0.2	6
953	Longitudinal Cytokine Profile in Patients With Mild to Critical COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 763292.	2.2	50
954	SARS-CoV-2-triggered mast cell rapid degranulation induces alveolar epithelial inflammation and lung injury. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 428.	7.1	44
955	Innate Receptors Expression by Lung Nociceptors: Impact on COVID-19 and Aging. <i>Frontiers in Immunology</i> , 2021, 12, 785355.	2.2	3
956	Not your usual drug-drug interactions: Monoclonal antibody-based therapeutics may interact with antiseizure medications. <i>Epilepsia</i> , 2022, 63, 271-289.	2.6	6
957	Mechanisms and Regulation of Cellular Senescence. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13173.	1.8	116
958	Tocilizumab improves 28-day survival in hospitalized patients with severe COVID-19: an open label, prospective study. <i>Respiratory Research</i> , 2021, 22, 317.	1.4	11
959	Chemokine-Based Therapeutics for the Treatment of Inflammatory and Fibrotic Convergent Pathways in COVID-19. <i>Current Pathobiology Reports</i> , 2021, 9, 93-105.	1.6	14

#	ARTICLE	IF	CITATIONS
961	Gout and the COVID-19 pandemic. <i>Current Opinion in Rheumatology</i> , 2022, 34, 111-117.	2.0	9
962	Antirheumatic Drugs against COVID-19 from the Perspective of Rheumatologists. <i>Pharmaceuticals</i> , 2021, 14, 1256.	1.7	10
963	Serial measurement of cytokines strongly predict COVID-19 outcome. <i>PLoS ONE</i> , 2021, 16, e0260623.	1.1	19
964	Can sulfasalazine as an old drug with immunomodulatory and anti-inflammatory effects be effective in COVID-19?. <i>Journal of Basic and Clinical Physiology and Pharmacology</i> , 2022, 33, 113-115.	0.7	6
965	A humanized mouse model of chronic COVID-19. <i>Nature Biotechnology</i> , 2022, 40, 906-920.	9.4	71
966	Binding of phosphatidylserine-positive microparticles by PBMCs classifies disease severity in COVID-19 patients. <i>Journal of Extracellular Vesicles</i> , 2021, 10, e12173.	5.5	19
968	Asymptomatic SARS-CoV-2 Infection Is Associated With Higher Levels of Serum IL-17C, Matrix Metalloproteinase 10 and Fibroblast Growth Factors Than Mild Symptomatic COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 821730.	2.2	21
969	Identifying Immunological and Clinical Predictors of COVID-19 Severity and Sequelae by Mathematical Modeling. <i>Frontiers in Immunology</i> , 2022, 13, 865845.	2.2	7
970	Relationship of inflammatory mediators and sex-related parameters in Jordanian adult men patients with Covid-19. <i>Journal of Medical Biochemistry</i> , 2022, 41, 474-482.	0.7	2
971	SARS-CoV-2 infection relaxes peripheral B cell tolerance. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	10
972	Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials. <i>International Immunopharmacology</i> , 2022, 109, 108786.	1.7	7
973	Soluble IL-2R Levels at Baseline Predict the Development of Severe Respiratory Failure and Mortality in COVID-19 Patients. <i>Viruses</i> , 2022, 14, 787.	1.5	6
974	High Titers of Low Affinity Antibodies in COVID-19 Patients Are Associated With Disease Severity. <i>Frontiers in Immunology</i> , 2022, 13, 867716.	2.2	15
975	Senicapoc treatment in COVID-19 Patients with Severe Respiratory Insufficiency – A Randomized, Open-Label, Phase II Trial. <i>Acta Anaesthesiologica Scandinavica</i> , 2022, .	0.7	3
976	Echocardiography findings in COVID-19 patients admitted to intensive care units: a multi-national observational study (the ECHO-COVID study). <i>Intensive Care Medicine</i> , 2022, 48, 667-678.	3.9	63
977	Systematic Review of the Common Pathophysiological Mechanisms in COVID-19 and Neurodegeneration: The Role of Bioactive Compounds and Natural Antioxidants. <i>Cells</i> , 2022, 11, 1298.	1.8	18
978	Nonresolving inflammation redux. <i>Immunity</i> , 2022, 55, 592-605.	6.6	35
979	An endogenously activated antiviral state restricts SARS-CoV-2 infection in differentiated primary airway epithelial cells. <i>PLoS ONE</i> , 2022, 17, e0266412.	1.1	14

#	ARTICLE	IF	CITATIONS
980	RNA-binding protein hnRNP UL1 binds $\hat{\text{I}}^{\text{B}}$ sites to attenuate NF- $\hat{\text{I}}^{\text{B}}$ -mediated inflammation. <i>Journal of Autoimmunity</i> , 2022, 129, 102828.	3.0	11
981	COVID-19 susceptibility, severity, clinical outcome and Toll-like receptor (7) mRNA expression driven by TLR7 gene polymorphism (rs3853839) in middle-aged individuals without previous comorbidities. <i>Gene Reports</i> , 2022, 27, 101612.	0.4	11
982	Angiotensin 2 Is Associated with Vascular Necroptosis Induction in Coronavirus Disease 2019 Acute Respiratory Distress Syndrome. <i>American Journal of Pathology</i> , 2022, 192, 1001-1015.	1.9	19
983	Down to a T: The Functional Importance of Lymphopenia in Severe COVID-19. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, , .	2.5	1
984	Interleukin-6 Test Strip Combined With a Spectrum-Based Optical Reader for Early Recognition of COVID-19 Patients With Risk of Respiratory Failure. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 796996.	2.0	4
985	Cytokine Elevation in Severe COVID-19 From Longitudinal Proteomics Analysis: Comparison With Sepsis. <i>Frontiers in Immunology</i> , 2021, 12, 798338.	2.2	19
986	Association between periodontal disease and the risk of COVID-19 complications and mortality: A systematic review. <i>Journal of International Society of Preventive and Community Dentistry</i> , 2021, 11, 626.	0.4	6
987	Hyper-inflammatory responses in COVID-19 and anti-inflammatory therapeutic approaches.. <i>BMB Reports</i> , 2021, , .	1.1	0
988	Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. <i>Stem Cells Translational Medicine</i> , 2022, 11, 688-703.	1.6	13
989	Efficient exploration of terpenoid biosynthetic gene clusters in filamentous fungi. <i>Nature Catalysis</i> , 2022, 5, 277-287.	16.1	33
990	High-affinity Fc $\hat{\text{I}}^{\text{3}}$ R11a genetic variants and potent NK $\hat{\text{A}}$ cell-mediated antibody-dependent cellular cytotoxicity (ADCC) responses contributing to severe $\hat{\text{A}}$ COVID-19. <i>Genetics in Medicine</i> , 2022, 24, 1449-1458.	1.1	12
991	Heart Failure Relapses in Response to Acute Stresses $\hat{\text{A}}$ “ Role of Immunological and Inflammatory Pathways. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 809935.	1.1	3
992	Massive release of TH2 cytokines induced a cytokine storm during a severe mast cell activation event in a patient with indolent systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 406-414.e16.	1.5	3
993	Landscape of Peripheral Blood Mononuclear Cells and Soluble Factors in Severe COVID-19 Patients With Pulmonary Fibrosis Development. <i>Frontiers in Immunology</i> , 2022, 13, 831194.	2.2	3
994	Cytokines from Bench to Bedside: A Retrospective Study Identifies a Definite Panel of Biomarkers to Early Assess the Risk of Negative Outcome in COVID-19 Patients. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4830.	1.8	8
995	Immunopathological changes, complications, sequelae and immunological memory in COVID-19 patients. <i>Heliyon</i> , 2022, 8, e09302.	1.4	7
996	Identification of serum metabolites enhancing inflammatory responses in COVID-19. <i>Science China Life Sciences</i> , 2022, 65, 1971-1984.	2.3	6
997	Patients with severe COVID-19 do not have elevated autoantibodies against common diagnostic autoantigens. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1116-1123.	1.4	3

#	ARTICLE	IF	CITATIONS
998	Probing the Immune System Dynamics of the COVID-19 Disease for Vaccine Designing and Drug Repurposing Using Bioinformatics Tools. <i>Immuno</i> , 2022, 2, 344-371.	0.6	2
999	Inflammasome activation in infected macrophages drives COVID-19 pathology. <i>Nature</i> , 2022, 606, 585-593.	13.7	276
1000	Systemic Inflammation Evaluated by Interleukin-6 or C-Reactive Protein in Critically Ill Patients: Results From the FROG-ICU Study. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	5
1001	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609.	2.6	14
1002	CLINICAL AND ECONOMIC ANALYSIS OF GENETICALLY ENGINEERED BIOLOGICS CONSUMPTION BY PATIENTS WITH COVID-19. <i>Farmatsiya I Farmakologiya</i> , 2022, 10, 198-206.	0.2	2
1003	Alpha-1 Antitrypsin Therapy Modifies Neutrophil Adhesion in Patients with Obstructive Lung Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 67, 76-88.	1.4	6
1004	Peroxiredoxin 6 mediates the protective function of curcumin pretreatment in acute lung injury induced by serum from patients undergoing one-lung ventilation in vitro. <i>BMC Pulmonary Medicine</i> , 2022, 22, 192.	0.8	2
1005	Survival Benefit of Tocilizumab in COVID-19 May Be Greater in Patients with Higher Measured Interleukin 6 Levels. <i>Covid</i> , 2022, 2, 578-585.	0.7	1
1006	Improvement in Long-COVID Symptoms Using Acupuncture: A Case Study. <i>Medical Acupuncture</i> , 2022, 34, 172-176.	0.3	4
1007	Acanthosis nigricans in the setting of severe pulmonary disease exacerbated by COVID-19 infection. <i>JAAD Case Reports</i> , 2022, 24, 78-81.	0.4	0
1009	ADAM10 and ADAM17 promote SARS-CoV-2 cell entry and spike protein-mediated lung cell fusion. <i>EMBO Reports</i> , 2022, 23, e54305.	2.0	57
1010	Single nucleotide polymorphisms located in <i>TNFA</i> , <i>IL1RN</i> , <i>IL6R</i> , and <i>IL6</i> genes are associated with COVID-19 risk and severity in an Iranian population. <i>Cell Biology International</i> , 2022, 46, 1109-1127.	1.4	18
1011	Upregulating Human Cathelicidin Antimicrobial Peptide LL-37 Expression May Prevent Severe COVID-19 Inflammatory Responses and Reduce Microthrombosis. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	15
1012	Toll-like Interleukin -1 Receptor Regulator (TILRR) Protein, a Major Modulator of Inflammation, is Expressed in Normal Human and Macaque Tissues and PBMCs. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 2925-2937.	1.6	0
1013	A phase I trial of cyclosporine for hospitalized patients with COVID-19. <i>JCI Insight</i> , 2022, 7, .	2.3	8
1014	Cytokine response over the course of COVID-19 infection in pregnant women. <i>Cytokine</i> , 2022, 154, 155894.	1.4	9
1015	Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro. <i>Biomedicine and Pharmacotherapy</i> , 2022, 150, 113058.	2.5	15
1016	Prognostic serum biomarkers in cancer patients with COVID-19: A systematic review. <i>Translational Oncology</i> , 2022, 21, 101443.	1.7	5

#	ARTICLE	IF	CITATIONS
1017	Role of hemogram-derived ratios in predicting ICU requirements in COVID-19 patients: A multicenter study. <i>IJID Regions</i> , 2022, , .	0.5	4
1018	Tocilizumab Accelerates Recovery in Patients With Severe COVID-19 Pneumonia on Venovenous Extracorporeal Membrane Oxygenation. <i>ASAIO Journal</i> , 2022, 68, 1010-1016.	0.9	3
1019	Organâ€specific immune response in lethal SARSâ€CoVâ€2 infection by deep spatial phenotyping. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	0
1020	IgG targeting distinct seasonal coronavirus- conserved SARS-CoV-2 spike subdomains correlates with differential COVID-19 disease outcomes. <i>Cell Reports</i> , 2022, 39, 110904.	2.9	9
1021	Immune response in COVID-19: what is next?. <i>Cell Death and Differentiation</i> , 2022, 29, 1107-1122.	5.0	69
1022	BCG Vaccination: A potential tool against COVID-19 and COVID-19-like Black Swan incidents. <i>International Immunopharmacology</i> , 2022, 108, 108870.	1.7	15
1023	An Artificial Intelligence-guided signature reveals the shared host immune response in MIS-C and Kawasaki disease. <i>Nature Communications</i> , 2022, 13, 2687.	5.8	37
1024	Development and evaluation of a machine learning-based in-hospital COVID-19 disease outcome predictor (CODOP): A multicontinental retrospective study. <i>ELife</i> , 2022, 11, .	2.8	5
1025	Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative?. <i>Pharmaceuticals</i> , 2022, 15, 616.	1.7	7
1026	Anti-nucleocapsid antibodies enhance the production of IL-6 induced by SARS-CoV-2â€N protein. <i>Scientific Reports</i> , 2022, 12, 8108.	1.6	13
1027	Predicting the Disease Severity of Virus Infection. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1368, 111-139.	0.8	0
1028	Depression, worry, and loneliness are associated with subsequent risk of hospitalization for COVID-19: a prospective study. <i>Psychological Medicine</i> , 2023, 53, 4022-4031.	2.7	10
1029	Effect of ArtemiC in patients with COVIDâ€19: A Phase II prospective study. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 3281-3289.	1.6	14
1030	TNF-related apoptosis-inducing ligand, interferon gamma-induced protein 10, and C-reactive protein in predicting the progression of SARS-CoV-2 infection: a prospective cohort study. <i>International Journal of Infectious Diseases</i> , 2022, 122, 178-187.	1.5	15
1031	A Multicenter Phaseâ€2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia. <i>Infectious Diseases and Therapy</i> , 0, , .	1.8	16
1032	SARS-CoV-2 accessory proteins reveal distinct serological signatures in children. <i>Nature Communications</i> , 2022, 13, .	5.8	22
1033	Extracorporeal Immunomodulation Treatment and Clinical Outcomes in ICU COVID-19 Patients. , 2022, 4, e0694.		10
1034	Anti-adhesion and Anti-inflammatory Potential of the Leaderless Class IIb Bacteriocin Enterocin DD14. <i>Probiotics and Antimicrobial Proteins</i> , 2022, 14, 613-619.	1.9	4

#	ARTICLE	IF	CITATIONS
1035	Pearson's patterns correlational of clinical risks at admissions with hospitalization outcomes during initial COVID-19 outbreak. <i>IScience</i> , 2022, 25, 104415.	1.9	1
1036	Inflammatory Markers and Auto-Abs to Type I IFNs in COVID-19 Convalescent Plasma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1037	Correlation of the TCR Diversity Indexes in the Peripheral Blood with Disease Susceptibility and Deterioration in COVID-19 Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1038	Soluble P2X7 Receptor Is Elevated in the Plasma of COVID-19 Patients and Correlates With Disease Severity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	19
1039	Gastrointestinal Involvement in SARS-CoV-2 Infection. <i>Viruses</i> , 2022, 14, 1188.	1.5	25
1040	Clinical Characteristics of Immune Response in Asymptomatic Carriers and Symptomatic Patients With COVID-19. <i>Frontiers in Microbiology</i> , 2022, 13, .	1.5	0
1043	Chemokines, soluble PD-L1, and immune cell hyporesponsiveness are distinct features of SARS-CoV-2 critical illness. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2022, 323, L14-L26.	1.3	15
1044	Target and drug predictions for SARS-CoV-2 infection in hepatocellular carcinoma patients. <i>PLoS ONE</i> , 2022, 17, e0269249.	1.1	2
1045	Intracranial Aneurysm Rupture after SARS-CoV2 Infection: Case Report and Review of Literature. <i>Pathogens</i> , 2022, 11, 617.	1.2	3
1046	$\text{TNF-}\alpha$ / $\text{IFN-}\beta$ synergy amplifies senescence-associated inflammation and SARS-CoV-2 receptor expression via hyperactivated $\text{JAK}/\text{STAT1}$. <i>Aging Cell</i> , 2022, 21, .	3.0	31
1049	Network pharmacology and experimental validation identify the potential mechanism of sophocarpine for COVID-19. <i>Journal of Medical Microbiology</i> , 2022, 71, .	0.7	2
1050	Timeline Kinetics of Systemic and Airway Immune Mediator Storm for Comprehensive Analysis of Disease Outcome in Critically Ill COVID-19 Patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1051	Cytokine Profile of Invasive Pulmonary Aspergillosis in Severe COVID-19 and Possible Therapeutic Targets. <i>Diagnostics</i> , 2022, 12, 1364.	1.3	5
1053	SARS-CoV-2 Delta variant isolates from vaccinated individuals. <i>BMC Genomics</i> , 2022, 23, .	1.2	2
1054	Sex-adjusted approach to baseline variables demonstrated some improved predictive capabilities for disease severity and survival in patients with Coronavirus Disease 19. <i>Informatics in Medicine Unlocked</i> , 2022, 31, 100982.	1.9	0
1055	Alicante-Winter Immunology Symposium in Health (A-Wish) and the Boule-SEI awards: A collaboration between the Spanish Society for immunology, the University of Alicante and the Jean Boule Group to honor the Balmis Expedition. <i>Current Research in Immunology</i> , 2022, 3, 136-145.	1.2	0
1056	The IL-1 β , IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. <i>Cell Reports Medicine</i> , 2022, 3, 100663.	3.3	175
1057	Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	31

#	ARTICLE	IF	CITATIONS
1058	Calibration and Validation of a Mechanistic COVID-19 Model for Translational Quantitative Systems Pharmacology – A Proof-of-Concept Model Development for Remdesivir. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 112, 882-891.	2.3	1
1059	SARS-CoV-2 M Protein Facilitates Malignant Transformation of Breast Cancer Cells. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
1060	Morphological changes without histological myocarditis in hearts of COVID-19 deceased patients. <i>Scandinavian Cardiovascular Journal</i> , 2022, 56, 166-173.	0.4	2
1062	Genetic variants in the NF- κ B signaling pathway (NFKB1, NFKBIA, NFKBIZ) and risk of critical outcome among COVID-19 patients. <i>Human Immunology</i> , 2022, 83, 613-617.	1.2	6
1063	Cytokines and microRNAs in SARS-CoV-2: What do we know?. <i>Molecular Therapy - Nucleic Acids</i> , 2022, 29, 219-242.	2.3	18
1064	Proteomic and clinical biomarkers for acute mountain sickness in a longitudinal cohort. <i>Communications Biology</i> , 2022, 5, .	2.0	6
1065	Children with psoriasis and COVID-19: factors associated with an unfavourable COVID-19 course, and the impact of infection on disease progression (Chi&PsoCov registry). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2076-2086.	1.3	11
1066	Efferocytosis of SARS-CoV-2-infected dying cells impairs macrophage anti-inflammatory functions and clearance of apoptotic cells. <i>ELife</i> , 0, 11, .	2.8	31
1067	SARS-CoV-2 and cancer: the intriguing and informative cross-talk. <i>Transfusion and Apheresis Science</i> , 2022, 61, 103488.	0.5	5
1068	Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1069	Connecting the dots between inflammatory cascades of obesity and COVID-19 in light of mortal consequences—a review. <i>Environmental Science and Pollution Research</i> , 2022, 29, 57040-57053.	2.7	3
1070	Abnormal antibodies to self-carbohydrates in SARS-CoV-2-infected patients. , 2022, 1, .		5
1071	A Pilot Study on COVID-19 Positive Subjects: An Excerpt of Post-Infection-Pro-Diabetic Disposition & Related Consequences in Correlation to Hepato-Pancreatic Bio-Markers, Pro-Inflammatory Cytokines and Other Risk Factors. <i>Indian Journal of Clinical Biochemistry</i> , 0, , .	0.9	0
1072	Monocytic-Myeloid Derived Suppressor Cells Suppress T-Cell Responses in Recovered SARS CoV2-Infected Individuals. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1073	Microvascular and proteomic signatures overlap in COVID-19 and bacterial sepsis: the MICROCODE study. <i>Angiogenesis</i> , 0, , .	3.7	8
1074	Plasma Markers of Neurologic Injury and Inflammation in People With Self-Reported Neurologic Postacute Sequelae of SARS-CoV-2 Infection. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	41
1076	Outcomes of multiple sclerosis patients admitted with COVID-19 in a large veteran cohort. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 64, 103964.	0.9	1
1078	Multiplex Technologies in COVID-19 Research, Diagnostics, and Prognostics: Battling the Pandemic. <i>Methods in Molecular Biology</i> , 2022, , 3-20.	0.4	2

#	ARTICLE	IF	CITATIONS
1079	Integration and Reanalysis of Four RNA-Seq Datasets Including BALF, Nasopharyngeal Swabs, Lung Biopsy, and Mouse Models Reveals Common Immune Features of COVID-19. <i>Immune Network</i> , 2022, 22, .	1.6	4
1080	Evaluating the Effects of Curcumin on the Cytokine Storm in COVID-19 Using a Chip-Based Multiplex Analysis. <i>Methods in Molecular Biology</i> , 2022, , 285-295.	0.4	3
1081	Evaluating The Utility of Interleukin-6, C -Reactive Protein (CRP) and Procalcitonin in Predicting Disease Severity and Prognosis in Hospitalized SARS-CoV-2 Patients: A North Indian Retrospective Study. <i>Arab Gulf Journal of Scientific Research</i> , 2022, , 48-59.	0.3	0
1082	The nervous system during COVID-19: Caught in the crossfire. <i>Immunological Reviews</i> , 2022, 311, 90-111.	2.8	9
1083	NKG2A Expression among CD8 Cells Is Associated with COVID-19 Progression in Hypertensive Patients: Insights from the BRACE CORONA Randomized Trial. <i>Journal of Clinical Medicine</i> , 2022, 11, 3713.	1.0	7
1084	Cytokine Profiles Associated With Acute COVID-19 and Long COVID-19 Syndrome. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	94
1085	Antigenic Determinants of SARS-CoV-2-Specific CD4+ T Cell Lines Reveals M Protein-Driven Dysregulation of Interferon Signaling. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1086	Thromboelastometry Predicts Thromboembolic Events, Hospital Length of Stay, and Mortality in Patients with COVID-19 Infection and Mild Hypoxemia: A Prospective Observational Study. <i>Journal of Blood Medicine</i> , 0, Volume 13, 363-372.	0.7	1
1087	Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19. <i>Cell Reports Medicine</i> , 2022, 3, 100680.	3.3	19
1088	Emergency Hematopoiesis in the Pathobiology of COVID-19: The Dark Side of an Early Innate Protective Mechanism. <i>Journal of Interferon and Cytokine Research</i> , 2022, 42, 393-405.	0.5	3
1089	Human cardiac organoids to model COVID-19 cytokine storm induced cardiac injuries. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2022, 16, 799-811.	1.3	15
1090	Periodontitis and COVID-19: Biological Mechanisms and Meta-analyses of Epidemiological Evidence. <i>Journal of Dental Research</i> , 2022, 101, 1430-1440.	2.5	30
1091	The Impact of COVID-19 Infection on Cognitive Function and the Implication for Rehabilitation: A Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7748.	1.2	26
1092	Therapeutic Targeting of Innate Immune Receptors Against SARS-CoV-2 Infection. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	3
1093	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	28
1094	From the Oligonucleotide purUUpurU to Cytokine Storm, Elevated Blood Viscosity, and Complications of Coronavirus Disease 2019. <i>Cureus</i> , 2022, , .	0.2	2
1095	Metabolite, protein, and tissue dysfunction associated with COVID-19 disease severity. <i>Scientific Reports</i> , 2022, 12, .	1.6	11
1096	Virofree, an Herbal Medicine-Based Formula, Interrupts the Viral Infection of Delta and Omicron Variants of SARS-CoV-2. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7

#	ARTICLE	IF	CITATIONS
1097	Heterogeneity in IgGâ€CD16 signaling in infectious disease outcomes*. Immunological Reviews, 2022, 309, 64-74.	2.8	9
1098	Inflammation and vascular dysfunction: The negative synergistic combination of diabetes and COVIDâ€19. Diabetes/Metabolism Research and Reviews, 2022, 38, .	1.7	7
1099	Neuromodulation Strategies to Reduce Inflammation and Improve Lung Complications in COVID-19 Patients. Frontiers in Neurology, 0, 13, .	1.1	9
1100	Altered gut microbiota patterns in COVID-19: Markers for inflammation and disease severity. World Journal of Gastroenterology, 2022, 28, 2802-2822.	1.4	13
1101	Insights into Endotheliopathy in COVID-19. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 926-928.	2.5	5
1102	One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment. Stem Cell Research and Therapy, 2022, 13, .	2.4	2
1103	Psychiatric Manifestations of COVID-19: A Literature Review. CNS and Neurological Disorders - Drug Targets, 2023, 22, 892-905.	0.8	3
1104	Changes in Symptoms Experienced by SARS-CoV-2-Infected Individuals â€ From the First Wave to the Omicron Variant. Frontiers in Virology, 0, 2, .	0.7	20
1106	A Comprehensive Analysis of Myocarditis in Formerly Healthy Individuals Following SARS-CoV-2 Vaccination (COVID-19 Immunization). Cureus, 2022, , .	0.2	1
1107	Immune Thrombocytopenia in Previously Healthy Individuals Following SARS-CoV-2 Vaccination (COVID-19 Immunization): A Descriptive Research of 70 Instances With a Focus on Biomarkers, Predictive Outcomes, and Consequences. Cureus, 2022, , .	0.2	2
1108	Hydrogen bonding penalty used for virtual screening to discover potent inhibitors for Papainâ€Like cysteine proteases of SARSâ€CoVâ€2. Chemical Biology and Drug Design, 2022, 100, 502-514.	1.5	4
1109	Myocardial Ischemia in Patients with COVID-19 Infection: Between Pathophysiological Mechanisms and Electrocardiographic Findings. Life, 2022, 12, 1015.	1.1	7
1110	Autoimmunity and SARSâ€CoVâ€2 infection: Unraveling the link in neurological disorders. European Journal of Immunology, 2022, 52, 1561-1571.	1.6	11
1111	SARS-CoV-2 Delta spike protein enhances the viral fusogenicity and inflammatory cytokine production. IScience, 2022, 25, 104759.	1.9	11
1114	Plasticity of natural killer cells in pregnant patients infected with SARS-CoV-2 and their neonates during childbirth. Frontiers in Immunology, 0, 13, .	2.2	4
1115	Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults. Nature Communications, 2022, 13, .	5.8	43
1116	COVIDâ€19, obesity, and immune response 2â€years after the pandemic: A timeline of scientific advances. Obesity Reviews, 2022, 23, .	3.1	6
1117	Differential chromatin accessibility in peripheral blood mononuclear cells underlies COVID-19 disease severity prior to seroconversion. Scientific Reports, 2022, 12, .	1.6	8

#	ARTICLE	IF	CITATIONS
1118	Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review. <i>World Journal of Critical Care Medicine</i> , 2022, 11, 269-297.	0.8	2
1119	Efferocytosis in lung mucosae: implications for health and disease. <i>Immunology Letters</i> , 2022, 248, 109-118.	1.1	3
1120	Percutaneous Auricular Vagus Nerve Stimulation Reduces Inflammation in Critical Covid-19 Patients. <i>Frontiers in Physiology</i> , 0, 13, .	1.3	10
1121	Characterisation of the blood RNA host response underpinning severity in COVID-19 patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	18
1122	Innate immunity to SARS-CoV-2 infection: A review. <i>Epidemiology and Infection</i> , 0, , 1-49.	1.0	9
1123	Plasmacytoid dendritic cells during COVID-19: Ally or adversary?. <i>Cell Reports</i> , 2022, 40, 111148.	2.9	14
1124	Clinical progress in MSC-based therapies for the management of severe COVID-19. <i>Cytokine and Growth Factor Reviews</i> , 2022, 68, 25-36.	3.2	10
1125	Size-based effects of anthropogenic ultrafine particles on activation of human lung macrophages. <i>Environment International</i> , 2022, 166, 107395.	4.8	9
1126	The effect of reparixin on survival in patients at high risk for in-hospital mortality: a meta-analysis of randomized trials. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1127	Mapping Scientific Productivity Trends and Hotspots in Remdesivir Research Publications: A Bibliometric Study from 2016 to 2021. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8845.	1.2	9
1128	Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection. <i>Nature Chemical Biology</i> , 2022, 18, 1056-1064.	3.9	26
1129	Systemic inflammation indices predict mortality in patients with COVID-19. <i>Journal of Health Sciences and Medicine</i> , 2022, 5, 1086-1091.	0.0	1
1130	Neurofilament light increases over time in severe COVID-19 and is associated with delirium. <i>Brain Communications</i> , 2022, 4, .	1.5	6
1131	Ubiquitination of SARS-CoV-2 NSP6 and ORF7a Facilitates NF- κ B Activation. <i>MBio</i> , 2022, 13, .	1.8	23
1132	Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase2a clinical trial. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	27
1133	Long-term implications of COVID-19 on bone health: pathophysiology and therapeutics. <i>Inflammation Research</i> , 2022, 71, 1025-1040.	1.6	18
1134	Stem Cells: A Promising Therapeutic Target for COVID-19. <i>Stem Cell Discovery</i> , 2022, 12, 1-27.	0.5	1
1135	A Portable and Low-Cost Centrifugal Microfluidic Platform for Multiplexed Colorimetric Detection of Protein Biomarkers. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1136	In vitro and in vivo pharmacodynamic activity of the new compound XC221GI in models of the viral inflammation of the respiratory tract. <i>Microbiology Independent Research Journal</i> , 0, 9, .	0.2	4
1137	Inhibition of human macrophage activation via pregnane neurosteroid interactions with toll-like receptors: Sex differences and structural requirements. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1138	Impaired ketogenesis ties metabolism to T cell dysfunction in COVID-19. <i>Nature</i> , 2022, 609, 801-807.	13.7	65
1139	Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. <i>Lancet, The</i> , 2022, 400, 359-368.	6.3	146
1140	Multiethnic Investigation of Risk and Immune Determinants of COVID-19 Outcomes. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	1
1141	Human Lung Fibroblasts Exhibit Induced Inflammation Memory via Increased IL6 Gene Expression and Release. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1142	The common regulatory pathway of COVID-19 and multiple inflammatory diseases and the molecular mechanism of cepharanthine in the treatment of COVID-19. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	5
1143	Comprehensive Cytokine Profiling of Patients with COVID-19 Receiving Tocilizumab Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7937.	1.8	2
1145	Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	12
1146	High Circulating Levels of the Homeostatic Chemokines CCL19 and CCL21 Predict Mortality and Disease Severity in COVID-19. <i>Journal of Infectious Diseases</i> , 2022, 226, 2150-2160.	1.9	12
1147	Immune responses to SARS-CoV-2 in dialysis and kidney transplantation. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 1816-1828.	1.4	9
1150	Timely administration of tocilizumab improves outcome of hospitalized COVID-19 patients. <i>PLoS ONE</i> , 2022, 17, e0271807.	1.1	10
1151	Impact of Immunotherapies on SARS-CoV-2-Infections and Other Respiratory Tract Infections during the COVID-19 Winter Season in IBD Patients. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2022, 2022, 1-9.	0.8	0
1153	Publicly available cytokine data: Limitations and opportunities. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 1053-1056.	1.5	2
1154	Coronavirus Disease-2019 and Implications on the Liver. <i>Clinics in Liver Disease</i> , 2023, 27, 27-45.	1.0	7
1155	The immune response as a double-edged sword: The lesson learnt during the COVID-19 pandemic. <i>Immunology</i> , 2022, 167, 287-302.	2.0	15
1156	Dysregulation of immunity in COVID-19 and SLE. <i>Inflammopharmacology</i> , 2022, 30, 1517-1531.	1.9	6
1157	Association between inflammatory cytokines/chemokines, clinical laboratory parameters, disease severity and in-hospital mortality in critical and mild COVID-19 patients without comorbidities or immune-mediated diseases. <i>Journal of Immunoassay and Immunochemistry</i> , 0, , 1-18.	0.5	1

#	ARTICLE	IF	CITATIONS
1158	Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1456-1468.	0.8	10
1159	Soluble angiotensin-converting enzyme 2 association with lipid metabolism. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
1160	Assessing the use of a micro-sampling device for measuring blood protein levels in healthy subjects and COVID-19 patients. <i>PLoS ONE</i> , 2022, 17, e0272572.	1.1	3
1161	Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	23
1162	Cellular heterogeneity in disease severity and clinical outcome: Granular understanding of immune response is key. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1163	Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients?. <i>Viruses</i> , 2022, 14, 1860.	1.5	0
1165	Plasma metabolome and cytokine profile reveal glycyproline modulating antibody fading in convalescent COVID-19 patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	11
1166	The Pharmacist's Role in Managing COVID-19 in Chronic Kidney Disease Patients: A Review of Existing Strategies and Future Implications. <i>Pharmacy (Basel, Switzerland)</i> , 2022, 10, 94.	0.6	1
1167	Nicotine in Combination with SARS-CoV-2 Affects Cells Viability, Inflammatory Response and Ultrastructural Integrity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9488.	1.8	1
1168	Using patient biomarker time series to determine mortality risk in hospitalised COVID-19 patients: A comparative analysis across two New York hospitals. <i>PLoS ONE</i> , 2022, 17, e0272442.	1.1	0
1169	Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9297.	1.8	4
1170	What is the role of prognostic indexes in COVID-19 patients with diabetes mellitus? Data of patients from Turkey. <i>Biomarkers in Medicine</i> , 0, , .	0.6	0
1171	Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 773-787.	0.5	11
1172	The Muslim Gaze and the COVID-19 Syndemic. <i>Religions</i> , 2022, 13, 780.	0.3	4
1173	Plasma biomarkers for systemic inflammation in COVID-19 survivors. <i>Proteomics - Clinical Applications</i> , 2022, 16, .	0.8	15
1174	Collective outbreak of severe acute histoplasmosis in immunocompetent Chinese in South America: the clinical characteristics and continuous monitoring of serum cytokines/chemokines. , 2022, 23, .		0
1175	A simple model of COVID-19 explains disease severity and the effect of treatments. <i>Scientific Reports</i> , 2022, 12, .	1.6	14
1176	The roles of cellular protease interactions in viral infections and programmed cell death: a lesson learned from the SARS-CoV-2 outbreak and COVID-19 pandemic. <i>Pharmacological Reports</i> , 2022, 74, 1149-1165.	1.5	5

#	ARTICLE	IF	CITATIONS
1177	Celastrol: A lead compound that inhibits SARS-CoV-2 replication, the activity of viral and human cysteine proteases, and virus-induced IL-6 secretion. <i>Drug Development Research</i> , 2022, 83, 1623-1640.	1.4	6
1179	A Preliminary Study about the Role of Reactive Oxygen Species and Inflammatory Process after COVID-19 Vaccination and COVID-19 Disease. <i>Clinics and Practice</i> , 2022, 12, 599-608.	0.6	3
1180	Clinical Research Progress of Small Molecule Compounds Targeting Nrf2 for Treating Inflammation-Related Diseases. <i>Antioxidants</i> , 2022, 11, 1564.	2.2	9
1181	Modeling SARS-CoV-2 and influenza infections and antiviral treatments in human lung epithelial tissue equivalents. <i>Communications Biology</i> , 2022, 5, .	2.0	11
1182	Experimental comparison of direct and indirect aptamer-based biochemical functionalization of electrolyte-gated graphene field-effect transistors for biosensing applications. <i>Analytica Chimica Acta</i> , 2022, 1222, 340177.	2.6	6
1183	Targeting Doublecortin-Like Kinase 1 (DCLK1)-Regulated SARS-CoV-2 Pathogenesis in COVID-19. <i>Journal of Virology</i> , 2022, 96, .	1.5	4
1184	Quantitative chest computed tomography combined with plasma cytokines predict outcomes in COVID-19 patients. <i>Heliyon</i> , 2022, 8, e10166.	1.4	0
1186	Stroke-induced changes to immune function and their relevance to increased risk of severe COVID-19 disease. , 0, , .		0
1187	Plasma biomarkers associated with survival and thrombosis in hospitalized COVID-19 patients. <i>International Journal of Hematology</i> , 2022, 116, 937-946.	0.7	11
1188	Brain region-specific microglial and astrocytic activation in response to systemic lipopolysaccharides exposure. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	7
1189	Persistent T-cell exhaustion in relation to prolonged pulmonary pathology and death after severe COVID-19: Results from two Norwegian cohort studies. <i>Journal of Internal Medicine</i> , 2022, 292, 816-828.	2.7	4
1191	Immune-related adverse events of biological immunotherapies used in COVID-19. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
1192	Expression Pattern of Inflammatory and Anti-Inflammatory Cytokines and Key Differential Transcription Factors in Peripheral Blood Mononuclear Cells of Iranian Coronavirus Disease 2019 Patients with Different Disease Severity. <i>Viral Immunology</i> , 2022, 35, 474-482.	0.6	2
1193	Whole blood DNA methylation analysis reveals respiratory environmental traits involved in COVID-19 severity following SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, .	5.8	14
1194	Incidence and risk factors of COVID-19 associated pneumothorax. <i>PLoS ONE</i> , 2022, 17, e0271964.	1.1	13
1195	IFN- β transforms the transcriptomic landscape and triggers myeloid cell hyperresponsiveness to cause lethal lung injury. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1197	Looking into the IL-1 of the storm: are inflammasomes the link between immunothrombosis and hyperinflammation in cytokine storm syndromes?. , 2022, 1, .		3
1198	A significant predictor of in-hospital and long-term mortality and progression in COVID-19 patients: The end-stage liver disease (MELD) score model. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	5

#	ARTICLE	IF	CITATIONS
1199	Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis. <i>Pharmacological Research</i> , 2022, 184, 106424.	3.1	14
1200	Computational exploration of the dual role of the phytochemical fortunellin: Antiviral activities against SARS-CoV-2 and immunomodulatory abilities against the host. <i>Computers in Biology and Medicine</i> , 2022, 149, 106049.	3.9	3
1201	Transposition of polymer-encapsulated small interfering RNA through lung surfactant models at the air-water interface. <i>Chemical Physics</i> , 2022, 563, 111704.	0.9	1
1202	Population-weighted exposure to green spaces tied to lower COVID-19 mortality rates: A nationwide dose-response study in the USA. <i>Science of the Total Environment</i> , 2022, 851, 158333.	3.9	10
1203	Interplay of LncRNAs NEAT1 and TUG1 in Incidence of Cytokine Storm in Appraisal of COVID-19 Infection. <i>International Journal of Biological Sciences</i> , 2022, 18, 4901-4913.	2.6	9
1204	Successful treatment of severe COVID-19 pneumonia, a case series with simultaneous interleukin-1 and interleukin-6 blockade with 1-month follow-up. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211164.	1.2	2
1205	Microorganisms in Pathogenesis and Management of Vitiligo. , 2022, , 189-223.		1
1206	The Disease-Modifying Role of Taurine and Its Therapeutic Potential in Coronavirus Disease 2019 (COVID-19). <i>Advances in Experimental Medicine and Biology</i> , 2022, , 3-21.	0.8	4
1207	In silico analysis of the interactions of <i>Clitoria ternatea</i> (L.) bioactive compounds against multiple immunomodulatory receptors. <i>AIP Conference Proceedings</i> , 2022, , .	0.3	0
1208	Laboratory Markers of COVID-19 in the Emergency Room. <i>Biomarkers in Disease</i> , 2022, , 1-28.	0.0	0
1209	Exploring extracellular vesicles as mediators of clinical disease and vehicles for viral therapeutics: Insights from the COVID-19 pandemic. , 2022, 3, 172-88.		1
1210	COVID-19 and the potential of Janus family kinase (JAK) pathway inhibition: A novel treatment strategy. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
1212	Perspective: repurposed Drugs for COVID-19. <i>Archives of Medical Science</i> , 2022, 18, 1378-1391.	0.4	3
1213	Blood Transcriptomes of SARS-CoV-2â€“Infected Kidney Transplant Recipients Associated with Immune Insufficiency Proportionate to Severity. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 2108-2122.	3.0	6
1214	Potential Therapeutic Role of Mesenchymal-Derived Stem Cells as an Alternative Therapy to Combat COVID-19 through Cytokines Storm. <i>Cells</i> , 2022, 11, 2686.	1.8	1
1215	Immune modulation as a consequence of SARS-CoV-2 infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1216	SARS-CoV-2 ORF8 is a viral cytokine regulating immune responses. <i>International Immunology</i> , 2023, 35, 43-52.	1.8	14
1217	Severe acute pancreatitis exhibits distinct cytokine signatures and trajectories in humans: a prospective observational study. <i>American Journal of Physiology - Renal Physiology</i> , 2022, 323, G428-G438.	1.6	6

#	ARTICLE	IF	CITATIONS
1218	Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial. <i>Intensive Care Medicine</i> , 2022, 48, 1525-1538.	3.9	13
1219	Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19. <i>Blood</i> , 2022, 140, 1993-1997.	0.6	8
1221	Mecanismos y efectos biológicos potenciales de la vitamina D en la COVID-19: una revisión narrativa. <i>Revista De Nutrición Clínica Y Metabolismo</i> , 2022, 5, .	0.3	0
1222	COVID-19 patients exhibit unique transcriptional signatures indicative of disease severity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1223	A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. <i>RMD Open</i> , 2022, 8, e002359.	1.8	9
1224	Clinical significance of anti-nucleocapsid-IgG sero-positivity in SARS-CoV-2 infection in hospitalized patients in North Dakota. <i>World Journal of Clinical Infectious Diseases</i> , 0, 12, 50-60.	0.5	0
1225	Low baseline IFN- γ response could predict hospitalization in COVID-19 patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
1226	NSP4 and ORF9b of SARS-CoV-2 Induce Pro-Inflammatory Mitochondrial DNA Release in Inner Membrane-Derived Vesicles. <i>Cells</i> , 2022, 11, 2969.	1.8	18
1227	The effects of consuming a Mediterranean style diet on associated COVID-19 severity biomarkers in obese/overweight adults: A systematic review. <i>Nutrition and Health</i> , 2022, 28, 647-667.	0.6	4
1228	Long COVID-19 and the Heart: Is Cardiac Mitochondria the Missing Link?. <i>Antioxidants and Redox Signaling</i> , 0, , .	2.5	6
1229	Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms. <i>European Respiratory Journal</i> , 0, , 2200970.	3.1	66
1230	The JAK1/2 Inhibitor Baricitinib Mitigates the Spike-Induced Inflammatory Response of Immune and Endothelial Cells In Vitro. <i>Biomedicines</i> , 2022, 10, 2324.	1.4	6
1231	Immunophenotypes of anti-SARS-CoV-2 responses associated with fatal COVID-19. <i>ERJ Open Research</i> , 0, , 00216-2022.	1.1	0
1232	Cytokine levels as predictors of mortality in critically ill patients with severe COVID-19 pneumonia: Case-control study nested within a cohort in Colombia. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
1233	Autoantibodies elicited with SARS-CoV-2 infection are linked to alterations in double negative B cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1234	Clinical characteristics and differential cytokine expression in hospitalized Taiwanese children with respiratory syncytial virus and rhinovirus bronchiolitis. <i>Journal of Microbiology, Immunology and Infection</i> , 2023, 56, 282-291.	1.5	3
1235	Immune Determinants of Viral Clearance in Hospitalised COVID-19 Patients: Reduced Circulating Na γ ve CD4+ T Cell Counts Correspond with Delayed Viral Clearance. <i>Cells</i> , 2022, 11, 2743.	1.8	9
1236	Upregulation of interleukin-19 in saliva of patients with COVID-19. <i>Scientific Reports</i> , 2022, 12, .	1.6	9

#	ARTICLE	IF	CITATIONS
1237	A shift in lung macrophage composition is associated with COVID-19 severity and recovery. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	33
1238	IL-4, IL-10, CCL2 and TGF- β 2 as potential biomarkers for severity in <i>Plasmodium vivax</i> malaria. <i>PLoS Neglected Tropical Diseases</i> , 2022, 16, e0010798.	1.3	1
1239	Implications at the ocular level of miRNAs modifications induced by SARS-CoV-2 infection. <i>Romanian Journal of Morphology and Embryology</i> , 2022, 63, 55-59.	0.4	2
1240	Insights into CD24 and Exosome Physiology and Potential Role in View of Recent Advances in COVID-19 Therapeutics: A Narrative Review. <i>Life</i> , 2022, 12, 1472.	1.1	6
1241	The Effects of H2S and Recombinant Human Hsp70 on Inflammation Induced by SARS and Other Agents In Vitro and In Vivo. <i>Biomedicines</i> , 2022, 10, 2155.	1.4	2
1243	A biomarker assay to risk-stratify patients with symptoms of respiratory tract infection. <i>European Respiratory Journal</i> , 2022, 60, 2200459.	3.1	3
1244	COVID-19 immunopathology: From acute diseases to chronic sequelae. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	24
1245	Starting signal: Aberrant kinase activation as a trigger for SARS-CoV-2 induced axonal damage. <i>Frontiers in Virology</i> , 0, 2, .	0.7	1
1246	Apolipoprotein-A-I for severe COVID-19-induced hyperinflammatory states: A prospective case study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
1247	Neutrophil-to-lymphocyte ratio as a predictor of clinical outcomes in critically ill COVID-19 patients: A retrospective observational study. <i>Health Science Reports</i> , 2022, 5, .	0.6	4
1248	Development of an In Vitro Model of SARS-CoV-Induced Acute Lung Injury for Studying New Therapeutic Approaches. <i>Antioxidants</i> , 2022, 11, 1910.	2.2	4
1249	Early stimulated immune responses predict clinical disease severity in hospitalized COVID-19 patients. <i>Communications Medicine</i> , 2022, 2, .	1.9	5
1251	Cardiovascular Factors Associated with COVID-19 from an International Registry of Primarily Japanese Patients. <i>Diagnostics</i> , 2022, 12, 2350.	1.3	3
1252	Human Cardiac Pericytes Are Susceptible to SARS-CoV-2 Infection. <i>JACC Basic To Translational Science</i> , 2023, 8, 109-120.	1.9	13
1253	A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility. <i>Npj Genomic Medicine</i> , 2022, 7, .	1.7	5
1254	association of baseline C-reactive protein, D-dimer, and lymphocytes levels with health-related quality of life in severe COVID-19 survivors. <i>International Journal of Health Sciences</i> , 0, , 10948-10961.	0.0	0
1255	Difference in mortality rates in hospitalized COVID-19 patients identified by cytokine profile clustering using a machine learning approach: An outcome prediction alternative. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
1256	An Immune Response to Heterologous ChAdOx1/BNT162b2 Vaccination against COVID-19: Evaluation of the anti-RBD Specific IgG Antibodies Titers and Interferon Gamma Release Assay (IGRA) Test Results. <i>Vaccines</i> , 2022, 10, 1546.	2.1	1

#	ARTICLE	IF	CITATIONS
1257	Assessment of plasma Catestatin in COVID-19 reveals a hitherto unknown inflammatory activity with impact on morbidity-mortality. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1258	The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals. <i>Clinical Proteomics</i> , 2022, 19, .	1.1	3
1259	Interleukin-17, a salivary biomarker for COVID-19 severity. <i>PLoS ONE</i> , 2022, 17, e0274841.	1.1	7
1260	In Vitro Evaluation of <i>Leuconostoc mesenteroides</i> Cell-Free-Supernatant GBUT-21 against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 1581.	2.1	4
1261	Dysfunctional purinergic signaling correlates with disease severity in COVID-19 patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
1262	Role of Matrix Degradation, Oxidative Stress, Inflammation & Trace Elements in COVID-19 Patients: A Multivariate Study from India. <i>Indian Journal of Clinical Biochemistry</i> , 2023, 38, 193-203.	0.9	5
1263	Druggable targets and therapeutic development for COVID-19. <i>Frontiers in Chemistry</i> , 0, 10, .	1.8	4
1264	Cytokine levels associated with favorable clinical outcome in the CAPSID randomized trial of convalescent plasma in patients with severe COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1266	How COVID-19 shaped mental health: from infection to pandemic effects. <i>Nature Medicine</i> , 2022, 28, 2027-2037.	15.2	124
1267	Yoga, Meditation, Breathing Exercises, and Inflammatory Biomarkers with Possible Implications in COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-28.	0.5	2
1268	Probing SARS-CoV-2-positive plasma to identify potential factors correlating with mild COVID-19 in Ghana, West Africa. <i>BMC Medicine</i> , 2022, 20, .	2.3	6
1269	Aberrant methylation of <i>Serpine1</i> mediates lung injury in neonatal mice prenatally exposed to intrauterine inflammation. <i>Cell and Bioscience</i> , 2022, 12, .	2.1	0
1270	Host Biomarkers Reflect Prognosis in Patients Presenting With Moderate Coronavirus Disease 2019: A Prospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	2
1271	Single-cell transcriptome atlas reveals protective characteristics of COVID-19 mRNA vaccine. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	3
1272	Interdisciplinary Approaches in Cancer Research. , 2022, , .		0
1274	A potent inflammatory response is triggered in asymptomatic blood donors with recent SARS-CoV-2 infection. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 0, 55, .	0.4	0
1275	Calprotectin Levels and Neutrophil Count Are Prognostic Markers of Mortality in COVID-19 Patients. <i>Diagnostics</i> , 2022, 12, 2554.	1.3	5
1278	The SARS-CoV-2 S1 Spike Protein Promotes MAPK and NF- κ B Activation in Human Lung Cells and Inflammatory Cytokine Production in Human Lung and Intestinal Epithelial Cells. <i>Microorganisms</i> , 2022, 10, 1996.	1.6	11

#	ARTICLE	IF	CITATIONS
1279	Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19. <i>Biomedicines</i> , 2022, 10, 2628.	1.4	1
1280	Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
1281	Timing of tofacitinib therapy is critical to improving outcomes in severe-critical COVID-19 infection: A retrospective study from a tertiary care hospital. <i>Medicine (United States)</i> , 2022, 101, e30975.	0.4	2
1282	Association of polymorphisms in long pentraxin 3 and its plasma levels with COVID-19 severity. <i>Clinical and Experimental Medicine</i> , 2023, 23, 1225-1233.	1.9	4
1283	The Effect of Nitazoxanide on the Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Clinical Drug Investigation</i> , 2022, 42, 1031-1047.	1.1	4
1285	Identification of Cysteine 270 as a Novel Site for Allosteric Modulators of SARS-CoV-2 Papain-Like Protease**. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	9
1286	SARS-CoV-2 Variant-Specific Infectivity and Immune Profiles Are Detectable in a Humanized Lung Mouse Model. <i>Viruses</i> , 2022, 14, 2272.	1.5	3
1287	COVID-19 Severity and Thrombo-Inflammatory Response Linked to Ethnicity. <i>Biomedicines</i> , 2022, 10, 2549.	1.4	4
1288	Assessment of Admission COVID-19 Associated Hyperinflammation Syndrome Score in Critically-Ill COVID-19 Patients. <i>Journal of Intensive Care Medicine</i> , 2023, 38, 70-77.	1.3	2
1289	Serial ferritin titer monitoring in COVID-19 pneumonia: valuable inflammatory marker in assessment of severity and predicting early lung fibrosis” prospective, multicentric, observational, and interventional study in tertiary care setting in India. <i>The Egyptian Journal of Internal Medicine</i> , 2022, 34, .	0.3	4
1290	COVID-19 disease and immune dysregulation. <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101401.	0.7	26
1291	Enhanced Label-Free Nanoplasmonic Cytokine Detection in SARS-CoV-2 Induced Inflammation Using Rationally Designed Peptide Aptamer. <i>ACS Applied Materials & Interfaces</i> , 2022, 14, 48464-48475.	4.0	3
1292	Digital Protein Detection in Bulk Solutions. <i>ACS Omega</i> , 2022, 7, 37714-37723.	1.6	1
1293	Clinical progression and outcomes of patients hospitalized with COVID-19 in humanitarian settings: A prospective cohort study in South Sudan and Eastern Democratic Republic of the Congo. <i>PLOS Global Public Health</i> , 2022, 2, e0000924.	0.5	0
1294	Treatment of severe COVID-19: an evolving paradigm. <i>Expert Opinion on Pharmacotherapy</i> , 2022, 23, 1887-1891.	0.9	5
1295	Interplay between SARS-CoV-2 and Cancer: Plausible Risk factors, Cellular Immune Responses, Cancer Directed Therapy- Current Challenges. <i>Infectious Disorders - Drug Targets</i> , 2022, 23, .	0.4	0
1296	Exploratory analysis of interleukin-38 in hospitalized COVID-19 patients. <i>Immunity, Inflammation and Disease</i> , 2022, 10, .	1.3	1
1297	Impairment of antiviral immune response and disruption of cellular functions by SARS-CoV-2 ORF7a and ORF7b. <i>IScience</i> , 2022, 25, 105444.	1.9	14

#	ARTICLE	IF	CITATIONS
1298	The IgG glycome of SARS-CoV-2 infected individuals reflects disease course and severity. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1299	CD169-mediated restrictive SARS-CoV-2 infection of macrophages induces pro-inflammatory responses. <i>PLoS Pathogens</i> , 2022, 18, e1010479.	2.1	15
1300	Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	8
1301	Therapeutic advances in COVID-19. <i>Nature Reviews Nephrology</i> , 2023, 19, 38-52.	4.1	67
1303	SARS-CoV-2-Infection (COVID-19): Clinical Course, Viral Acute Respiratory Distress Syndrome (ARDS) and Cause(s) of Death. <i>Medical Sciences (Basel, Switzerland)</i> , 2022, 10, 58.	1.3	6
1304	Is SARS-CoV-2 a Risk Factor of Bipolar Disorder?â€”A Narrative Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 6060.	1.0	4
1305	Circulating tumor necrosis factor receptors are associated with mortality and disease severity in COVID-19 patients. <i>PLoS ONE</i> , 2022, 17, e0275745.	1.1	4
1306	Identification of Cysteine 270 as a Novel Site for Allosteric Modulators of SARSâ€™CoVâ€™2 Papainâ€™Like Protease. <i>Angewandte Chemie</i> , 0, , .	1.6	0
1308	A population-based cohort study of sex and risk of severe outcomes in covid-19. <i>European Journal of Epidemiology</i> , 2022, 37, 1159-1169.	2.5	10
1309	CD8+ T-cell immune escape by SARS-CoV-2 variants of concern. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1310	Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19. <i>Vaccines</i> , 2022, 10, 1762.	2.1	7
1311	One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	16
1312	Thrombopoietin participates in platelet activation in COVID-19 patients. <i>EBioMedicine</i> , 2022, 85, 104305.	2.7	3
1313	Pre-infection antiviral innate immunity contributes to sex differences in SARS-CoV-2 infection. <i>Cell Systems</i> , 2022, 13, 924-931.e4.	2.9	6
1314	Evaluation of Hepcidin Level in COVID-19 Patients Admitted to the Intensive Care Unit. <i>Diagnostics</i> , 2022, 12, 2665.	1.3	2
1315	A 9-mRNA signature measured from whole blood by a prototype PCR panel predicts 28-day mortality upon admission of critically ill COVID-19 patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1316	Are Antisense Long Non-Coding RNA Related to COVID-19?. <i>Biomedicines</i> , 2022, 10, 2770.	1.4	4
1317	The Infected Lungs and Brain Interface in COVID-19: The Impact on Cognitive Function. <i>NeuroImmunoModulation</i> , 2022, 29, 269-281.	0.9	2

#	ARTICLE	IF	CITATIONS
1318	Anti-Inflammatory Approach in Chronic Dialysis Patients with SARS-CoV-2: ATA or PMMA Dialyzers?. Blood Purification, 2023, 52, 210-218.	0.9	3
1319	Exploration of blood-derived coding and non-coding RNA diagnostic immunological panels for COVID-19 through a co-expressed-based machine learning procedure. Frontiers in Immunology, 0, 13, .	2.2	9
1320	Metabolic modeling of single bronchoalveolar macrophages reveals regulators of hyperinflammation in COVID-19. IScience, 2022, 25, 105319.	1.9	6
1321	Predicting COVID-19 severity. , 2023, , 431-440.		0
1322	COVID-19 disease severity to predict persistent symptoms: a systematic review and meta-analysis. Primary Health Care Research and Development, 2022, 23, .	0.5	12
1323	SARS-CoV-2 infection downregulates myocardial ACE2 and potentiates cardiac inflammation in humans and hamsters. American Journal of Physiology - Heart and Circulatory Physiology, 2022, 323, H1262-H1269.	1.5	10
1324	Prevalence, Risk Factors, and Outcomes of Gout Flare in Patients Hospitalized for PCR-Confirmed COVID-19: A Multicenter Retrospective Cohort Study. Journal of Rheumatology, 2023, 50, 556-563.	1.0	1
1325	Elevated Plasma D-Dimer Concentrations in Adults after an Outpatient-Treated COVID-19 Infection. Viruses, 2022, 14, 2441.	1.5	4
1326	Unbalanced networks and disturbed kinetics of serum soluble mediators associated with distinct disease outcomes in severe COVID-19 patients. Frontiers in Immunology, 0, 13, .	2.2	2
1327	The effect of transpyloric enteral nutrition on inflammatory response and prognosis for patients with Corona Virus Disease-19 in intensive care unit: A STROBE compliant study. Medicine (United Tj ETQq1 1 0.78434 4 rgBT2/Overlook		
1328	Immune profiles to distinguish hospitalized versus ambulatory COVID-19 cases in older patients. IScience, 2022, 25, 105608.	1.9	2
1329	Prognostic peripheral blood biomarkers at ICU admission predict COVID-19 clinical outcomes. Frontiers in Immunology, 0, 13, .	2.2	1
1330	High levels of soluble RAGE are associated with a greater risk of mortality in COVID-19 patients treated with dexamethasone. Respiratory Research, 2022, 23, .	1.4	2
1331	Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyond. IScience, 2022, 25, 105507.	1.9	10
1332	Systems biology approach reveals a common molecular basis for COVID-19 and non-alcoholic fatty liver disease (NAFLD). European Journal of Medical Research, 2022, 27, .	0.9	3
1333	COVID-19 associated liver injury: A general review with special consideration of pregnancy and obstetric outcomes. World Journal of Gastroenterology, 0, 28, 6017-6033.	1.4	1
1334	Advanced development and mechanism of sepsis-related acute respiratory distress syndrome. Frontiers in Medicine, 0, 9, .	1.2	6
1335	Interleukin-6 and Outcome of Chronic Hemodialysis Patients with SARS-CoV-2 Pneumonia. Medicina (Lithuania), 2022, 58, 1659.	0.8	1

#	ARTICLE	IF	CITATIONS
1336	Selection of Ideal Reference Genes for Gene Expression Analysis in COVID-19 and Mucormycosis. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	7
1339	Pathophysiological mechanisms of thrombosis in acute and long COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
1340	Merging microfluidics with luminescence immunoassays for urgent point-of-care diagnostics of COVID-19. <i>TrAC - Trends in Analytical Chemistry</i> , 2022, 157, 116814.	5.8	13
1342	GPR183 antagonism reduces macrophage infiltration in influenza and SARS-CoV-2 infection. <i>European Respiratory Journal</i> , 2023, 61, 2201306.	3.1	15
1343	Cytokine Profiling in Different SARS-CoV-2 Genetic Variants. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14146.	1.8	10
1344	Plasminogen Activator Inhibitor-1 Levels as an Indicator of Severity and Mortality for COVID-19. <i>Å°stanbul Kuzey Klinikleri</i> , 2022, , .	0.1	3
1345	An adaptable in vitro cytokine release assay (CRA): Susceptibility to cytokine storm in COVID-19 as a model. <i>Current Research in Immunology</i> , 2022, 3, 239-243.	1.2	0
1346	Inflammatory markers and auto-Abs to type I IFNs in COVID-19 convalescent plasma cohort study. <i>EBioMedicine</i> , 2023, 87, 104414.	2.7	7
1347	Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression. <i>Diabetes Research and Clinical Practice</i> , 2023, 195, 110205.	1.1	8
1348	Gender Differences Associated with Hyper-Inflammatory Conditions in COVID-19 Patients. , 2022, .		0
1349	Immune-Targeted Therapies for COVID-19. , 2022, , 451-468.		0
1350	UTILITY OF INFLAMMATORY MARKERS FOR TOCILIZUMAB IN COVID-19 PATIENTS: A SINGLE-SITE RETROSPECTIVE STUDY. <i>Journal of Ayub Medical College, Abbottabad: JAMC</i> , 2022, 34, 781-785.	0.1	0
1351	A novel diG motif in ORF3a protein of SARS-Cov-2 for intracellular transport. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	4
1352	Neuropsychiatric dimensions of COVID-19 - literature review. <i>Journal of Education, Health and Sport</i> , 2022, 13, 85-89.	0.0	0
1353	Association of cellular immunity with severity of COVID-19 from the perspective of antigen-specific memory T cell responses and cross-reactivity. <i>Inflammation and Regeneration</i> , 2022, 42, .	1.5	13
1354	Transcriptional differences between coronavirus disease 2019 and bacterial sepsis. <i>Virology Journal</i> , 2022, 19, .	1.4	3
1355	COVID-19 Pneumonia: Clinical Manifestations. <i>Clinics in Chest Medicine</i> , 2022, , .	0.8	0
1357	Immunomodulatory agents for COVID-19 pneumonia. <i>Clinics in Chest Medicine</i> , 2022, , .	0.8	1

#	ARTICLE	IF	CITATIONS
1358	N-acetylcysteine Reduces Inflammasome Activation Induced by SARS-CoV-2 Proteins In Vitro. <i>International Journal of Molecular Sciences</i> , 2022, 23, 14518.	1.8	11
1359	Persistent viral infections and their role in heart disease. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	10
1360	Preparing for the next pandemic: Simulation-based deep reinforcement learning to discover and test multimodal control of systemic inflammation using repurposed immunomodulatory agents. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1361	Homeopathy as an Adjuvant to Standard Care in Moderate and Severe Cases of COVID-19: A Single-Blind, Randomized, Placebo-Controlled Study. <i>Homeopathy</i> , 2023, 112, 184-197.	0.5	5
1362	Age-dependent effect of the IFIH1/MDA5 gene variants on the risk of critical COVID-19. <i>Immunogenetics</i> , 0, , .	1.2	2
1363	FEATURES OF PATHOGENESIS, COURSE AND THERAPY OF PNEUMONIA UNDER COVID-19 (Literature Review). , 2022, 22, 220-225.	0.1	1
1364	COVID-19 subphenotypes at hospital admission are associated with mortality: a cross-sectional study. <i>Annals of Medicine</i> , 2023, 55, 12-23.	1.5	3
1365	Respiratory infections and cancer. , 2022, , 15-30.		0
1366	Manipulation of innate immune signaling pathways by SARS-CoV-2 non-structural proteins. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	8
1367	Potential role of <scp>AIM2</scp> inflammasome in <scp>SARSâ€CoV</scp>â€ infection. <i>Scandinavian Journal of Immunology</i> , 2023, 97, .	1.3	2
1368	The role of <scp>HMGB1</scp> in <scp>COVIDâ€19â€induced</scp> cytokine storm and its potential therapeutic targets: A review. <i>Immunology</i> , 2023, 169, 117-131.	2.0	8
1369	Biological age and environmental risk factors for dementia and stroke: Molecular mechanisms. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	5
1370	SARS-CoV-2 viral protein ORF3A injures renal tubules by interacting with TRIM59 to induce STAT3 activation. <i>Molecular Therapy</i> , 2023, 31, 774-787.	3.7	8
1371	The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. <i>Nature Reviews Immunology</i> , 2023, 23, 304-316.	10.6	56
1372	The Histone Methyltransferase MLL1/KMT2A in Monocytes Drives Coronavirus-Associated Coagulopathy and Inflammation. <i>Blood</i> , 0, , .	0.6	2
1373	Molecular states during acute COVID-19 reveal distinct etiologies of long-term sequelae. <i>Nature Medicine</i> , 2023, 29, 236-246.	15.2	27
1374	Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?. <i>Drugs</i> , 2023, 83, 1-36.	4.9	4
1377	In Silico Prediction of Hub Genes Involved in Diabetic Kidney and COVID-19 Related Disease by Differential Gene Expression and Interactome Analysis. <i>Genes</i> , 2022, 13, 2412.	1.0	0

#	ARTICLE	IF	CITATIONS
1378	Neutrophils and macrophages drive TNF-induced lethality via TRIF/CD14-mediated responses. <i>Science Immunology</i> , 2022, 7, .	5.6	5
1379	Can Lactoferrin, a Natural Mammalian Milk Protein, Assist in the Battle against COVID-19?. <i>Nutrients</i> , 2022, 14, 5274.	1.7	5
1380	Potential therapeutic applications of extracellular vesicles in the immunopathogenesis of COVID-19. <i>Pathology Research and Practice</i> , 2023, 241, 154280.	1.0	6
1382	Ontological Analysis of Coronavirus Associated Human Genes at the COVID-19 Disease Portal. <i>Genes</i> , 2022, 13, 2304.	1.0	1
1383	Longitudinal Analysis of Urinary Cytokines and Biomarkers in COVID-19 Patients with Subclinical Acute Kidney Injury. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15419.	1.8	4
1385	Macrophages and T cells interplay during SARS-CoV-2 variants infection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1386	Validation of a specialized evaluation system for COVID-19 in Japan: A retrospective, multicenter cohort study. <i>Journal of Infection and Chemotherapy</i> , 2022, , .	0.8	0
1387	COVID-19 plasma exosomes promote proinflammatory immune responses in peripheral blood mononuclear cells. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
1388	COVID-19 plasma proteome reveals novel temporal and cell-specific signatures for disease severity and high-precision disease management. <i>Journal of Cellular and Molecular Medicine</i> , 2023, 27, 141-157.	1.6	6
1389	Significance of Catecholamine Biosynthetic/Metabolic Pathway in SARS-CoV-2 Infection and COVID-19 Severity. <i>Cells</i> , 2023, 12, 12.	1.8	5
1390	The natural killer cell-associated rs9916629<i>C</i> allele is a novel genetic risk factor for fatal COVID-19. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	5
1391	Utility of lung ultrasound in selecting older patients with hyperinflammatory phase in COVID-19 pneumonia. A monocentric, cross-sectional pilot study. <i>Journal of Gerontology and Geriatrics</i> , 0, , 1-7.	0.2	0
1392	Correlation between Thyroid Responses and Inflammatory Cytokines in Critically Ill COVID-19 Patients. <i>Biomedicines</i> , 2023, 11, 26.	1.4	1
1393	Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 151, 818-831.	1.5	13
1394	Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2023, 23, 484-495.	4.6	8
1395	Covid-19: o papel das Citocinas IL-1, IL-6 e TNF- α na resposta inflamatória. <i>Brazilian Journal of Health Review</i> , 2023, 6, 225-256.	0.0	0
1396	Design, synthesis, and biological investigation of oxadiazolyl, thiadiazolyl, and pyrimidinyl linked antipyrine derivatives as potential non-acidic anti-inflammatory agents. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2023, 38, .	2.5	4
1397	Predictive markers related to local and systemic inflammation in severe COVID-19-associated ARDS: a prospective single-center analysis. <i>BMC Infectious Diseases</i> , 2023, 23, .	1.3	3

#	ARTICLE	IF	CITATIONS
1399	Serum Catestatin Level as a Stratification Assessment Tool in Non-Critical COVID-19 Patients. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 1136.	1.2	0
1400	Clinical Outcome of Coronavirus Disease 2019 in Patients with Primary Antibody Deficiencies. <i>Pathogens</i> , 2023, 12, 109.	1.2	2
1401	A novel scoring system for early assessment of the risk of the COVID-19-associated mortality in hospitalized patients: COVID-19 BURDEN. <i>European Journal of Medical Research</i> , 2023, 28, .	0.9	3
1402	Hemodialysis-Associated Immune Dysregulation in SARS-CoV-2-Infected End-Stage Renal Disease Patients. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1712.	1.8	4
1403	Correlation of ferritin with the duration of illness, disease severity, oxygenation status, ventilatory requirement, and lung fibrosis in COVID-19 pneumonia: A single-center experience of 1000 cases in tertiary care setting in India. , 0, .		0
1404	Zymosan Particle-Induced Hemodynamic, Cytokine and Blood Cell Changes in Pigs: An Innate Immune Stimulation Model with Relevance to Cytokine Storm Syndrome and Severe COVID-19. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1138.	1.8	3
1405	Analysis of Biochemical and Inflammatory Markers for Predicting COVID-19 Severity: Insights From a Tertiary Healthcare Institution of Eastern India. <i>Cureus</i> , 2023, , .	0.2	0
1406	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities. <i>PLoS Pathogens</i> , 2023, 19, e1011063.	2.1	7
1407	COVID-19â€™s immuno-pathology and cardiovascular diseases. <i>Journal of Investigative Medicine</i> , 2023, 71, 71-80.	0.7	6
1409	COVID-19 presentation and outcomes in patients with inflammatory rheumatic and musculoskeletal diseases receiving IL6-receptor antagonists prior to SARS-CoV-2 infection. <i>Journal of Translational Autoimmunity</i> , 2023, 6, 100190.	2.0	0
1410	Is Nuclear Factor Erythroid 2-Related Factor 2 a Target for the Intervention of Cytokine Storms?. <i>Antioxidants</i> , 2023, 12, 172.	2.2	6
1411	Pharmacokinetic/Pharmacodynamic Modeling of Dexamethasone Anti-Inflammatory and Immunomodulatory Effects in LPS-Challenged Rats: A Model for Cytokine Release Syndrome. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2023, 384, 455-472.	1.3	8
1412	A portable and low-cost centrifugal microfluidic platform for multiplexed colorimetric detection of protein biomarkers. <i>Analytica Chimica Acta</i> , 2023, 1245, 340823.	2.6	4
1413	Concern about the Effectiveness of mRNA Vaccination Technology and Its Long-Term Safety: Potential Interference on miRNA Machinery. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1404.	1.8	2
1414	Severity of Illness Scores and Biomarkers for Prognosis of Patients with Coronavirus Disease 2019. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 075-090.	0.8	2
1415	Aspects and issues of marketing authorisation and use of medicinal products for COVID-19 prevention during the pandemic. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2022, 22, 361-381.	0.2	2
1416	Levilimab clinical efficacy for interleukin-6 receptor inhibition in COVID-19 and its potential for treating cytokine release syndrome of other aetiologies. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2022, 22, 446-459.	0.2	0
1417	Cytomegalovirus Seropositivity in Older Adults Changes the T Cell Repertoire but Does Not Prevent Antibody or Cellular Responses to SARS-CoV-2 Vaccination. <i>Journal of Immunology</i> , 2022, 209, 1892-1905.	0.4	7

#	ARTICLE	IF	CITATIONS
1418	Bystander effect of SARS-CoV-2 spike protein on human monocytic THP-1 cell activation and initiation of prothrombogenic stimulus representing severe COVID-19. <i>Journal of Inflammation</i> , 2022, 19, .	1.5	4
1419	A Counterintuitive Neutrophil-Mediated Pattern in COVID-19 Patients Revealed through Transcriptomics Analysis. <i>Viruses</i> , 2023, 15, 104.	1.5	0
1420	HIF-1 α -Dependent Metabolic Reprogramming, Oxidative Stress, and Bioenergetic Dysfunction in SARS-CoV-2-Infected Hamsters. <i>International Journal of Molecular Sciences</i> , 2023, 24, 558.	1.8	3
1421	Blood transcriptome responses in patients correlate with severity of COVID-19 disease. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1422	Coordinated Loss and Acquisition of NK Cell Surface Markers Accompanied by Generalized Cytokine Dysregulation in COVID-19. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1996.	1.8	3
1423	The role of T α cell immunity in COVID-19. , 2023, , 129-140.		0
1424	Innate immune responses in COVID-19. , 2023, , 63-128.		0
1425	High titers of neutralizing SARS-CoV-2 antibodies six months after symptom onset are associated with increased severity in COVID-19 hospitalized patients. <i>Virology Journal</i> , 2023, 20, .	1.4	3
1426	Links between COVID-19 and Alzheimer's Disease—What Do We Already Know?. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 2146.	1.2	9
1427	Adherence to the Mediterranean Diet Association with Serum Inflammatory Factors Stress Oxidative and Appetite in COVID-19 Patients. <i>Medicina (Lithuania)</i> , 2023, 59, 227.	0.8	1
1429	SARS-CoV-2 Establishes a Productive Infection in Hepatoma and Glioblastoma Multiforme Cell Lines. <i>Cancers</i> , 2023, 15, 632.	1.7	3
1430	Laboratory characteristics of cytokine storm syndrome in COVID-19 infection. , 2023, , 141-160.		0
1431	The Influence of Sex on Characteristics and Outcomes of Coronavirus-19 Patients: A Retrospective Cohort Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 1118.	1.0	0
1432	Applications of multiomics data in COVID-19. , 2023, , 351-365.		0
1433	Efficient Targeted Delivery of Bifunctional Circular Aptamer-CASO Chimera to Suppress the SARS-CoV-2 Proliferation and Inflammation. <i>Small</i> , 2023, 19, .	5.2	3
1434	Characterization of METRN β as a novel biomarker of Coronavirus disease 2019 severity and prognosis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
1435	Histology and cytokine levels in hepatic injury accompanying a case of non-severe COVID-19. <i>Clinical Journal of Gastroenterology</i> , 0, , .	0.4	0
1436	Innate immune recognition against SARS-CoV-2. <i>Inflammation and Regeneration</i> , 2023, 43, .	1.5	8

#	ARTICLE	IF	CITATIONS
1437	Benefits of high-dose intravenous immunoglobulin on mortality in patients with severe COVID-19: An updated systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	5
1438	COVID-19 Causes Ferroptosis and Oxidative Stress in Human Endothelial Cells. <i>Antioxidants</i> , 2023, 12, 326.	2.2	18
1439	Multiplex sensing of IL-10 and CRP towards predicting critical illness in COVID-19 infections. <i>Biosensors and Bioelectronics: X</i> , 2023, 13, 100307.	0.9	2
1440	Complete blood count in the elderly vs. selected biochemical parameters associated with inflammation. Results of PolSenior2 study. <i>Diagnostyka Laboratoryjna I Wiadomości PTDL</i> , 2022, 57, 195-203.	0.0	0
1441	The role of spike protein entry inhibitors in the treatment of mild-to-moderate covid-19 in nonhospitalized patients. <i>Journal of Lung, Pulmonary & Respiratory Research</i> , 2022, 9, 52-59.	0.3	0
1442	Comment on "Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression". <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 367-370.	0.8	0
1443	Different cytokine and chemokine profiles in hospitalized patients with COVID-19 during the first and second outbreaks from Argentina show no association with clinical comorbidities. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1444	The double sides of NLRP3 inflammasome activation in sepsis. <i>Clinical Science</i> , 2023, 137, 333-351.	1.8	3
1445	Anthocyanin bioaccessibility and anti-inflammatory activity of a grape-based 3D printed food for dysphagia. <i>Innovative Food Science and Emerging Technologies</i> , 2023, 84, 103289.	2.7	5
1446	Role of IP-10 to Predict Clinical Progression and Response to IL-6 Blockade With Sarilumab in Early COVID-19 Pneumonia. A Subanalysis of the SARICOR Clinical Trial. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	0
1447	SARS-CoV-2 Related Antibody-Dependent Enhancement Phenomena In Vitro and In Vivo. <i>Microorganisms</i> , 2023, 11, 1015.	1.6	8
1448	Ultradiluted SARS-CoV-2 Spike Protein mitigates hyperinflammation in lung via ferritin and MMP-9 regulation in BALB/c mice. <i>Virus Research</i> , 2023, 329, 199091.	1.1	2
1449	The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2. <i>Antiviral Research</i> , 2023, 213, 105590.	1.9	4
1450	Stress levels, psychological symptoms, and C-reactive protein levels in COVID-19: A cross-sectional study. <i>Journal of Affective Disorders</i> , 2023, 330, 216-226.	2.0	3
1451	Low dose vs high dose tocilizumab in COVID-19 patients with hypoxemic respiratory failure. <i>Journal of Critical Care</i> , 2023, 76, 154291.	1.0	0
1452	Phase-separation: a possible new layer for transcriptional regulation by glucocorticoid receptor. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
1453	Immunomodulatory effect of sulfated galactofucan from marine macroalga <i>Turbinaria conoides</i> . <i>International Journal of Biological Macromolecules</i> , 2023, 238, 124021.	3.6	0
1454	Evaluation of altered miRNA expression pattern to predict COVID-19 severity. <i>Heliyon</i> , 2023, 9, e13388.	1.4	7

#	ARTICLE	IF	CITATIONS
1455	Controlling Inflammation Improves Aging Skeletal Muscle Health. <i>Exercise and Sport Sciences Reviews</i> , 2023, 51, 51-56.	1.6	4
1456	Host Response of Syrian Hamster to SARS-CoV-2 Infection including Differences with Humans and between Sexes. <i>Viruses</i> , 2023, 15, 428.	1.5	6
1457	Characteristics and Potential Roles of Natural Killer Cells During SARS-CoV-2 Infection. <i>Infectious Diseases & Immunity</i> , 2023, 3, 29-35.	0.2	0
1458	Human influenza virus infection elicits distinct patterns of monocyte and dendritic cell mobilization in blood and the nasopharynx. <i>ELife</i> , 0, 12, .	2.8	4
1460	Immune cell population and cytokine profiling suggest age dependent differences in the response to SARS-CoV-2 infection. <i>Frontiers in Aging</i> , 0, 4, .	1.2	5
1461	Understanding Neutrophil Dynamics during COVID-19 Infection. <i>Applied Sciences (Switzerland)</i> , 2023, 13, 2409.	1.3	0
1462	Comment on "Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression". <i>World Journal of Gastrointestinal Oncology</i> , 0, 15, 368-371.	0.8	0
1464	Circulating Interleukin-8 Dynamics Parallels Disease Course and Is Linked to Clinical Outcomes in Severe COVID-19. <i>Viruses</i> , 2023, 15, 549.	1.5	3
1465	Impact of COVID-19 Pandemic on Frontline Pembrolizumab-Based Treatment for Advanced Lung Cancer. <i>Journal of Clinical Medicine</i> , 2023, 12, 1611.	1.0	0
1466	Immune Dysregulation in Acute SARS-CoV-2 Infection. <i>Pathogens and Immunity</i> , 2022, 7, 143-170.	1.4	2
1467	Blood Inflammatory Biomarkers Differentiate Inpatient and Outpatient Coronavirus Disease 2019 From Influenza. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	0
1468	Essential Oil of <i>Cestrum diurnum</i> L.: GC/MS Analysis, <i>in Vitro</i> and <i>in Silico</i> Anti-CoV-2 Effects and Inhibitory Activity against LPS-induced Inflammation. <i>Chemistry and Biodiversity</i> , 2023, 20, .	1.0	0
1469	Engineered antibody cytokine chimera synergizes with DNA-launched nanoparticle vaccines to potentiate melanoma suppression in vivo. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1470	Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia. <i>Respiratory Research</i> , 2023, 24, .	1.4	7
1471	The role of interleukin-6 and janus kinases in the pathogenesis, and treatment of SARS-CoV-2. <i>Journal of Lung, Pulmonary & Respiratory Research</i> , 2022, 9, 17-32.	0.3	1
1472	Innate immune cell activation causes lung fibrosis in a humanized model of long COVID. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	18
1473	Integrated Metabolic and Inflammatory Signatures Associated with Severity of, Fatality of, and Recovery from COVID-19. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	4
1474	Biomarker Profiles Associated with COVID-19 Severity and Mortality. <i>Current Issues in Molecular Biology</i> , 2023, 45, 1998-2012.	1.0	1

#	ARTICLE	IF	CITATIONS
1476	SARS-CoV-2 spike protein promotes inflammatory cytokine activation and aggravates rheumatoid arthritis. <i>Cell Communication and Signaling</i> , 2023, 21, .	2.7	4
1477	The Defenders of the Alveolus Succumb in COVID-19 Pneumonia to SARS-CoV-2 and Necroptosis, Pyroptosis, and PANoptosis. <i>Journal of Infectious Diseases</i> , 2023, 227, 1245-1254.	1.9	6
1478	Elevated inflammatory markers as predictors of mortality in people with diabetes and COVID-19. <i>Journal of Diabetes, Metabolic Disorders & Control</i> , 2022, 9, 27-31.	0.2	0
1479	Neutrophil Extracellular Traps in Airway Diseases: Pathological Roles and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5034.	1.8	11
1480	The effect of ACE2 receptor, IFN- $\hat{I}3$, and TNF- $\hat{I}z$ polymorphisms on the severity and prognosis of the disease in SARS-CoV-2 infection. <i>Journal of Investigative Medicine</i> , 0, , 108155892311583.	0.7	0
1481	New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4922.	1.8	3
1482	Understanding COVID-19 in children: immune determinants and post-infection conditions. <i>Pediatric Research</i> , 2023, 94, 434-442.	1.1	11
1483	Therapeutic potency of compound RMY-205 for pulmonary fibrosis induced by SARS-CoV-2 nucleocapsid protein. <i>Cell Chemical Biology</i> , 2023, 30, 261-277.e8.	2.5	1
1484	Pharmacological potential of <i>Withania somnifera</i> (L.) Dunal and <i>Tinospora cordifolia</i> (Willd.) Miers on the experimental models of COVID-19, T cell differentiation, and neutrophil functions. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	8
1485	Severe COVID-19 <i>versus</i> multisystem inflammatory syndrome: comparing two critical outcomes of SARS-CoV-2 infection. <i>European Respiratory Review</i> , 2023, 32, 220197.	3.0	2
1486	A Pilot Study on Blood Components in COVID-19 Affected Subjects: A Correlation to UPR Signalling and ER-Stress. <i>Indian Journal of Clinical Biochemistry</i> , 0, , .	0.9	0
1487	SARS-CoV-2 spike protein induces IL-18-mediated cardiopulmonary inflammation via reduced mitophagy. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	14
1488	Emerging viral infections in immunocompromised patients: A great challenge to better define the role of immune response. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	6
1489	Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study). <i>EClinicalMedicine</i> , 2023, 57, 101895.	3.2	1
1490	Lymphangitic Carcinomatosis of Possible Urothelial Origin. <i>Cureus</i> , 2023, , .	0.2	0
1491	Repurposing 1,2,4-oxadiazoles as SARS-CoV-2 PLpro inhibitors and investigation of their possible viral entry blockade potential. <i>European Journal of Medicinal Chemistry</i> , 2023, 252, 115272.	2.6	4
1492	Infection with SARS-CoV-2 Is Associated with Elevated Levels of IP-10, MCP-1, and IL-13 in Sepsis Patients. <i>Diagnostics</i> , 2023, 13, 1069.	1.3	1
1493	Plasma proteomics of SARS-CoV-2 infection and severity reveals impact on Alzheimer's and coronary disease pathways. <i>IScience</i> , 2023, 26, 106408.	1.9	4

#	ARTICLE	IF	CITATIONS
1494	Colchicine reduces the activation of NLRP3 inflammasome in COVID-19 patients. <i>Inflammation Research</i> , 2023, 72, 895-899.	1.6	2
1495	Proinflammatory Responses in SARS-CoV-2 and Soluble Spike Glycoprotein S1 Subunit Activated Human Macrophages. <i>Viruses</i> , 2023, 15, 754.	1.5	1
1498	Neutrophilic inflammation promotes SARS-CoV-2 infectivity and augments the inflammatory responses in airway epithelial cells. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
1499	Erythrocytes Functionality in SARS-CoV-2 Infection: Potential Link with Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5739.	1.8	2
1500	Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial. <i>Thrombosis and Haemostasis</i> , 2023, 123, 723-733.	1.8	1
1501	Characterization of the immune impairment of patients with tuberculosis and COVID-19 coinfection. <i>International Journal of Infectious Diseases</i> , 2023, , .	1.5	11
1502	Patients with advanced pancreatic and biliary cancer appear vulnerable to SARS-CoV-2 Omicron variant: An observational study during the COVID-19 outbreak in Shanghai. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1503	Laboratory Markers of COVID-19 in the Emergency Room. <i>Biomarkers in Disease</i> , 2023, , 889-916.	0.0	0
1504	Photobiomodulation Reduces the Cytokine Storm Syndrome Associated with COVID-19 in the Zebrafish Model. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6104.	1.8	2
1505	Prospective Roles of Tumor Necrosis Factor-Alpha (TNF- α) in COVID-19: Prognosis, Therapeutic and Management. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6142.	1.8	17
1506	Corticosteroids reduce pathologic interferon responses by downregulating STAT1 in patients with high-risk COVID-19. <i>Experimental and Molecular Medicine</i> , 2023, 55, 653-664.	3.2	2
1507	Identification of two early blood biomarkers ACE and CLEC12A for improved risk stratification of critically ill COVID-19 patients. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
1508	Cellular and molecular features of COVID-19 associated ARDS: therapeutic relevance. <i>Journal of Inflammation</i> , 2023, 20, .	1.5	2
1509	Cytokine Storm Syndromes in Pediatric Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, , .	2.0	1
1510	A low dose of RBD and TLR7/8 agonist displayed on influenza virosome particles protects rhesus macaque against SARS-CoV-2 challenge. <i>Scientific Reports</i> , 2023, 13, .	1.6	2
1511	Immunometabolic interference between cancer and COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1513	Identifying diseases associated with Post-COVID syndrome through an integrated network biology approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2024, 42, 652-671.	2.0	2
1514	Characterisation of the pro-inflammatory cytokine signature in severe COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4

#	ARTICLE	IF	CITATIONS
1515	Alzheimer's Disease and COVID-19 Pathogenic Overlap: Implications for Drug Repurposing. <i>Canadian Journal of Neurological Sciences</i> , 2024, 51, 161-172.	0.3	0
1516	A review of cytokine-based pathophysiology of Long COVID symptoms. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	28
1518	TNF α aggravates detrimental effects of SARS-CoV-2 infection in the liver. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
1519	Oral Supplementation with AHCC [®] , a Standardized Extract of Cultured <i>Lentinula edodes</i> Mycelia, Enhances Host Resistance against SARS-CoV-2 Infection. <i>Pathogens</i> , 2023, 12, 554.	1.2	1
1520	Pregnancy-specific responses to COVID-19 revealed by high-throughput proteomics of human plasma. <i>Communications Medicine</i> , 2023, 3, .	1.9	4
1521	Elevated Interleukin-37 Associated with Dengue Viral Load in Patients with Dengue Fever. <i>Current Microbiology</i> , 2023, 80, .	1.0	0
1522	In Patients Hospitalized for Community-Acquired Pneumonia, SARS-CoV-2 Is Associated with Worse Clinical Outcomes When Compared to Influenza. <i>Pathogens</i> , 2023, 12, 571.	1.2	1
1523	Neurological damages in COVID-19 patients: Mechanisms and preventive interventions. <i>MedComm</i> , 2023, 4, .	3.1	4
1524	Comparison of antibody response to coronavirus disease 2019 vaccination between patients with solid or hematologic cancer patients undergoing chemotherapy. <i>Asia-Pacific Journal of Clinical Oncology</i> , 0, , .	0.7	0
1525	Cellular and molecular biomarkers of long COVID: a scoping review. <i>EBioMedicine</i> , 2023, 91, 104552.	2.7	20
1526	Quantitative proteomics analysis of COVID-19 patients: Fetuin-A and tetranectin as potential modulators of innate immune responses. <i>Heliyon</i> , 2023, 9, e15224.	1.4	2
1527	YoÄŸun BakÄ±m Äcenesinde yatan Covid-19'lu Gebe ve LohusalarÄ±n Mortalite Risk Faktörleri. <i>Ege TÄ±p Bilimleri Dergisi</i> , 0, , .	0.1	0
1528	iL13Pred: improved prediction of IL-13 inducing peptides using popular machine learning classifiers. <i>BMC Bioinformatics</i> , 2023, 24, .	1.2	0
1529	Distinctive Dynamics and Functions of the CD4+CD25+FOXP3+ Regulatory T Cell Population in Patients with Severe and Mild COVID-19. <i>Journal of Immunology</i> , 2023, 210, 1687-1699.	0.4	4
1530	Fighting cytokine storm and immunomodulatory deficiency: By using natural products therapy up to now. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	9
1531	The Multifaceted Role of Annexin A1 in Viral Infections. <i>Cells</i> , 2023, 12, 1131.	1.8	1
1532	Host Expression Profiling from Diagnostic COVID-19 Swabs Associate Upper Respiratory Tract Immune Responses with Radiologic Lung Pathology and Clinical Severity. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	0
1533	Mapping CircRNA \leftrightarrow miRNA \leftrightarrow mRNA regulatory axis identifies hsa_circ_0080942 and hsa_circ_0080135 as a potential theranostic agents for SARS-CoV-2 infection. <i>PLoS ONE</i> , 2023, 18, e0283589.	1.1	3

#	ARTICLE	IF	CITATIONS
1534	Cancer and COVID-19: unravelling the immunological interplay with a review of promising therapies against severe SARS-CoV-2 for cancer patients. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	4
1535	Prospects of Novel and Repurposed Immunomodulatory Drugs against Acute Respiratory Distress Syndrome (ARDS) Associated with COVID-19 Disease. <i>Journal of Personalized Medicine</i> , 2023, 13, 664.	1.1	0
1536	A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions. <i>Npj Systems Biology and Applications</i> , 2023, 9, .	1.4	3
1537	Investigational Use of Mesenchymal Stem/Stromal Cells and Their Secretome as Add-On Therapy in Severe Respiratory Virus Infections: Challenges and Perspectives. <i>Advances in Therapy</i> , 2023, 40, 2626-2692.	1.3	8
1538	Circulating proteins to predict COVID-19 severity. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
1539	Anthropometric Measurements and Admission Parameters as Predictors of Acute Respiratory Distress Syndrome in Hospitalized COVID-19 Patients. <i>Biomedicines</i> , 2023, 11, 1199.	1.4	2
1541	SARS-CoV-2 Infection to Premature Neuronal Aging and Neurodegenerative Diseases: Is there any Connection with Hypoxia?. <i>CNS and Neurological Disorders - Drug Targets</i> , 2024, 23, 431-448.	0.8	2
1542	Role of Pineapple and its Bioactive Compound Bromelain in COVID 19. <i>Current Nutrition and Food Science</i> , 2024, 20, 305-316.	0.3	0
1543	Therapeutic strategies for COVID-19: progress and lessons learned. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 449-475.	21.5	112
1545	TNFepitope: A webserver for the prediction of TNF- $\hat{\pm}$ inducing epitopes. <i>Computers in Biology and Medicine</i> , 2023, 160, 106929.	3.9	2
1546	Repurposed Drugs/Potential Pharmacological Agents Targeting Cytokine Release and Induction of Coagulation in COVID-19. , 2023, , 100-136.		0
1547	The Open, Randomized, Positive Control Clinical Trial of Guluronic Acid (G2013) on SARS-CoV-2 Patients. <i>Current Drug Discovery Technologies</i> , 2023, 20, .	0.6	0
1548	Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
1549	Spontaneous cancer remission after COVID-19: insights from the pandemic and their relevance for cancer treatment. <i>Journal of Translational Medicine</i> , 2023, 21, .	1.8	6
1550	Identification of Distinct Clinical Phenotypes of Critically Ill COVID-19 Patients: Results from a Cohort Observational Study. <i>Journal of Clinical Medicine</i> , 2023, 12, 3035.	1.0	0
1551	COVID-19 and Multiorgan Response: The Long-Term Impact. <i>Current Problems in Cardiology</i> , 2023, 48, 101756.	1.1	2
1583	Inflammation and aging: signaling pathways and intervention therapies. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	63
1589	Comorbid Obesity and Its Impact on Diabetes and COVID-19. <i>Contemporary Endocrinology</i> , 2023, , 93-107.	0.3	0

#	ARTICLE	IF	CITATIONS
1691	Coculture of Human Dendritic and T Cells for the Study of Specific T Cell-Mediated Responses Against Food Allergens. <i>Methods in Molecular Biology</i> , 2024, , 175-190.	0.4	1
1713	Hypersensitivity Reactions Following Onabotulinum Toxin A Touch-up Injection Possibly Associated with Covid-19 Infection. <i>Aesthetic Plastic Surgery</i> , 0, , .	0.5	0
1725	Inflammation and Diabetes Mellitus. <i>Contemporary Endocrinology</i> , 2023, , 55-77.	0.3	0
1740	Identification of GRB10 Expression as a Novel Blood Biomarker for Prognosis of COVID-19 Severity. <i>IFMBE Proceedings</i> , 2024, , 917-929.	0.2	0
1747	A single-dose of intranasal vaccination with a live-attenuated SARS-CoV-2 vaccine candidate promotes protective mucosal and systemic immunity. <i>Npj Vaccines</i> , 2023, 8, .	2.9	0
1772	Management of Immunosuppressed Dermatology Patients During COVID-19. <i>Updates in Clinical Dermatology</i> , 2023, , 109-120.	0.1	0
1783	Editorial: Updates and new concepts in regulation of pro-inflammatory gene expression by steroid hormones, volume II. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	0
1799	Coronavirus and the Cytoskeleton of Virus-Infected Cells. <i>Sub-Cellular Biochemistry</i> , 2023, , 333-364.	1.0	0
1800	Mesenchymal stromal cells and pleiotropic therapeutic advantages in COVID-19 management. , 2024, , 279-306.		0
1802	Cytokine storm in COVID-19 and other diseases: emerging therapeutic interventions. , 2024, , 209-241.		0